Regulation of immunometabolic processes in atherosclerosis and nonalcoholic fatty liver disease by liver receptor homolog 1 by Stein, Matthias Alexander Sokrates
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Regulation of immunometabolic processes in atherosclerosis and nonalcoholic
fatty liver disease by liver receptor homolog 1
Stein, Matthias Alexander Sokrates
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-178311
Habilitation
Published Version
Originally published at:
Stein, Matthias Alexander Sokrates. Regulation of immunometabolic processes in atherosclerosis and
nonalcoholic fatty liver disease by liver receptor homolog 1. 2018, University of Zurich, Faculty of
Medicine.
 
 
 
Habilitationsschrift 
 
 
 
 
Regulation of Immunometabolic Processes in 
Atherosclerosis and Nonalcoholic Fatty Liver 
Disease by Liver Receptor Homolog 1 
 
 
 
 
Zur Erlangung der Venia Legendi der Universität Zürich 
 
 
 
 
 
 
Verfasst von 
Matthias Alexander Sokrates Stein 
 
 
 
 
Zürich, 8. Mai 2018 
  
 
Preface	
In this habilitation treatise I focus on the work that was performed to analyze the function of the nuclear 
receptor liver receptor homolog 1 (LRH-1) in the development of atherosclerosis and nonalcoholic fatty 
liver disease. 
I started exploring transcriptional networks in the fruit fly Drosophila melanogaster during my Master 
(diploma) thesis. This study in developmental biology was carried out at the Max Planck Institute for 
Developmental Biology in Tübingen and performed under the supervision of Ingrid Lohmann. I also got 
substantial support from Petra Stöbe and Zhongzhao Zhai to analyze the interaction of the transcription 
factor Deformed during Drosophila embryogenesis. 
Christian Matter introduced me to the atherosclerosis research during an interview for a PhD thesis 
early in 2008. The impact of this disease as the leading cause of mortality in the world on one side, 
and the fascinating biomedical complexity on the other side caught my attention. Atherogenesis is 
triggered and influenced by genetic, epigenetic and environmental factors and encompasses various 
organs and many different cell types. Therefore, there is a lot be learned and discover at various levels, 
from small molecular protein interactions to metabolic processes affecting whole-body physiology. I 
joined Christian Matter’s group to perform my PhD thesis, and since then my primary research interest 
has been to study how molecular network affect the development of this chronic immunometabolic 
disease. 
During my PhD thesis at the Institute of Physiology at the University of Zurich I studied the role of a 
specific protein deacetylase in atherosclerosis in mice and primary human cells. During this time, I got 
valuable support from my thesis committee members and lab colleagues, including Christian Matter, 
Burkhard Becher, Michael Hottiger, Walter Wahli, Alexander Breitenstein, Christian Besler, Stephan 
Winnik, Gabriela Kania, and Przemyslaw Blyszczuk. Our studies revealed important anti-inflammatory 
functions of this deacetylase in athero-thrombotic diseases, which are summarized and discussed in 
my PhD thesis. 
After completion of my PhD in March 2011, I moved to Lausanne to perform my postdoctoral work in 
the lab of Kristina Schoonjans at the École Polytechnique Fédérale de Lausanne. In her lab I analyzed 
the function of the transcription factor LRH-1 in atherosclerosis and nonalcoholic fatty liver disease, 
another important chronic metabolic disease. During this time, I greatly benefited from the input and 
help of Kristina Schoonjans, Johan Auwerx, Pan Xu, Vera Lemos, Dongryeol Ryu, Alessia Perino, 
Maaike Oosterveer, Xu Wang, Li Hao, Karim Gariani, Jef Verbeek, and Norman Moullan. We 
discovered exciting mechanisms involved in the metabolic regulation of atherosclerosis and 
nonalcoholic fatty liver disease using mouse models and exploring human data. Moreover, during these 
years I expanded my research field from a rather focused view on the arteries and the cells within the 
atherosclerotic plaques towards a systemic view, taking into account the systemic effects driven by 
other organs, especially the liver. 
 
Supported by an Ambizione Grant of the Swiss National Science Foundation, I lead my own 
independent research team at the Center for Molecular Cardiology at the University of Zurich since 
February 2016. My incorporation into the center was possible due to the kind support of the chairman 
and the director of the Center for Molecular Cardiology, i.e. Thomas Lüscher and Giovanni Camici. I 
would like to also acknowledge my current team members, Sara Oppi and Stefanie Nusser-Stein, who 
are paving up a common scientific path by contributing most valuable ideas and experiments. 
Currently, we are studying the function of two transcriptional corepressors in atherogenesis in mice, 
cell models, human data, and also building up bed-to-benchside collaborations with clinical teams. 
Here again we are benefiting from the fruitful collaborations with national and international colleagues, 
including Maaike Oosterveer, Dongryeol Ryu, Kristina Schoonjans, Johan Auwerx, Fatima Bosch, 
Fumio Matsuzaki, Christian Matter, Elena Osto, Theofanis Karayannis, Evan Williams, Alexander 
Leitner, Martin Geiger, and Zoran Rancic. 
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1.	Abstract	
The metabolic syndrome is a cluster of interconnected diseases, including insulin resistance, obesity, 
hypertension, and dyslipidemias, and it is tightly associated with the development of atherosclerosis, 
nonalcoholic fatty liver disease (NAFLD), and type 2 diabetes mellitus. NALFD is one of the primary 
causes of liver disease in the world and it is strongly associated with cardiovascular risk factors. The 
disease encompasses different stages of liver disorders, starting with the excessive massive 
accumulation of hepatic triglycerides. Atherosclerosis is the primary cause of myocardial infarction and 
stroke, two of the leading causes of mortality in the world. One hallmark of the disease is the excessive 
accumulation of cholesterol in monocyte-derived macrophages within atherosclerotic lesions. Both 
atherosclerosis and NAFLD are immunometabolic diseases, i.e. chronic diseases that are affected by 
both metabolic and immunological triggers and signaling networks. 
The signaling cascades that are activated by inflammatory and metabolic mediators converge at key 
transcriptional regulators, which in turn coordinate the expression of specific target genes. Together 
with colleagues I demonstrated that the nuclear receptor homolog-1 (LRH-1) affects the development 
of both atherosclerosis and NAFLD by regulating immunometabolic processes. We showed that 
atherosclerosis-prone mice carrying a mutation that abolishes the SUMOylation of the nuclear receptor 
(i.e. LRH-1 K289R) are significantly protected from atherosclerosis development in mice challenged 
with a high-cholesterol diet. This atheroprotection was regulated by the corepressor prospero-related 
homeobox 1 (PROX1), which normally transrepresses the transcription of genes involved in hepatic 
reverse cholesterol transport. On the other side, we showed that this same LRH-1 mutation promotes 
the development of NAFLD and early signs of steatohepatitis if mice are challenged with a lipogenic 
high-fat high-sucrose diet. These studies highlighted that a single posttranslational modification of a 
specific residue of a transcriptional regulator is sufficient to modulate the function of the protein and 
the corresponding cellular and metabolic processes, which consequently can affect the development 
of these complex chronic diseases. 
In this habilitation I will summarize these two major studies as well as other work that underline the 
crucial function that this nuclear receptor exerts in the liver and macrophages under different genetic 
backgrounds and dietary challenges. These studies are of high translational potential given the 
availability of specific LRH-1 agonists and antagonists that could potentially be used to modulate the 
development and/or progression of these chronic diseases. 
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2.	Atherosclerosis	and	nonalcoholic	fatty	liver	disease	
Atherosclerosis is the primary cause of myocardial infarction and stroke, two of the leading causes of 
mortality in the world (1, 2). In a simplified view one could describe atherosclerosis as a disease 
characterized by the thickening of blood vessels due to atherosclerotic plaques that are caused by the 
accumulation of immune cells and lipids, especially cholesterol. The disease most likely co-evolved 
with humans: Special 3 dimensional computer tomography-based imaging reconstructions of old 
mummified corpses revealed that the people living up to 4000 years ago had atherosclerotic lesions 
(3). These lesions could be detected in mummies from archaic to middle age periods, from different 
cultures, and found in different places of the world (3). 
Atherosclerosis is a chronic immunometabolic disease, and its development starts early in a human 
life. One hallmark of the disease is the excessive accumulation of cholesterol in monocyte-derived 
macrophages within atherosclerotic lesions. The first fatty streak lesions may arise during embryonic 
development, and clinical correlation studies suggest that maternal hypercholesterolemia might 
promote the formation of lesion in the fetus (4, 5). The complex pathophysiology is triggered by genetic 
and environmental risk factors (6, 7). Moreover, disease progression is affected by medical 
complications, such as diabetes and obesity, and environmental factors, such as dietary metabolites 
(e.g. cholesterol, specific fatty acids, carnitine) (6-8). Importantly, these risk factors converge on 
various molecular processes, including inflammatory and/or metabolic responses, in diverse organs 
and the cells within atherosclerotic plaques. The developmental process of atheromatous plaque 
formation is locally driven by the interaction between modified lipoproteins, activated endothelial cells, 
an cell from the innate and adaptive immune system (1). The main steps in the development of 
atherosclerotic plaques are illustrated in Figure 1. 
The signaling cascades that are activated by inflammatory and metabolic mediators converge at key 
transcriptional regulators, which in turn coordinate the expression of specific target genes (9). Whether 
individual target genes are activated or repressed depends on several other factors, such as folding 
and compaction of the chromatin, posttranslational modifications of histones by chromatin-modifying 
enzymes, functional alterations by noncoding RNAs, and recruitment of the transcriptional machinery, 
including transcription factors and importantly also transcription cofactors, i.e. transcriptional 
corepressors and coactivators (10-12). 
Mouse models of atherosclerosis 
Most wildtype mouse strains display a different lipoprotein profile than humans and are resistant to 
develop atherosclerosis (13). Therefore, genetic mouse models with a ‘humanized’ lipoprotein profile 
are commonly used to study atherosclerosis in mice, including apolipoprotein E (Apoe-/-) and LDL 
receptor (Ldlr-/-) knockout mice, as well as the E3L.CETP mice (14-17). Apoe knockout mice develop 
marked hypercholesterolemia, having most cholesterol in the VLDL subfractions, develop 
atherosclerosis spontaneously, and display a strong immunologically-driven phenotype (16). Ldlr 
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knockout mice have most cholesterol in the LDL fractions, comparable to humans, develop 
atherosclerotic plaques upon high cholesterol feeding, and are the preferred model to study cholesterol 
metabolism (15). E3L.CETP are Apoe knockout mice that additionally contain a human cholesteryl 
ester transfer protein (CETP) gene, which is normally not present in mice, and therefore can be used 
to study processes linked to CETP function (17). The atherosclerotic phenotype of these mice is 
aggravated after feeding them a high-cholesterol plus high-fat diet. 
Nonalcoholic fatty liver disease 
Nonalcoholic fatty liver disease (NAFLD) is one of the primary causes of liver disease in the world. Its 
prevalence correlates with the incidence of obesity, but also lean persons are affected (18). NAFLD 
encompasses different stages of liver disorders. The earliest stage of the disease is characterized by 
the massive accumulation of triglycerides in the liver, which is termed hepatic steatosis and is 
considered a benign condition. Chronic exposure to these lipids can lead to more severe stages of the 
diseases, such as nonalcoholic steatohepatitis (NASH), which is further characterized by ballooning of 
the hepatocytes, infiltration of immune cells, and formation of fibrotic lesions into the liver. NASH may 
further progress to cirrhosis, in which scar tissue replaces hepatocytes, and promote the development 
of hepatocellular carcinoma (Figure 2A) (19-21). 
Figure 1. Model of atherogenesis. This scheme illustrates the development of an atherosclerotic plaque from 
left to right in a longitudinal section of an arterial vessel. (1) Upon activation by metabolic or inflammatory 
triggers, endothelial cells express adhesion molecules (Ad. mol.) that promote the recruitment of immune cells, 
such as blood monocytes (Mono). These cells then infiltrate the arterial intima, where monocyte differentiate 
into macrophages (Macro) and interact with other immune cells, such as neutrophils (Neutro) and T cells. (2) 
Increased uptake of modified lipoproteins via scavenger receptors or decreased cholesterol efflux accelerates the 
accumulation of intracellular free cholesterol and cholesteryl ester-loaded lipid droplets that promote foam cell 
formation. (3) Macrophage foam cells eventually die and fall apart, thereby forming a necrotic core. (4) 
Advanced, vulnerable plaques can rupture and thereby form an arterial thrombus, which can lead to a myocardial 
infarction or stroke. RBC, red blood cell; VSMC, vascular smooth muscle cell. 
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The development of hepatic steatosis is highly heterogeneous, and the excessive accumulation of 
triglycerides can be caused by an imbalance between the acquisition and disposal of fatty acids. 
Different processes coordinate this balance, such as the uptake of dietary fatty acids from 
chylomicrons, the uptake of free fatty acids from lipolysis in the adipose tissue, the storage of fatty 
acids as triglycerides in hepatic lipid droplets, the secretion of triglycerides into VLDL particles, the 
breakdown of fatty acids in mitochondrial beta oxidation, and the synthesis of fatty acids (de novo 
lipogenesis) (Figure 2B) (19, 22, 23). 
Figure 2. Stages of nonalcoholic fatty liver disease (NAFLD) and hepatic fatty acid metabolism. (A) 
Masson’s trichrome staining of representative liver sections from different stages of NAFLD. CV, central vein. 
(B) Scheme illustrating the major processes regulating fatty acid metabolism in the liver and highlighting 
important enzymes. SREBP-1, sterol regulatory element binding transcription factor 1; ChREBP, carbohydrate-
responsive element-binding protein; ATGL, adipose triglyceride lipase; HSL, hormone-sensitive lipase. Adapted 
from (19). 
Dietary models of NAFLD 
Different dietary approaches can be undertaken to study NAFLD in mice, rat and other experimental 
animal models. The first experimental model that was used was a methionine- and choline-deficient 
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diet, which induces hepatic fibrosis upon chronic treatment. However, mice under a methionine- and 
choline-deficient diet loose body weight and do not develop hepatic insulin resistance, and are 
therefore only partially comparable to NALFD in humans. Newer dietary approaches include a high-fat 
diet alone, or a moderate to high-fat diet in combination with other lipogenic supplements or fibrosis-
inducing agents, such as cholesterol, fructose, sucrose or bleomycin. These diets do also better 
resemble the pathophysiological changes observed in NAFLD patients (24-29).  
Association of NAFLD with cardiovascular disease 
NALFD is the hepatic component of the metabolic syndrome, and it is strongly associated with insulin 
resistance, obesity, hypertension, and dyslipidemia, which are well established cardiovascular risk 
factors. Clinical studies demonstrated that patients with NAFLD have increased circulating and hepatic 
proinflammatory and procoagulant markers according to the stage of their disease (30, 31). Moreover, 
the expression of classical atherogenic genes is impaired in patients with NASH. This leads to adverse 
cardiovascular function in NAFLD patients, such as increased oxidative stress and endothelial 
dysfunction, hypercoagulability, and accelerated development of atherosclerosis (30-32). This 
impaired cardiovascular function is the primary cause of premature mortality and morbidity in NAFLD 
patients (30-33). 
3.	The	beneficial	hepatic	role	of	LRH-1	in	atherogenesis	
Liver receptor homolog 1 (LRH-1 or NR5A2) is a nuclear receptor with diverse biological functions 
ranging from follicle maturation in the ovary to cell cycle regulation in different tissues. In the liver, LRH-
1 is an important regulator of cholesterol and bile salt metabolism (34-37). Previous studies suggested 
that LRH-1 might play an important function in the pathogenesis of atherosclerosis (38-41). For 
example, LRH-1 regulates the hepatic expression of Scavenger receptor B type I (Scarb1) (40), a gene 
that is highly expressed in the liver, where it facilitates the uptake of cholesteryl esters from high-
density lipoproteins (HDL), and thus plays a crucial role in the reverse cholesterol transport. The 
reverse cholesterol transport is an anti-atherogenic process in which excessive cholesterol from 
peripheral tissues is transported to the liver via high-density lipoproteins, where it can be further 
converted into bile acids or be excreted with the bile (Figure 3) (42). Dysfunctional reverse cholesterol 
transport may lead to excessive accumulation of cholesterol in peripheral tissues or the liver, and 
therefore stimulate macrophage foam cell formation and disease progression (43). 
Unlike many other nuclear receptors, murine LRH-1 does not require ligand binding to be activated 
(44), although recent studies suggest that specific phospholipid species might act as endogenous LRH-
1 ligands (45). Instead, LRH-1 transcriptional activity is significantly modified upon interaction with 
transcriptional repressors (46-48), and/or by posttranslational modifications like SUMOylation and 
phosphorylation (49-51). Whereas LRH-1 phosphorylation results in an increase in its transcriptional 
activity, SUMOylation represses its function. Although it has not yet been established which 
physiological stimuli trigger LRH-1 SUMOylation, two models show how the SUMOylated form might 
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be kept transcriptionally inactive: (1) The SUMOylated protein translocates into nuclear bodies and is 
thereby physically separated from the chromatin; (2) the recruitment of corepressor complexes leads 
to a transrepression of target genes (49, 52, 53). 
Figure 3. Forward and reverse cholesterol transport (RCT). Left side, scheme illustrating the forward, cyclic 
cholesterol transport that is mainly mediated via low-density lipoproteins (LDLs). Right side, the main carriers 
in the reverse cholesterol transport pathway are high-density lipoproteins (HDLs), which transport peripheral 
cholesterol back to the liver. 
SUMOylation of LRH-1 reduces its transcriptional activity 
We mutated 4 different lysine residues to study potential SUMOylation-defective forms of LRH-1 in 
vitro (Figure 4A). Importantly, we discovered that mutating the endogenous lysine K289 to arginine 
(K289R) increased the transcriptional activity of LRH-1 (gain-of-function) and prevented the 
SUMOylation of the protein (Figure 4B, C) (54). We then generated a mouse model which contains a 
single nucleotide substitution at DNA level that leads to the LRH-1 K289R mutation at protein level 
(54). 
SUMOylation-defective LRH-1 mice develop less atherosclerotic lesions 
To analyzed how atherosclerosis development is affected in this LRH-1 gain-of-function mouse model, 
we crossbred it to atherosclerosis-prone Ldlr knockout mice and challenged the mice with a high 
cholesterol diet. Importantly, our initial hypothesis that LRH-1 may be an atheroprotective factor hold 
true as the Ldlr-/- Lrh-1 K289R (LL-K289R) mice developed significantly less atheromatous lesions than 
the Ldlr-/- Lrh-1 WT (LL-WT) control mice after being exposed to a high-cholesterol diet (HCD) for 14 
weeks (Figure 5) (54). 
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Figure 4. LRH-1 K289R blocks SUMOylation and displays increased transcriptional activity in vitro. (A) 
Model of LRH-1 highlighting the lysine residues that were mutated. DBD, DNA-binding domain; FTZ, Fushi-
tarazu homology domain; LBD, ligand-binding domain; AF2, activation function 2 domain. (B) Luciferase assay 
performed in HEK 293T cells that were co-transfected with a pGL3::(LRHRE)5-TK-LUC and a pCMV plasmid 
coding for the wildtype or indicated mutant LRH-1 constructs. (C) Immunoprecipitation of V5-tagged LRH-1 to 
detect the SUMOylated band of LRH-1 (arrowheads). HEK 293T cells were transfected with pCMV-V5::LRH-
1 WT or pCMV-V5::LRH-1 K289R, pCMV::PIAS3, and/or pcDNA-HA::SUMO-1-HA. Mean ± s.e.m., 
**p<0.01, ***p<0.001. Adapted from (54). 
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Figure 5. LRH-1 gain-of-function 
prevents atherogenesis. (A, B) 
Quantification of atherosclerotic lesions  
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abdominal aortas of Ldlr-/- Lrh-1 K289R 
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Red O to visualize neutral lipids. Scatter 
plot displaying the mean. **p<0.01, 
***p<0.001.  Adapted from (54). 
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We further demonstrated that LRH-1 K289R promotes reverse cholesterol transport, accelerates biliary 
flow, and thus enhances fecal excretion of cholesterol. This enhanced hepatic reverse cholesterol 
transport in LL-K289R mice was a consequence of an increased expression of genes involved in 
cholesterol transport, such as Scarb1, Abcg5 and Abcg8. Moreover, we showed that the increased 
expression of these cholesterol transporters is secondary to a compromised interaction of LRH-1 
K289R with an important transcriptional corepressor, i.e. PROX1. In wildtype mice, LRH-1 interacts 
with PROX1 to transrepress reverse cholesterol transport genes. In LL-K289R mice, the LRH-1-
PROX1 interaction is impaired, leading to an enhanced expression of the cholesterol transporters, and 
thereby promotes the hepatic reverse cholesterol transport (Figure 6) (37, 54). 
	
4.	The	protective	function	of	LRH-1	in	macrophages	
LRH-1 is primarily expressed in organs of the enterohepatic axis (34-37), and its expression is much 
lower in macrophages compared to the liver (54). However, together with colleagues from the 
University of Toulouse we discovered that its expression can be modulated in macrophages according 
to their polarization (55). In fact, stimulation of macrophages with the strong pro-inflammatory 
lipopolysaccharide (LPS) further reduced the expression of Lrh-1 (Nr5a2) to almost undetectable levels 
(Figure 7a). Conversely, stimulation with anti-inflammatory cytokines increased its expression in 
murine and human macrophages (Figure 7a, b), suggesting that LRH-1 could play an important 
function in alternative macrophage polarization.  
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protection by LRH-1. 
Scheme illustrating how 
LRH-1 regulates central 
hepatic functions, 
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metabolism and reverse 
cholesterol transport, and 
glucose sensing. Adapted 
from (37). 
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Figure 7. Lrh-1 expression is induced in interleukin 13 (IL-13)-stimulated macrophages. Mouse (a) and 
human (b) macrophages were stimulated with the indicated endotoxin or cytokines. Mean ± s.e.m., *p<0.05, 
**p<0.01. Adapted from (55). 
Further experiments demonstrated that STAT6 regulates the expression of Lrh-1 upon interleukin 13 
(IL-13) treatment (55). Myeloid cell-specific deletion of the nuclear receptor confirmed that LRH-1 plays 
an important role in the regulation of alternative macrophage polarization. The expression of several 
anti-inflammatory (M2 polarization) genes was increased, whereas the expression of various pro-
inflammatory (M1 polarization) genes was reduced in control mice (Lrh-1M+/+) treated with IL-13 (Figure 
8). Importantly, these transcriptional effects were lost myeloid cell-specific Lrh-1 knockout (Lrh-1M-/-) 
mice (Figure 8) (55). 
 
Figure 8. LRH-1 promotes alternative macrophage polarisation. Expression of pro- or anti-inflammatory 
genes in IL-13 stimulated peritoneal macrophages from myeloid cell-specific Lrh-1 knockout (Lrh-1M-/-) or 
control mice (Lrh-1M+/+). Mean ± s.e.m., *p<0.05, **p<0.01 compared to the untreated control, #p<0.05, ##p<0.01 
compared to Lrh-1M+/+ stimulated with IL-13. Adapted from (55). 
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Further experiments revealed that LRH-1 regulates the expression of two cytochrome… genes, i.e. 
Cyp1a1 and Cyp1b1. The transcriptional regulation of these genes by LRH-1 was confirmed in 
luciferase reporter assays combined with site-directed mutagenesis (Figure 9). These two cytochrome 
P450-family enzymes convert arachidonic acid (AA) into 15-hydroxyeicosatetraenoic acid (15-HETE), 
an endogenous PPARg activator, which in turn mediates the downstream polarization effects of LRH-
1 (55). Our collaborators could further demonstrate that this pathway plays a protective antifungal 
function upon Candida albicans infection in mice (55). 
 
5.	The	deleterious	role	of	LRH-1	in	liver	steatosis	
The two previous studies presented in this cumulative thesis showed that LRH-1 exerts protective 
effects in the liver in the context of atherosclerosis development, and in macrophages to activate anti-
inflammatory pathways. Other previous studies demonstrated that hepatic LRH-1 also regulates 
glucose and lipid metabolism, and activation of LRH-1 with the ligand phospholipid 
dilauroylphosphatidylcholine (DLPC) protected insulin resistant mice against hepatic steatosis and 
improved glucose homeostasis (45, 56-58). Since DLPC exerted these beneficial effects in the liver, 
we were wondering if the same would be observed in our gain-of-function mouse model. Therefore, 
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we performed a series of studies to assess the role of nonSUMOylatable LRH-1 K289R in de novo 
lipogenesis and fatty liver development. 
The best way to study de novo lipogenesis in mice is to fast them for a prolonged period and then refed 
them for few hours prior to analysis. During the fasting period the hepatic de novo lipogenesis process, 
including the transcription of various lipogenesis gene and their enzymatic function, is shut down. Upon 
refeeding this process is then quickly reactivated at both transcriptional and posttranslational level (59). 
We used two experimental groups to analyze de novo lipogenesis: the ‘fasted’ group was fasted for 24 
hours, and the ‘refed’ group was fasted for 18 hours and then refed for 6 hours (Figure 10A) (60). 
We performed these fast-refeeding experiments with both the Lrh-1 WT and Lrh-1 K289R mice. 
Notably, we observed that the posttranslational cleavage and activity of sterol regulatory element 
binding transcription factor 1 (SREBP-1) was strongly increased in Lrh-1 K289R compared to Lrh-1 
WT mice (Figure 10B, C). SREBP-1 is a master regulator of de novo lipogenesis genes and it is 
activated upon posttranslational cleavage by specific endopeptidases at the Golgi apparatus, thereby 
rendering a transcriptionally active protein that migrates to the nucleus and activates target gene 
expression (61). 
 
Figure 10. LRH-1 K289R affects the posttranslational processing of SREBP-1. (A) Experimental setup 
displaying the fasted and refed mouse groups. (B)  Western blot of SREBP-1, P62, SCD1, and HSP90 on hepatic 
lysates from fasted or refed Lrh-1 WT or K289R mice. (C) Heatmap of the microarray expression analysis of 
SREBP-1 and SREBP-2 target genes. Log2 scale. n.s., not significant, for all other transcripts p<0.05. Adapted 
from (60). 
We also assessed if the increased processing and activity of SREBP-1 drives de novo lipogenesis in 
vivo. Staining of liver section with Oil-red O and analysis of hepatic triglyceride content displayed 
increased lipid content in the liver of Lrh-1 K289R compared to Lrh-1 WT mice (Figure 11A, B). 
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Furthermore, the fractional de novo synthesis of different fatty acids was also enhanced in Lrh-1 K289R 
mice (Figure 11C-E), while the chain elongation of preexisting fatty acids was not altered (60). 
 
Figure 11. Lrh-1 K289R mice display increased de novo lipogenesis. (A) Representative Oil-red O stained 
liver sections from Lrh-1 WT or K289R mice. (B) Quantification of hepatic triglcerides in Lrh-1 WT or K289R 
livers. (C-E) Fractional de novo synthesis of palmitate (C), stearate (D), and oleate (E) in Lrh-1 WT or K289R 
mice. Mean ± s.e.m., *p<0.05, **p<0.01 relative to Lrh-1 WT. §p<0.001 relative to fasted mice. Adapted from 
(60). 
In order to identify the link between LRH-1 (a transcriptional factor that is only localized in nuclei) and 
SREBP-1 (whose processing happens at the ER and Golgi apparatus), we analyzed transcriptomic 
data to identify hits that could affect SREBP-1 processing. In this manner we identified oxysterol 
binding protein-like 3 (OSBPL3), a member of a lipid transfer protein family that transfers lipids between 
the plasma and endoplasmic reticulum membrane (62-64). The expression of OSBPL3 was strongly 
increased at mRNA and protein level in Lrh-1 K289R compared to Lrh-1 WT livers (Figure 12A-D), and 
we further revealed that Osbpl3 is a direct LRH-1 target gene (60). Consistently, others reporter that 
the expression of Osbpl3 is strongly reduced in mice with hepatic Lrh-1 deficiency (65).  Moreover, by 
using in vivo Osbpl3 silencing or overexpression approaches we demonstrated that the processing of 
SREBP-1 was altered, suggesting that the LRH-1-OSBPL3 axis induces SREBP-1 maturation and de 
novo lipogenesis (60). 
To assess the role of LRH-1 K289R in a chronic NAFLD model, we treated mice with a high-fat high 
sucrose (HFHS) diet for 17 weeks. Interestingly, Lrh-1 K289R mice developed a stronger fatty liver 
phenotype compared to Lrh-1 WT livers (Figure 13A), which was associated with increased hepatic 
expression levels of OSBPL3 and enhanced plasma levels of alanine transaminase (ALAT) and 
aspartate aminotransferase (ASAT) (Figure 13B-D). 
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Figure 12. LRH-1 K289R affects the posttranslational processing of SREBP-1. (A) Heatmap of the 
microarray expression analysis of oxysterol-binding protein family members. Log2 scale. (B-D) Expression of 
Osbpl3 mRNA (B, C), and Western blot of OSBPL3 and HSP90 on hepatic lysates from fasted or refed Lrh-1 
WT or K289R mice. Mean ± s.e.m., *p<0.05, §p<0.01. Adapted from (60). 
To evaluate if OSBPL3 could also play a role in NAFLD in humans, we analyzed OSBPL3 expression 
levels in different human NALFD and NASH studies, including a human study that was undertaken to 
compare patients with mild versus advanced NAFLD (66). Interestingly, the expression OSBPL3 
clearly increased in patients with advanced NAFLD and tightly clustered with markers of fibrosis (Figure 
14). 
 
Figure 13. LRH-1 K289R affects the posttranslational processing of SREBP-1. (A) Representative liver 
sections of Lrh-1 WT or K289R mice with the indicated staining. (B) Western blot of OSBPL3 on hepatic lysates 
Lrh-1 WT or K289R mice. (C, D) Plasma levels of ALAT and ASAT in Lrh-1 WT or K289R mice. Mean ± s.e.m., 
**p<0.01, ***p<0.001. Adapted from (60). 
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This study highlighted that the LRH-1-OSBPL3-SREBP-1 axis play a significant function in de novo 
lipogenesis and the development of NALFD in mice, and suggests that the same pathway might also 
be relevant in humans with NAFLD. 
 
Figure 14. LRH-1 K289R affects the posttranslational processing of SREBP-1. Heatmap of the microarray 
expression analysis of OSBPL3 and markers of inflammation and fibrosis in mild and advanced NAFLD patients. 
Log2 scale. Adapted from (60), raw data from (66). 
6.	The	detrimental	contribution	of	LRH-1	to	hepatocellular	
carcinoma	
Besides regulating glucose and lipid metabolism, LRH-1 also coordinates cell proliferation and cancer 
development in the intestine and pancreas (67-70). These findings raised the question about its 
contribution in liver cancer development. Since earlier studies suggested that LRH-1 would act as an 
oncogene, we primarily analyzed the development of hepatic cancer in mice lacking Lrh-1 specifically 
in the liver (Lrh-1hep-/- mice) (57). We treated the mice with diethylnitrosamine (DEN), a chemical that 
is known to induce hepatocellular carcinoma in experimental animal models (71). 
Upon DEN treatment control wildtype Lrh-1hep+/+ mice developed many and large hepatic tumors 
(Figure 15A-C). Conversely, Lrh-1hep-/- mice developed markedly less liver tumors upon DEN treatment 
(Figure 15A-C). Moreover, analysis of the transcriptome of the livers from both genotypes, revealed 
that the expression of several genes involved in the metabolism of amino acids and derivatives was 
strongly downregulated in Lrh-1hep-/- mice (Figure 15D) (72). 
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Figure 15. Hepatic deletion of Lrh-1 protects against DEN-induced liver cancer. (A) Experimental setup 
displaying the injection time of DEN and assessment of the phenotype at 6 and 10 moths of age. (B) 
Representative images of livers from 10-month-old Lrh-1hep-/- and Lrh-1hep+/+ mice. (C) Total tumor count (left 
side) and tumor size distribution (right side) from 10-month-old Lrh-1hep-/- and Lrh-1hep+/+ mice. (D) Heatmap of 
the microarray expression analysis from genes involved in metabolism of amino acids and derivatives. Log2 
scale. Mean ± s.e.m., *p<0.05, **p<0.01, ***p<0.001. Adapted from (72). 
Cancer cells alter several metabolic processes to promote tumor development and progression. One 
common phenomenon if the switch from an oxidative to a glycolytic metabolic state (73). During this 
transition glucose is converted into lactate instead of entering the tricarboxylic acid (TCA) cycle. As a 
consequence, cancer cells rely more on glutamine to refill TCA cycle intermediates (74, 75). Such a 
‘refilling’ of intermediates of a metabolic pathway is termed anaplerosis (73). 
Subsequent characterization of Lrh-1hep-/- and Lrh-1hep+/+ mice, combined with a series of in vitro 
experiments and in vivo glutamine flux analysis, revealed that LRH-1 is a direct transcriptional activator 
of glutaminase 2 (Gls2), and consequently controls glutamine-induced anaplerosis, regulates mTOR 
pathway activity, and induces cell proliferation (72).  
In line with these finding, shRNA mediated silencing of Lrh-1 or Gls2 in Hepa 1.6 cells induced 
significantly less tumor growth after injection into athymic nude mice (Figure 16A). Taken together, 
these experiments demonstrated that LRH-1 plays a critical role in glutamine processing and has a 
striking impact on hepatocellular cancer development in mice (Figure 16B). 
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Figure 16. The LRH-1-GLS2 axis promotes tumor development. (A) Tumor development in athymic nude 
mice injected with Lrh-1 or Gls2-silenced Hepa 1.6 cells. (B)  Model displaying how the LRH-1-GLS2 axis 
promotes glutamine-induced anaplerosis, cell growth and proliferation. Mean ± s.e.m., **p<0.01. Adapted from 
(72). 
7.	The	protective	function	of	SIRT7	in	hepatic	steatosis	
SIRT7 is a member of the family of sirtuins deacetylases that is primarily localized in the nucleus. In 
collaboration with Dongryeol Ryu, Young Suk Jo, Giuseppe Lo Sasso, Johan Auwerx, and other 
colleagues, we studied the metabolic function of SIRT7. Interestingly, we could demonstrate that 
whole-body Sirt7 knockout mice displayed a dysmorphic phenotype, including cardiac dysfunction, 
reduced exercise performance, hepatic microvesicular steatosis, and age-related hearing loss (76). To 
verify if these functions also occur upon targeted deletion of Sirt7 in specific tissues, we generated and 
phenotyped a liver-specific knockout mouse line. Consistently with the whole-body Sirt7 knockout, the 
liver-specific knockout mice developed liver microvesicular steatosis, which is characterized by 
excessive triglyceride accumulation (Figure 17A-C) (76). 
 
Figure 17. Liver-specific deletion of Sirt7 promotes hepatic steatosis. (A) Quantification of hepatic 
triglycerides in 55-week-old male Sirt7hep+/+ (white dots) or Sirt7hep-/- (red squares) mice. (B, C) Representative 
hematoxylin & eosin (B), and Oil Red O staining (C). Mean ± s.e.m., **p<0.01. Adapted from (76). 
Liver-specific Sirt7 knockout mice had an impaired expression of several important nuclear-encoded 
mitochondrial proteins, which led to a reduction in mitochondrial oxidative phosphorylation (OXPHOS) 
complex formation and oxygen consumption rate (OCR) (Figure 18A-C) (76). 
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Figure 18. Liver-specific deletion of Sirt7 leads to mitochondrial dysfunction. (A) Western blot analysis 
showing SIRT7, MRPL49, various OXPHOS subunits, and TOM40 in liver of Sirt7hep+/+ and Sirt7hep-/-. (B) Blue 
native-PAGE of hepatic OXPHOS complexes. (C) OCR of liver lysates from 42-week-old male Sirt7hep+/+ and 
Sirt7hep-/- mice. (n = 5 per group).  Mean ± s.e.m., *p<0.05, **p<0.01. Adapted from (76). 
All these phenotypes are related to mitochondrial dysfunction. Indeed, our data showed that SIRT7 
deacetylates distinct lysine residues of GA repeat binding protein beta 1 (GABPβ1), a master regulator 
of nuclear-encoded mitochondrial genes. Therefore, genetic deletion of Sirt7 enhances multisystemic 
mitochondrial dysfunction (76). Of note, the precise function of this important sirtuin in atherosclerosis 
has not yet been studied and/or published. 
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8.	Conclusions	and	perspectives	
The central function of transcriptional complexes in chronic immunometabolic 
diseases 
The field of immunometabolic regulation in chronic inflammatory diseases got substantial attention in 
the last years (77-85). The research studies presented here – as well as my previous and ongoing 
studies – clearly demonstrate that transcription factors and cofactors play a central role in 
(i) integrating the information from upstream intracellular signaling pathways, 
(ii) coordinating the expression of target genes, 
(iii) regulating the downstream response of the cell, 
(iv) and thereby affecting the development of chronic inflammatory diseases, such as 
atherosclerosis and NAFLD (54, 55, 60, 76, 86-90). 
Several of the transcriptional regulators that I studied in the past were known to affect metabolic 
processes, such as the LRH-1, SIRT1, and PGC-1a. Interestingly, our studies demonstrated that these 
factors also affect inflammatory pathways in different organs and tissues. For examples, we showed 
that the SIRT1 mediates immunometabolic functions in endothelial cells, macrophages, and the liver 
by deacetylating and thereby suppressing the NF-kB signaling pathway and by regulating hepatic 
proprotein convertase subtilisin/kexin type 9 (PCSK9) expression (86-89). The work shown here 
indicates how LRH-1 regulates central metabolic and inflammatory processes in the liver and 
macrophages, thereby affecting the development of atherosclerosis, NAFLD, liver cancer, and fungal 
infection (37, 54, 55, 60, 72). 
In conclusion, these studies demonstrated that specific transcriptional complexes, consisting of 
transcription factors and cofactors, exert a central function to integrate upstream information and 
regulate the expression of downstream target genes, and thereby act as central immunometabolic 
regulators. While the role of many transcription factors is well described, we know much less about 
transcription cofactors. About 300 transcription cofactors are known to exist in mice and human cells 
(91). However, only a fraction of those is expressed in a specific cell type or tissue, and their function 
is restricted to certain pathways and transcription factors (11, 12). Some of these factors are involved 
in inflammatory mechanisms, others known to exert metabolic functions. The identification of 
transcriptional regulators that exert important immunometabolic functions in chronic diseases, such as 
atherosclerosis and nonalcoholic fatty liver disease, will be a major focus of my future research. 
LRH-1 as a therapeutic target 
Our study revealed that gain-of-function of LRH-1 prevented the development of atherosclerosis in an 
atherosclerosis-prone mouse model, but promoted hepatic steatosis in a dietary NAFLD model (54, 
60). Moreover, hepatic deletion of Lrh-1 led to a clear protection against the development of 
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hepatocellular carcinoma (72). The identification of small molecule agonists and antagonists as well 
as the discovery that specific phospholipid species act as endogenous agonists of LRH-1 (45, 92-94), 
suggest that the receptor could be a bona fide druggable target. Activation of LRH-1 with small 
molecule agonists could be beneficial to promote reverse cholesterol transport and biliary cholesterol 
excretion to prevent atherosclerosis development (Figure 19) (38, 54, 95) as well as to treat diabetes 
(45, 56). An alternative would be the development of drugs that activate specific isopeptidases that 
remove the SUMO peptide from LRH-1, thereby increasing its transcriptional activity (49, 52, 54, 60, 
96, 97). On the other side, inhibition of hepatic LRH-1 might be a therapeutic approach to prevent the 
development of NAFLD and hepatic cancer (Figure 19). Future studies will be necessary to: 
- Describe the mechanistic difference leading to these unexpected and controversial phenotypes, i.e. 
atherosclerotic protection on one side and the potential development of NAFLD on the other side. For 
instance, it was demonstrated that specific phospholipid species may act as endogenous LRH-1 
activators (45). A different content and composition of these phospholipids in the different diets could 
lead to protective effects in one disease model, while promote the progression of another model. 
- To reveal the impact of pharmacological LRH-1 modulation using specific LRH-1 agonist and/or 
antagonist on these diseases and analyze potential adverse effects (92-94, 98, 99). 
Figure 19. Potential therapeutic applications by modulating LRH-1 function. Scheme illustrating the (A) 
beneficial anti-atherogenic effect that could be driven by pharmacological LRH-1 activation, and (B) the 
protective effects on NAFLD and liver cancer that could be mediated via LRH-1 inhibition. 
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SUMMARY
Reverse cholesterol transport (RCT) is an antiathero-
genicprocess inwhichexcessivecholesterol frompe-
ripheral tissues is transported to the liver and finally
excreted fromthebodyvia thebile.Thenuclear recep-
tor liver receptorhomolog1 (LRH-1) drivesexpression
of genes regulating RCT, and its activity can bemodi-
fiedbydifferentposttranslationalmodifications.Here,
we show that atherosclerosis-prone mice carrying
a mutation that abolishes SUMOylation of LRH-1 on
K289R develop less aortic plaques than control litter-
mates when exposed to a high-cholesterol diet. The
mechanism underlying this atheroprotection involves
an increase in RCT and its associated hepatic genes
and is secondary to a compromised interaction of
LRH-1 K289R with the corepressor prospero homeo-
box protein 1 (PROX1). Our study reveals that the
SUMOylation statusof a single nuclear receptor lysine
residue can impact the development of a complex
metabolic disease such as atherosclerosis.
INTRODUCTION
Atherosclerosis is a disease characterized by excessive
cholesterol accumulation in vessel walls. It evolves from a com-
plex interplay between hypercholesterolemia, dyslipidemia, and
chronic inflammation and encompasses several tissues and
organs (Weber and Noels, 2011). Rupture of an atherosclerotic
plaque may lead to a myocardial infarction or stroke, two of
the primary causes ofmorbidity andmortality in theworld (Weber
and Noels, 2011).
Liver receptor homolog 1 (LRH-1 or NR5A2) is a member of the
NR5A subfamily of nuclear receptors (NRs) that binds as amono-
mer to its response elements (Fayard et al., 2004). The transcrip-
tional activity of LRH-1 is governed by multiple factors, including
the binding of ligands and posttranslational modifications, which
together define its interaction with transcriptional coregulators
(Fernandez-Marcos et al., 2011; Lee and Moore, 2008). LRH-1
is highly expressed in tissues of the enterohepatic axis, where it
has diverse molecular and physiological functions (Fayard et al.,
2004) ranging from local glucocorticoidproduction in the intestine
(Coste et al., 2007) to glucose sensing in the liver (Oosterveer
et al., 2012). Interestingly, one of the first described LRH-1 target
genes is scavenger receptor B type 1 (Scarb1) (Schoonjans et al.,
2002), a gene that is expressed in many tissues and plays
important functions in reverse cholesterol transport (RCT), an
antiatherogenic process in which excessive cholesterol from
peripheral tissues is transported to the liver and finally excreted
via the bile (Rosenson et al., 2012). Although several other LRH-
1 target genes involved in cholesterol metabolism have been
identified, including carboxl ester lipase (Cel) (Fayard et al.,
2003), ATP binding cassette member subfamily G5 (Abcg5),
Abcg8 (Freeman et al., 2004), and apolipoprotein M (Apom)
(Venteclef et al., 2008), so far no study has demonstrated that
LRH-1 activity is critical for proper RCT or atherogenesis.
LRH-1 is targeted for SUMOylation by E3-SUMO ligases at
several lysine residues, and this conserved reversible posttrans-
lational modification affects its transcriptional activity (Chalkia-
daki and Talianidis, 2005; Lee et al., 2005; Talamillo et al.,
2013; Venteclef et al., 2010; Ward et al., 2013). SUMOylation of
human LRH-1 is considered to attenuate its transcriptional activ-
ity, yet the mechanistic basis underlying this repression is poorly
understood. Although one study reported that the SUMOylated
form of LRH-1 is sequestered into promyelocytic leukemia
(PML) protein bodies (Chalkiadaki and Talianidis, 2005), another
study proposed that SUMO modification of LRH-1 stabilizes the
recruitment of the transcriptional nuclear receptor corepressor 1
and histone deacetylase 3 (NCoR1/Hdac3) corepressor complex
through its association with G protein pathway suppressor 2
(GPS2) (Venteclef et al., 2010).
In this study, we demonstrate that mice carrying a mutation on
lysine 289 of LRH-1 (Lrh1 K289R mice) display reduced LRH-1
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SUMOylation and increased expression of genes regulating
cholesterol transport. When crossbred to atherosclerosis-prone
low-density lipoprotein receptor (Ldlr) knockout mice, Ldlr/
Lrh-1 K289R mice show improved RCT and diminished athero-
sclerosis development in comparison to control mice. Mechanis-
tically, this effect is attributed to the specific loss of interaction of
the mutated form of LRH-1 with the corepressor PROX1, thereby
increasing the expression of LRH-1 target genes involved in RCT.
RESULTS
Non-SUMOylatable LRH-1 K289R Displays Increased
Transcriptional Activity In Vitro
The murine LRH-1 protein has several lysine (K) residues that
could be SUMOylated. They are located in the DNA binding
domain, hinge region, or ligand binding domain (Figure 1A). On
the basis of previous studies (Lee et al., 2005), we mutated the
most relevant K residues to non-SUMOylatable arginines (R)
and analyzed their potential to trans-activate a heterologous
LRH-1 reporter by transient transfection assays (Figure 1B).
Interestingly, the K289R mutation displayed the highest tran-
scriptional activity, whereas the remaining K mutations (K173R,
K213R, or K329R) had neither an effect as single mutations nor
an additive effectwhenmutated together with K289R (Figure 1B).
Next, we analyzed whether the enhanced activity of LRH-1
K289R was also associated with a reduction in the SUMOylation
status. Human embryonic kidney 293T (HEK293T) cells trans-
fected with either LRH-1 wild-type (WT) or LRH-1 K289R were
cotransfected with either PIAS3 SUMO ligase alone or in combi-
nation with SUMO-1 substrate. Basal LRH-1 WT SUMOylation
was clearly detectable, whereas it was nearly undetectable
in LRH-1 K289R (Figure 1C). Cotransfection with PIAS3 and
SUMO-1 slightly increased SUMOylation of LRH-1 WT (Fig-
ure 1C). Notably, LRH-1 K289R SUMOylation remained low after
PIAS3 and SUMO-1 cotransfection, showing that mutating a sin-
gle K residue can affect the total SUMOylation status of the tran-
scription factor (Figure 1C). Moreover, cotransfection of LRH-1
WT or LRH-1 K289R with the isopeptidase sentrin/SUMO-spe-
cific protease 1 (SENP1) efficiently removed the SUMO modifi-
cation from only LRH-1 WT (Figure 1D). The SUMO acceptor
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Figure 1. Non-SUMOylatable LRH-1 K289R Displays Increased Reporter Activity and Impaired SUMOylation In Vitro
(A) Schematic overview of LRH-1 highlighting the lysine residues that were mutated. DBD, DNA binding domain; FTZ, fushi tarazu homology domain; LBD, ligand
binding domain; AF2, activation function 2 domain.
(B) Luciferase assay performed in HEK293T cells that were cotransfected with a pGL3::(LRHRE)5-TK-LUC and a pCMV plasmid coding for LRH-1 WT or the
outlined mutant constructs. n = 3. The experiment was replicated three times.
(C) Immunoprecipitation of V5-tagged LRH-1 to detect the SUMOylated band of LRH-1 (arrowheads). HEK293T cells were transfected with pCMV-V5::LRH-1WT
or pCMV-V5::LRH-1 K289R, pCMV::PIAS3, and/or pcDNA-HA::SUMO-1-HA. The experiment was replicated at least three times.
(D) Immunoprecipitation of V5-tagged LRH-1 to detect the SUMOylated band of LRH-1 in HEK293T cells that were transfected with pCMV-V5::LRH-1 (WT or
K289R) and pCMV-FLAG::SENP1. The experiment was replicated at least three times.
(E) Residues adjacent to K289 are required for SUMOylation and function of LRH-1 activity. Luciferase assay was performed in HEK293T cells that were
cotransfectedwith a pGL3::(LRHRE)5-TK-LUC and pCMVplasmid coding for LRH-1WT or the outlinedmutant constructs. n = 3 from three separate experiments.
(F) Immunoprecipitation of V5-tagged LRH-1 to detect SUMOylation of the different mutant constructs used in (E).
Data are represented as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 relative to Lrh-1 WT, as determined by ANOVA and Bonferonni post hoc or Student’s
t test. Arrowheads, LRH-1*SUMO-1 band; x, short exposure; z,long exposure.
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motif J-K-x-E is found in many SUMOylated proteins. Although
the lysine residue can be targeted for SUMOylation, the adjacent
hydrophobic (J) and acidic glutamate (E) residues are also
necessary tomediate the conjugation with the SUMOE2 enzyme
Ubc9 (Bernier-Villamor et al., 2002). Mutation of these two sites
(I288A and E291V) also increased LRHRE-driven reporter activ-
ity (Figure 1E) and reduced LRH-1 SUMOylation (Figure 1F),
showing that not only the lysine but also an intact SUMOacceptor
motif is crucial for the SUMO-dependent function of LRH-1.
LRH-1 K289R Activates Selected Target Genes In Vivo
To understand the relevance of this particular SUMO acceptor
lysine residue, we carried out comparative alignment studies.
Alignment of the amino acids surrounding the murine LRH-1
K289 with other species demonstrated that this particular
SUMO acceptor motif is highly conserved in vertebrates but
not in the chordate lancelet (Branchiostoma floridae), sea urchin
(Strongylocentrotus purpuratus), fruit fly (Drosophila mela-
nogaster), or roundworm (Caenorhabditis elegans; Figures 2A;
Figure S1A available online). However, homologous proteins in
C. elegans and D. melanogaster have other sites that can be tar-
geted for SUMOylation (Talamillo et al., 2013; Ward et al., 2013).
Next, we compared the murine LRH-1 protein sequence with
other monomeric NRs with special focus on the highly variable
and intrinsically disordered hinge region (Krasowski et al.,
2008). Besides the close homolog NR5A1 (SF-1), only the reti-
noic-acid-receptor-related orphan receptors (RORs:NR1F1,
NR1F2, and NR1F3) displayed somewhat homologous hinge
regions (Figure S1B). Closer alignment of LRH-1 with NR5A1
and the three RORs showed that only NR1F1 and NR1F2 contain
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Figure 2. The LRH-1 SUMOAcceptorMotif Is Conserved in Vertebrates, andMutation of Its Lysine Triggers Activation of Cholesterol Homeo-
stasis Genes In Vivo
(A) Alignment of the amino acid sequence surrounding the murine LRH-1 K289 residue with other species. The blue-lined box highlights the aligned amino acids
homologous to the SUMO acceptor motif, and the gray shading marks the sequences with an intact SUMO acceptor sequence.
(B) Protein alignment of LRH-1 (NR5A2) with other monomeric NR showing conserved sequences surrounding the LRH-1 K289 residue. Green, high homology;
red, low homology.
(C) Overview of the genomic and protein sequence surrounding the K289R mutation. Mutation of a single nucleotide (AAG/ AGG) at genomic level leads to
K289R mutation of the translated protein.
(D) Venn diagram depicting the number of genes that are significantly up- or downregulated in Lrh-1hep/ (n = 8) in comparison to Lrh-1hep+/+ (Oosterveer et al.,
2012) (n = 8) as well as Lrh-1 K289R (n = 7) in comparison to Lrh-1 WT (n = 7) mice.
(E) Heatmap displaying the expression of selected LRH-1 target genes in the corresponding genotypes (n = 4 per genotype).
(F) Hepatic expression of genes that regulate cholesterol homeostasis in Lrh-1 WT (n = 8) and Lrh-1 K289R (n = 9) mice.
Data are represented as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 relative to Lrh-1 WT, as determined by Student’s t test. See also Figures S1
and S2.
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the conserved SUMO acceptor motif (Figure 2B). These bio-
informatic data suggest that SUMOylation of this site is specific
for a very small subset of NRs and highlights the functional
importance of the hinge region in these selected NRs.
To analyze the physiological impact of the K289R mutation on
LRH-1 function in vivo, we generated a knockin mouse line con-
taining the K289R mutation Lrh-1 K289R (Figures 2C and S2A).
The offspring of Lrh-1 K289R breeders were born under normal
Mendelian and sex ratios, and no apparent dysmorphic pheno-
type could be observed in these mice (data not shown). The
mutation did not affect the expression of LRH-1 in the liver in
comparison to Lrh-1 WT and hepatocyte-specific Lrh-1hep+/+
mice (Figure S2B). Then, we performed microarray analyses on
livers in order to compare the transcriptome of hepatocyte-spe-
cific Lrh-1hep/ (Oosterveer et al., 2012) and Lrh-1 K289R mice
to their corresponding controls. Only 57 of the 244 genes
(23.4%) whose expression was decreased in Lrh-1hep/ mice
were induced in Lrh-1 K289R mice (Figure 2D and Table S1).
Several of the established LRH-1 target genes that are reduced
in Lrh-1hep/ mice were oppositely regulated in Lrh-1 K289R
mice (Figure 2E). Intriguingly, most of the selected hepatic
LRH-1 target genes involved in cholesterol metabolism were
increased in Lrh-1 K289R in comparison to Lrh-1 WT mice, as
determined by qPCR analyses (Figure 2F). Although hepatic
expression of Cyp8b1 was nearly absent in hepatocyte-specific
Lrh-1hep/mice (Mataki et al., 2007), it was onlymildly enhanced
in Lrh-1 K289Rmice (Figure 2F). This was reflected in the compo-
sition of bile acids in the gallbladder. Although the total bile acid
content did not differ, Lrh-1 K289R mice had slightly increased
tauro-conjugated cholic acid (tCA) and less tauro-conjugated
muricholic acid (tMCA) (Figure S2C). Altogether, these data
show that LRH-1 K289R exhibits increased transcriptional activ-
ity on a selected subset of LRH-1 target genes and cannot be
described as a global constitutive active LRH-1 form.
LRH-1 K289R Protects against Atherosclerosis
Development
Given that many of the genes affected in Lrh-1 K289R mice are
involved in cholesterol homeostasis, we hypothesized that
LRH-1 K289Rmay affect cholesterol metabolism, and hence hy-
percholesterolemia-driven diseases, such as atherosclerosis. To
study the role of LRH-1 K289R in atherosclerosis, we crossbred
Lrh-1 WT and Lrh-1 K289R mice to atherosclerotic-prone Ldlr
knockout mice in order to generate Ldlr/ Lrh-1 WT (LL-WT)
or Ldlr/ Lrh-1 K289R (LL-K289R) mice. Then, 8-week-old LL-
WT or LL-K289R mice were subjected to a high-cholesterol
diet (HCD) for 14 weeks. Body and liver weight (Figures S3A
and S3B), and also gross morphology of other organs, were
similar between the different genotypes (data not shown).
Notably, en face plaque analyses of the thoraco-abdominal aorta
demonstrated that LL-K289R mice developed significantly less
atherosclerotic plaques than LL-WT mice and also accumulated
less cholesterol in their aortas (Figures 3A–3C). Advanced pla-
que analyses of the aortic sinus stained for collagen imaging
revealed no changes in necrotic core size, cap thickness, or
collagen content in LL-K289R in comparison to LL-WT mice
(Figures S3C–S3E). Total plasma cholesterol did not differ be-
tween the mice, and plasma triglyceride levels were only slightly
reduced before administering the HCD andwere not significantly
changed upon HCD feeding (Figures S3F and S3G). Although no
changes in triglyceride content were observed in the lipoprotein
fractions, a small reduction in the cholesterol content of the
low-density lipoprotein subfraction of LL-K289R mice could be
noticed (Figures S3H and S3I). Furthermore, hepatic triglyceride
content was not changed in overnight fasted LL-K289R mice,
whereas cholesterol content was only slightly increased (Fig-
ure 3D). Stainings of liver cryosections showed no apparent dif-
ference in neutral lipid content and cellular morphology between
the two genotypes (Figure 3E). These data demonstrate that
LL-K289R mice develop less atherosclerosis, possibly as a
consequence of improved RCT.
To assess a potential contribution of macrophages in the
observed phenotype, we measured Lrh-1 in isolated thioglyco-
late-elicited peritonealmacrophages. In comparison to its expres-
sion in the liver, Lrh-1 was barely detectable in macrophages
under the conditions analyzed (Figure S4A; bioGPS Lrh-1 expres-
sion pattern, http://biogps.org/#goto=genereport&id=26424).
Furthermore, treatment with acetylated LDL (acLDL) to trigger
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Figure 3. LRH-1 K289R Protects against
Atherosclerosis Progression
(A) Quantification of aortic plaque area in Ldlr/
Lrh-1 WT (LL-WT) or Ldlr/ Lrh-1 K289R (LL-
K289R) mice. n = 11 per genotype.
(B) Quantification of the cholesterol content in
aortic lipid extracts of LL-WT (n = 9) and LL-K289R
(n = 8) mice.
(C) Representative aortas of LL-WT and LL-K289R
mice stained with Oil-Red O.
(D) Quantification of cholesterol and triglyceride
contents in hepatic lipid extracts of LL-WT and
LL-K289R mice. n = 6 per genotype.
(E) Representative images of hematoxylin and
eosin and Oil-Red O (ORO) staining of hepatic
sections of LL-WT and LL-K289R mice. The white
scale bar represents 200 mm, and the black scale
bar represents 50 mm.
Data are represented as means ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.001 relative to LL-WT, as
determined by Mann-Whitney U or Student’s
t tests. See also Figure S3.
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foam cell formation or lipopolysaccharide (LPS) in order to eval-
uate the inflammatory response did not trigger any significant
difference in acetylated LDL accumulation, Scarb1 expression,
or inflammatory markers between Lrh-1 WT and K289R macro-
phages (Figures S4B–S4H), suggesting that the effects on aortic
lipid accumulation are not likely related to differential macrophage
function.
LRH-1 K289R Protects against Atherosclerosis by
Promoting RCT
Intrigued by the marked decrease of atherosclerotic lesions in
LL-K289R mice and the increased expression of genes involved
in hepatic cholesterol homeostasis in Lrh-1 K289R mice (Fig-
ure 2F), we analyzed the expression of genes involved in RCT
in the liver. Notably, hepatic expression of Abca1, Abcg5,
Abcg8, Apoe, and Scarb1 was significantly increased in LL-
K289R in comparison to LL-WT mice (Figure 4A). Given that
many of these genes are also expressed in the intestine
and contribute to whole-body cholesterol homeostasis, we
analyzed their expression pattern in the duodenum, jejunum,
and ileum. Surprisingly, none of these transcripts was
increased in any of the three intestinal sections (Figure 4B).
Moreover, microarray analyses of jejunal sections from Lrh-1
K289R and Lrh-1 WT mice did not display differential expres-
sion of cholesterol and lipoprotein regulators that are ex-
pressed in livers and intestine (Figure S4I), indicating that
LRH-1 K289R specifically induces the expression of cholesterol
transport regulators in the liver.
To analyze whether the increased expression of RCT genes
has physiological consequences, we performed in vivo macro-
phage-to-feces RCT and biliary flux studies. In vivo RCT analysis
was performed by injecting peritoneal macrophages that were
loaded with [3H]-cholesterol (3H tracer) ex vivo into recipient
LL-K289R and LL-WT mice. 3H-tracer counts were significantly
increased in the fecal cholesterol fraction of LL-K289R in com-
parison to LL-WT mice, whereas no major differences were
observed in the fecal bile acid pool or the plasma, hepatic, or
biliary pools (Figures 4C–4H). Furthermore, gallbladder cannula-
tion revealed that bile flow was increased in LL-K289R in com-
parison to LL-WT mice (Figure 4I). In line with the increased
bile flow, biliary cholesterol, bile acids, and phospholipids excre-
tion were also enhanced in LL-K289R in comparison to LL-WT
mice (Figures 4J–4L). These data establish LRH-1 K289R as a
potent mediator of bile secretion and RCT in vivo.
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Figure 4. Improved Reverse Cholesterol Transport and Biliary Sterol Excretion in LL-K289R Mice
(A) Hepatic expression of genes affecting cholesterol metabolism in LL-WT and LL-K289R mice. n = 9 per genotype.
(B) Intestinal expression of genes affecting cholesterol metabolism in LL-WT and LL-K289R mice. Duod, duodenum; Jejun, jejunum. n = 9 per genotype.
(C–H) LL-WT and LL-K289Rmice were injected with 3H-cholesterol loaded LL-WTmacrophages. Detection of 3H-tracer in plasma (C), fecal cholesterol (Chol; D),
fecal bile acids (BA; E), liver (F), bile cholesterol fraction (G), and bile BA fraction (H). n = 10 LL-WT; n = 12 LL-K289R.
(I–L) Bile excretion (I) and biliary secretion rates of Chol (J), BA (K), and phospholipids (PL; L). n = 10 per genotype.
Data are represented as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 relative to LL-WT, as determined by Mann-Whitney U or Student’s t tests. See also
Figure S4.
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Liver-Specific Lrh-1 Knockout Mice Do Not Develop
Increased Atherosclerosis
Even though the transcriptome and targeted gene expression
analyses argue against Lrh-1 K289R as a simple constitutively
active form of LRH-1 (Figures 2D–2F), we nevertheless explored
whether the hepatocyte-specific Lrh-1hep/micewould yield an
opposite phenotype on RCT and atherosclerosis development.
Therefore, we crossbred hepatocyte-specific Lrh-1hep/ with
Ldlr/ mice in order to generate Ldlr/ Lrh-1hep+/+ (Ld-WT) or
Ldlr/ Lrh-1hep/ (Ld-LKO) mice and fed them an HCD for
12 weeks. Body and liver weight did not differ between the geno-
types (Figures S5A and S5B). Interestingly, Ld-LKO did not
develop more atherosclerotic lesions than Ld-WT mice (Figures
5A and 5B), although the expression of the RCT regulators (Fig-
ure 5C) and binding of LRH-1 to the Abcg5/Abcg8 intergenic
promoter (Freeman et al., 2004) (Figure S5C) was significantly
lower in the Ld-LKO liver. Moreover, in vivo RCT analysis demon-
strated an increased fecal sterol content in Ld-LKO mice, which
could explain why these mice do not develop more atheroscle-
rotic lesions (Figures 5D–5I). The increase of fecal sterols in
Lrh-1hep/mice most likely stems from the compromised intes-
tinal sterol absorption, which was previously reported to be the
consequence of reduced Cyp8b1 in the liver shifting the bile
acid pool toward more hydrophilic bile acids (Figure 5C) (Mataki
et al., 2007; Out et al., 2011).
Compromised Binding of LRH-1 K289R with the
Corepressor PROX1 Derepresses Hepatic RCT Genes
Several corepressors have been reported to fine-tune the activity
of LRH-1 in a context specific manner. In the liver, corepressors
such as small heterodimer partner (SHP or NR0B2) and prospero
homeobox protein 1 (PROX1) as well as the NCOR1/HDAC3
corepressor complex can repress LRH-1 activity (Goodwin
et al., 2000; Lee and Moore, 2002; Lu et al., 2000; Qin et al.,
2004; Venteclef et al., 2010). To test the assumption that LRH-1
SUMOylation affects the interaction of LRH-1with potential core-
pressors, we carried out coimmunoprecipitation experiments in
HEK293T cells transfected with LRH-1 WT or LRH-1 K289R in
the presence of the corepressor SHP, PROX1, or NCOR1. Sur-
prisingly, we observed that the interaction between LRH-1 and
PROX1was lost ormuchweaker when LRH-1 K289Rwas ectop-
ically expressed (Figure 6A), whereas no difference in interaction
was observed with SHP or detected with NCOR1 (data not
shown). This would suggest that optimal PROX1-LRH-1 interac-
tionmay at least require transient SUMOylation of K289 of LRH-1
WT. To assess this possibility, we coexpressed the isopeptidase
SENP1 in order to enzymatically remove SUMO from its
substrates. SENP1 robustly reduced the interaction between
LRH-1 WT and PROX1, supporting the hypothesis that the
SUMOylation status affects the interaction (Figure 6B), which
might be direct or be mediated by a third partner. Interestingly,
the weaker interaction observed between PROX1 and LRH-1
K289R was further reduced by addition of SENP1, suggesting
that other SUMOylatable sites in the protein complex may
enhance the interaction between the two proteins (Figure 6B).
Given that loss of binding to the corepressor PROX1 would pro-
vide a mechanistic basis for explaining the enhanced activity
of LRH-1 K289R, we next explored whether differential Prox1
expression between liver and intestine could explain the absence
of effects on intestinal RCT genes in Lrh-1 K289R mice (Fig-
ure 4B). Interestingly, Prox1 mRNA was almost undetectable
in the small intestine and only marginally expressed in the colon
in comparison to liver (Figure 6C; bioGPS Prox1 expression
pattern, http://biogps.org/#goto=genereport&id=26424), thus
most likely contributing to the differential expression of RCT
genes between liver and intestine.
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Figure 5. Liver-Specific Lrh-1 Knockout Mice Do Not Develop More Atherosclerosis
(A) Quantification of aortic plaque area in Ldlr/ Lrh-1hep+/+ (Ld-WT, n = 12) or Ldlr/ Lrh-1hep/ (Ld-LKO, n = 11) mice.
(B) Representative aortas of Ld-WT and Ld-LKO mice stained with Oil-Red O.
(C) Hepatic expression of genes affecting cholesterol metabolism in Ld-WT and Ld-LKO mice. n = 9 per genotype.
(D–I) Ld-WT and Ld-LKOmice were injected with 3H-cholesterol loaded Ld-WTmacrophages. Detection of 3H tracer in plasma (D), fecal cholesterol (E), fecal BA
(F), liver (G), bile Chol fraction (H), and bile BA fraction (I). n = 13 Ld-WT; n = 10 Ld-LKO.
Data are represented as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 relative to LL-WT, as determined by Student’s t test. See also Figure S5.
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To study the molecular effect of the PROX1-LRH-1 interaction
in more detail, we decided to use primary hepatocytes. Notably,
both Lrh-1 and Prox1 transcripts were reduced to 25% of their
expression in whole livers but were clearly detectable (Fig-
ure S6A). We isolated primary hepatocytes from Lrh-1hep/
mice and infected them with an adenovirus containing
the LRH-1 WT or K289R followed by ectopic expression
of PROX1. Interestingly, while expression of Abcg1 was not
affected or rather increased in cells overexpressing PROX1,
the expression of Scarb1, Abcg5, and Abcg8 was diminished
in cells in which LRH-1 WT, but not LRH-1 K289R, was reconsti-
tuted (Figures 6D and S6B), demonstrating that the repressive
function of PROX1 on LRH-1 activity depends on an intact
LRH-1 K289 SUMOylation site. Furthermore, LRH-1 K289R
failed to bind PROX1 in transfected primary hepatocytes,
whereas LRH-1 WT/PROX1 interaction was intact (Figure 6E),
demonstrating that the LRH-1/PROX1 complex can assemble
in vitro and ex vivo. To assess whether we could mimic the effect
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Figure 6. Compromised Binding of LRH-1 K289R with Prox1 Derepresses Hepatic RCT Genes
(A) LRH-1/Prox1 CoIP in HEK293T cells overexpressing V5-tagged LRH-1 (WT or K289R) and FLAG-tagged Prox1. The experiment was replicated at least three
times.
(B) LRH-1/Prox1 CoIP in HEK293T cells overexpressing V5-tagged LRH-1 (WT or K289R), FLAG-tagged Prox1, and FLAG-tagged SENP1. The experiment was
replicated three times.
(C) Comparative Prox1 expression in liver, duodenum (Duod), jejunum (Jejun), ileum, and colon of LL-WT and LL-K289R mice. n = 9 per genotype.
(D) Expression of Scarb1, Abcg5, Abcg8, Abca1, and Abcg1 in Lrh-1hep/ primary hepatocytes that were infected or transfected with LRH-1 (WT or K289R) and
Prox1. n = 3. The experiment was replicated with three batches of primary cells.
(E) LRH-1/Prox1 CoIP in primary hepatocytes that were infected or transfected with V5-tagged LRH-1 (WT or K289R) and FLAG-tagged Prox1. n = 2 from
independent batches of primary hepatocytes.
(F and G) Effect of overexpression (F) and small-interfering-RNA-mediated silencing (G) of Prox1 in WT primary hepatocytes n = 3. The experiment was replicated
with two batches of primary cells.
(H) Model showing how LRH-1WT and LRH-1 K289R regulate the expression of key genes controlling hepatic cholesterol transport and its consequence on RCT
and atherosclerosis. S, SUMO-1.
Data are represented as means ± SEM. *p < 0.05 and **p < 0.01 relative to non-Prox-1-transfected controls, as determined by Student’s t test. See also
Figure S6.
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of LRH-1/PROX1 interaction in a physiologically relevant cell
model, we next overexpressed or silenced Prox1 in WT pri-
mary hepatocytes. While overexpression of Prox1 reduced the
expression of the RCT regulators (Figure 6F), silencing of Prox1
had the opposite effect (Figure 6G). Altogether, our data suggest
that SUMOylated LRH-1 WT recruits the corepressor PROX1
and hence is unable to selectively activate the transcription of
important cholesterol receptors and transporters (Figure 6H). If
SUMOylation of LRH-1 is defective as in our LRH-1 K289R
mutant, then the PROX1-mediated repression is weakened or
lost, thereby facilitating the induction of RCT genes and dimin-
ishing the progression of atherosclerosis (Figure 6H).
DISCUSSION
Posttranslational modification by SUMO affects the function
of a large number of nuclear proteins, including NRs (Geiss-
Friedlander and Melchior, 2007; Treuter and Venteclef, 2011).
Although various NRs have emerged as reversible SUMO targets
modulating almost every aspect of NR function in cell models,
very few studies have established in vivo functional roles of NR
SUMOylation in health or disease. This is rather surprising given
the prominent role of NRs in the pathogenesis of diseases
and the repressive imprint of SUMOylation on NR activity. In
this study, we have generated a mouse model harboring a
K289R mutation that strongly affects LRH-1 SUMOylation and
function. We demonstrate that loss of SUMOylation by mutating
the critical lysine acceptor site in the LRH-1 protein is sufficient to
protect mice against the development of a chronic metabolic
disease such as atherosclerosis. More importantly, we provide
evidence that the beneficial effect on atherosclerosis is caused
by enhancing the transcription of hepatic RCT genes, such as
Abca1, Abcg5, Abcg8, and Scarb1, without any involvement of
gut- or macrophage-specific RCT genes. These findings are
consistent with a recent study in Drosophila showing that
SUMOylation of the LRH-1 homolog Ftz-f1 affects the expres-
sion of the scavenger receptor Snmp1, which is required for
cellular cholesterol uptake and subsequent steroid synthesis
(Talamillo et al., 2013), suggesting that LRH-1 SUMOylation
may impact on a similar physiologically conserved pathway.
Alignment of the protein sequence of LRH-1with other NRs re-
vealed that, aside from SF-1, only members of the ROR family
have a hinge region that is comparable to that of LRH-1 (Fig-
ure 2B). Although in SF-1, mutation of two conserved SUMO
acceptor lysine residues in the hinge region leads to a striking
developmental phenotype in mice, characterized by inappro-
priate sonic hedgehog signaling and impaired endocrine tissue
development (Lee et al., 2011a), our study shows that disruption
of only one of these conserved SUMO sites in LRH-1 has a sig-
nificant impact on adult homeostasis and protects against the
development of a chronic disease. Surprisingly, SUMOylation
of the homologous motif in RORa seems to activate instead
of repressing its transcriptional activity (Hwang et al., 2009);
however, its physiological properties have not been reported.
These studies collectively indicate that SUMOylation of the hinge
region has profound functional consequences among a very
small subset of NRs.
The mechanistic features by which SUMO modulates the ac-
tivity of NRs vary considerably and can range from interference
with- to promotion of protein-protein interactions or alternatively
competition with other PTMs (Geiss-Friedlander and Melchior,
2007; Jentsch and Psakhye, 2013). Our data suggest a role for
LRH-1 SUMOylation in promoting protein-protein interactions.
This finding is in line with previous studies showing that
SUMOylation of LRH-1 K224, the human lysine residue corre-
sponding to mouse LRH-1 K289, binds to a transcriptional core-
pressor complex consisting of NCOR1, HDAC3, and GPS2 and
regulates the expression of acute phase response genes in hu-
man hepatoma cells (Venteclef et al., 2010). Interestingly, this
study further demonstrated that mouse LRH-1 binding to the
haptoglobin promoter was reduced in Sumo1 knockout in com-
parison to WT livers. In our study, we reveal an unanticipated
mechanism by demonstrating that LRH-1 K289R fails to bind
another corepressor (i.e., PROX1), and we furthermore show
that this impacts on the RCT genes, ultimately leading to
enhanced bile flow and atheroprotection. The study by Venteclef
et al. (2010), along with our work, propose that SUMOylation of a
single K residue of LRH-1 promotes the recruitment of specific
corepressor complexes. Importantly, our data demonstrate
that the effect of LRH-1 SUMOylation depends on tissue-spe-
cific corepressor interaction.
The physiological stimuli and timing that affect LRH-1
SUMOylation in the liver are unknown. In primary granulosa
cells, SUMO-driven sequestration of LRH-1 into nuclear bodies
is abruptly reversed by cAMP and results in the induction
of LRH-1 target genes (Yang et al., 2009). Intriguingly, this is
accompanied by a robust reduction of the Ubc9 and Pias3
genes, which are part of the SUMO conjugation machinery.
Conversely, expression of the SUMO-specific isopeptidase
Senp2 was increased. Although the crosstalk with the cAMP
signaling has not been evaluated in the context of LRH-1
SUMOylation in liver cells, it is tempting to speculate that
different physiological and/or pharmacological cues could
trigger specific posttranslational modifications in LRH-1, which
in turn could recruit specific corepressor complexes.
Several studies have identified natural or synthetic LRH-1 ac-
tivators and inhibitors (Ingraham and Redinbo, 2005). A recent
study has identified the unusual phospholipid dilauroyl phospha-
tidylcholine as an LRH-1 ligand (Lee et al., 2011b). Future studies
should test whether ligand activation, posttranslational modifi-
cations such as SUMOylation, and coregulator recruitment are
interconnected. The tissue and context-specific nature of such
effects may offer an ideal therapeutic window for activating a
receptor and exploit beneficial effects, without causing adverse
effects that are common with NR therapeutics (Marciano et al.,
2014). In this context, it is important to point out that the biolog-
ical effects of LRH-1 K289R cannot be compared to those
induced by a gain-of-function of LRH-1 or by a potential drug
that would enhance the activity of LRH-1 in a broader manner.
In fact, the Lrh-1 K289R mice show increased activation of
selected LRH-1 target genes, whereas other targets are not
affected. The Lrh-1 K289R mice also seem to display no effects
on RCT in the gut, most likely because LRH-1 and PROX-1 are
not coexpressed in the same cells of the crypt-villus epithelium
(Botrugno et al., 2004) or because of the low abundance of
PROX-1 in the intestinal mucosa (Figure 6C). Likewise, no
changes on Scarb1 gene expression could be detected in mac-
rophages (Figure S4E). Such a restriction of the effects of LRH-1
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to selected tissues—in this case, the liver—and a subset of
target genes, may be the key to drive only antiatherogenic ef-
fects of LRH-1. A better understanding into how SUMOylation
of LRH-1 and ensuing coregulator recruitment can bemodulated
will be instrumental and may provide opportunities for pharma-
cological intervention to combat common diseases, such as
atherosclerosis.
EXPERIMENTAL PROCEDURES
Animal Studies
The generation of the Lrh-1 K289R mouse model is described in detail in the
Supplemental Experimental Procedures. Congenic C57Bl/6J Lrh-1 WT or
Lrh-1 K289R mice were crossbred with congenic C57Bl/6J Ldlr knockout
mice in order to generate Ldlr/ Lrh-1 WT (LL-WT) or Ldlr/ Lrh-1 K289R
(LL-K289R) mice. LL-WT and LL-K289Rmice were kept on an HCD (1.25% to-
tal cholesterol, Harlan TD.94059) for 14 weeks starting at the age of 8 weeks.
Similarly, congenic C57Bl/6J Lrh-1hep/ and Lrh-1hep+/+ mice (Oosterveer
et al., 2012) were crossbred with Ldlr/ mice in order to generate Ldlr/
Lrh-1hep+/+ (Ld-WT) or Ldlr/ Lrh-1hep/ (Ld-LKO) mice and fed a HCD for
12 weeks. All animal procedures were approved by the Swiss authorities
(Canton of Vaud, animal protocols ID #2561 and #2768) and performed in
accordance with our institutional guidelines.
Site-directed mutagenesis, subcellular fractionation of liver tissue, immuno-
precipitation (IP), Coimmunoprecipitation (CoIP), and western blotting are
explained in the Supplemental Experimental Procedures.
Protein Alignment
All protein alignments were performed with the standard Geneious (Blosum62
matrix) or ClustalW (BLOSUM matrix) algorithm from the Geneious software
(http://www.geneious.com).
Gene Expression and Analysis
RNA was extracted from the livers and jejunums of ad libitum fed Lrh-1 WT
(n = 7) and Lrh-1 K289R (n = 7) mice and from liver of ad libitum fed Lrh-
1hep+/+ (n = 8) and Lrh-1hep/ (n = 8) mice with TRIZOL (Invitrogen) and
purified with the RNeasy Cleanup Kit for Microarray Analysis (QIAGEN). For
quantitative RT-PCR (qRT-PCR), cDNA was generated with the QuantiTect
Reverse Transcription Kit (QIAGEN) and analyzed by qPCR with a LightCycler
480 Real-Time PCRSystem (Roche), and the primers are listed in the Table S2.
Expression data were normalized to 36B4 or B2M mRNA levels. Microarray
analysis was performed with the Affymetrix MouseGene 1.0 ST or Affymetrix
MouseGene 2.0 ST array and normalized with the robust multiarray average
method. A table of reciprocally regulated transcripts is provided in Table S1.
Venn diagram analysis and heatmaps were performed with GENE-E (http://
www.broadinstitute.org/cancer/software/GENE-E/index.html). For the Venn
diagram, the overlap of nominally significantly changed genes (p < 0.05 and
fold changeR 1.5) among the groups was analyzed.
Chromatin Immunoprecipitation
ChIP analysiswas performed as described previously withminormodifications
(Duggavathi et al., 2008). DNA was purified with the PCR Clean-up extrac-
tion kit (Macherey-Nagel), after which qPCR was performed as described
previously (Mataki et al., 2007). Data were normalized to the input (fold differ-
ences = 2(Ct sample  Ct input)). ChIP primer sequences are listed in Table S3.
Lipoprotein Separation
Pooled plasma samples were subjected to fast protein liquid chromatography
gel filtration with a Superose 6 Column (GE Healthcare). Individual fractions
were assayed for cholesterol and triglyceride concentrations with commer-
cially available enzymatic assays (Roche).
Hepatic Lipid Analyses
Hepatic lipids were extracted according to the Bligh and Dyer (1959) protocol.
Triglyceride and cholesterol contents in plasma and hepatic lipid fractions
were quantified with enzymatic assays (Roche).
Cholesterol Uptake and LPS Stimulation of Peritoneal Macrophages
Thioglycolate-elicited peritoneal macrophages were harvested, cultured, and
starved in vitro and then loaded with 50 mg/ml DiI-labeled acetylated LDL for
4 hr in order to assess the cholesterol uptake or 10 ng/ml LPS for 4 hr in order
to analyze the expression of inflammatory markers.
Reverse Cholesterol Transport
RCT protocol was adapted from Meissner et al. (2010). In brief, thioglycolate-
elicited mouse peritoneal macrophages were harvested, cultured in vitro,
loaded with 50 mg/ml acetylated LDL and 3 mCi/ml 3H-cholesterol for 24 hr,
and equilibrated in RPMI 1640 medium containing 1% penicillin/streptomycin
and 0.2% BSA for 6 hr. For in vivo RCT, two million labeled LL-WT macro-
phages were injected intraperitoneally into recipient LL-WT or LL-K289R
mice. Mice were sacrificed 48 hr postinjection, and plasma, liver, gallbladder,
and feces were stored at 80C until further analysis. Counts within liver were
determined after the solubilization of the tissue. Fecal samples were dried,
weighed, and thoroughly ground. Then, aliquots were separated into bile
acid and neutral sterol fractions prior to liquid scintillation counting.
Bile Flow and Bile Composition
Bile duct cannulation was performed as described previously (Kruit et al.,
2005) with LL-WT and LL-K289R mice. In brief, hepatic bile was collected
for 30 min from the common bile duct via cannulation of the gallbladder, and
bile flow was determined gravimetrically assuming a density of 1 g/ml for
bile. Bile composition was analyzed by high performance liquid chromatog-
raphy (HPLC) tandem mass spectrometry as described previously (Mataki
et al., 2007).
Primary Cell Culture
Primary hepatocytes from hepatocyte-specific Lrh-1hep/ mice were isolated
with LiberaseBlendzyme (Roche) perfusion as described previouslywithminor
modifications (Ryu et al., 2011). Lrh-1hep/ hepatocytes were plated in Dul-
becco’s modified Eagle’s medium 4.5 g/l glucose with 10% fetal bovine
serum. Cells were infected with an adenovirus expressing LRH-1 WT or
LRH-1 K289R 4 hr after plating followed by transfection of a Prox1 plasmid
with Lipofectamine 2000 (Invitrogen). Cells were lysed 48 hr postinfection
and used for subsequent analysis.
Reporter Assays
Transient transfections in HEK293T cells were performed with Lipofectamine
2000 (Invitrogen) or JetPEI (Polyplus) as previously described (Oosterveer
et al., 2012). In brief, cells were transfected with pTK-GL3 reporter constructs
driven by a heterologous promoter consisting of multiple consensus LRH-1
response elements (pGL3::(LRHRE)5-TK-LUC) in the presence of either
pCMX::LRH-1 WT or the KR mutant constructs. Luciferase activities were
measured 24 hr posttransfection and normalized to b-galactosidase activities.
Immunohistochemistry
En face plaque analysis was performed on thoraco-abdominal aortae that
were fixed with 10% paraformaldehyde overnight and then stained with Oil-
Red O (Stein et al., 2010). Aortic sinuses were cut into 5-mm-thick serial cryo-
sections and stained with Sirius Red in order to measure necrotic core size,
cap thickness, and collagen content (Stein et al., 2010). Means were taken
from n = 6 mice per genotype, and three serial cryosections were evaluated
from each mouse.
Statistical Analyses
Data are expressed as means ± SEM. Analysis of en face atherosclerotic pla-
que content and bile excretion rates was carried out with Mann-Whitney U
tests. Comparison of differences between two groups of other experiments
was assessed with unpaired two-tailed Student’s t tests. Multiple group com-
parisonswere assessedbyone-wayANOVAandBonferonni post hoc tests. p<
0.05 was considered statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001).
ACCESSION NUMBERS
All microarray data are accessible at the NCBI Gene Expression Omnibus
under number GSE59333.
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Molecular basis for the regulation of the nuclear
receptor LRH-1
Sokrates Stein and Kristina Schoonjans
Liver receptor homolog-1 (LRH-1) is a nuclear receptor (NR)
with diverse functions in development, differentiation and
metabolism and has been extensively studied in the
enterohepatic system. While initially described as an orphan
NR, recent studies suggest that specific phospholipids act as
endogenous LRH-1 ligands. Although binding of ligands may
enhance its transcriptional activation, posttranslational
modifications (PTMs) and binding of coregulators and other
NRs have emerged as mechanisms to fine-tune the selective
regulation of LRH-1 target genes. In this review article, we will
discuss how LRH-1 is regulated by PTMs and binding of
ligands and coregulators, and explain some metabolic
consequences with a special focus on liver physiology.
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Introduction
Liver receptor homolog-1 (LRH-1, also known as nuclear
receptor subfamily 5 group A member 2 (Nr5a2), fushi
tarazu factor I (FTZ-F1), a-fetoprotein transcription fac-
tor (FTF), pancreas homolog receptor 1 (PHR-1), human
B1-binding factor (hB1F), and Cyp7A promoter-binding
factor (CPF)) is a member of the NR5A subfamily of
nuclear receptors (NRs) that was first identified in an
evolutionary tree analysis of the Drosophila Ftz-F1 NR
group [1]. LRH-1 is mainly expressed in exocrine pan-
creas, ovaries, and tissues of the enterohepatic axis and
has diverse functions in development, differentiation and
metabolism (Figure 1) [2–4]. In the ovaries LRH-1
regulates steroid synthesis and ovulation [5–12], and is
crucial during mouse gestation [13]. LRH-1 also affects
ovarian follicle maturation and fertility through its actions
in the hypothalamus [14]. In the pancreas, LRH-1 is
critically required for adequate production and secretion
of the pancreatic digestive juice [15,16].
LRH-1 has been tightly linked with cell proliferation
[17–19], local immune homeostasis [20,21] and cancer
[17,22,23]. The recent identification of LRH-1 in the
control of stemness [24,25,26,27] may furthermore pro-
vide new insights that could be directly relevant to
understand the protumorigenic actions of LRH-1.
The role of LRH-1 has been extensively characterized in
the liver. In this review we will focus on the multiple
factors that regulate the transcriptional activity of LRH-1,
such as potential ligands, posttranslational modifications
and binding of coregulators. These multiple modes of
regulation will be discussed in the context of the emer-
ging actions of LRH-1 in liver physiology.
Orphan or adopted?
LRH-1 was originally classified as an orphan NR based on
its constitutive activity and the lack of known endogenous
ligand. This simple view has been in part revisited with
the structures of mouse and human LRH-1 LBD
proteins. These studies revealed that different phospho-
lipid species, including phosphatidyl glycerol, phospha-
tidyl ethanolamine and phosphatidyl choline, as well as
the second messengers phosphatidyl inositols, can bind to
the large ligand binding pocket of human LRH-1, but
much less to mouse LRH-1 [28,29]. A cluster of non-
conserved residues in the human LBD seems to be
essential for proper binding of phospholipids [28]. More-
over, while structural modifications of the ligand-binding
pocket do not affect the transcriptional activity of mouse
LRH-1 [30], F342W I416W mutations at the LBD of
human LRH-1 markedly reduce binding of specific phos-
pholipid species, which in turn hinders the recruitment of
coactivators and diminishes the transcriptional potential
of LRH-1 [31]. Together these structural studies reveal
important species differences, which may reflect differ-
ences in constitutive activity. Of interest, recent studies
identified the phospholipid dilauroyl phosphatidyl-
choline (DLPC) as a potent ligand of human and mouse
LRH-1 in vitro, and showed that LRH-1 is required to
mediate the antidiabetic effects of DLPC in two inde-
pendent mouse models of diabesity [32,33]. In line
with previously established functions of LRH-1 [34,35],
DLPC treatment of hepatocytes induced the expression
of genes involved in bile acid synthesis, further support-
ing the notion that DLPC can induce LRH-1 activity.
Taken together, these structural and functional studies
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suggest that albeit LRH-1 can be active in the absence of
ligand, specific phospholipid binding can further enhance
its transcriptional activity.
Posttranslational regulation
Most NR are also targeted by different PTMs, in-
cluding phosphorylation, acetylation, ubiquitination,
and SUMOylation. Phosphorylation of the serine resi-
dues S238 and S243 in the hinge region of the human
LRH-1 protein by the mitogen-activated protein kinase
ERK1/2 has been shown to enhance its activity [36].
Another study suggests that LRH-1 is acetylated in the
basal state and is bound by the small heterodimer
partner (SHP)-sirtuin 1 (SIRT1) transrepressive  com-
plex. What is driving the acetylation and deacetylation
of LRH-1 is not established, yet its acetylation status is
surprisingly not modulated by SIRT1 [37]. It will be
interesting to further establish the functional relevance
and metabolic consequences of both PTMs in cellular
and animal models.
Reversible covalent modification by small ubiquitin-like
modifier-1 (SUMO-1) protein, or SUMOylation, has been
extensively studied [38]. LRH-1 is targeted for SUMOy-
lation by E3-SUMO ligases at both conserved and distinct
lysine residues in different species, and reduces its
transcriptional activity [39,40,41,42,43]. Different
mechanisms have been proposed to explain how this
transcriptional attenuation is achieved. Using different
bioimaging techniques, it was shown that SUMOylation
of LRH-1 translocates the transcription factor from the
chromatin to promyelocytic leukemia protein (PML)
nuclear bodies and prevents it from being transcription-
ally active. Conversely, de-SUMOylation of the protein
releases it from PML bodies and allows it to induce the
expression of target genes [40]. Localization of SUMOy-
lated LRH-1 to nuclear bodies can furthermore be sup-
pressed by forskolin and cholera toxin treatment in rat
primary granulosa cells, suggesting that cAMP signaling
can modulate the SUMOylation status of LRH-1 and its
localization to nuclear bodies [44].
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Other studies suggest that the SUMOylation of LRH-1
affects the recruitment of co-regulators, which in turn
modulates the expression of its target genes. This model
has been described for two different corepressors of
LRH-1. SUMOylation of LRH-1 was reported to stabilize
a transcriptional corepressor complex comprised of the
nuclear receptor corepressor 1 (NCOR1) and histone
deacetylase 3 (HDAC3). The interaction of SUMOylated
LRH-1 with this corepressor complex is mediated by the
G protein pathway suppressor 2 (GPS2), and regulates the
induction of several acute phase response proteins [41].
Recent data from our own group suggest that another
corepressor, prospero-related homeobox 1 (PROX1), is
recruited to SUMOylated LRH-1 and transrepresses
specific gene programs. Using non-SUMOylatable
LRH-1 K289R knock-in mice on an atherosclerotic back-
ground, we could further demonstrate that loss of LRH-1
SUMOylation leads to increased expression of genes
regulating reverse cholesterol transport (RCT) and
enhanced RCT in vivo (Figure 2), hence culminating
in the protection against the development of atheroscle-
rosis [45]. Another study performed in Drosophila
demonstrated that SUMOylation of its LRH-1 homol-
ogue, Ftz-f1, impacts the metamorphosis process from
larval to pupal transition by modulating the expression of
the scavenger receptor Snmp1, which is required for
proper lipid homeostasis in steroidogenic tissues [43].
This is reminiscent to the regulation of scavenger receptor
B1 (Scarb1) by LRH-1 in mouse liver [45,46]. These
studies suggest that the role of SUMOylated LRH-1 in
cholesterol and lipid homeostasis might be evolutionary
conserved.
SUMOylation of LRH-1 also plays an important role in
the generation of induced pluripotent stem cells (iPS)
[25]. The four common factors that are used to induce
iPS are OCT4, SOX2, KLF4, and c-MYC [47]. Interest-
ingly, LRH-1 can be used to replace OCT4, and SUMOy-
lation mutants of LRH-1 further enhance the
reprogramming efficiency [25], highlighting that this
posttranslational modification affects diverse molecular
functions of LRH-1.
Binding of co-regulators
NRs are not only modulated by ligand binding and
PTMs, but also by coregulator recruitment. Several tis-
sue-specific coactivators and corepressor can fine-tune the
transcriptional activity of LRH-1 in a context specific
manner. In the ovary, for example, LRH-1 function is
regulated by the coactivator peroxisome proliferator-acti-
vated receptor gamma coactivator 1-alpha (PGC-1a) and
the corepressor DAX-1 (NR0B1) [48]. In the liver, other
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corepressors such as small heterodimer partner (SHP or
NR0B2) and PROX1 as well as the NCOR1/HDAC3
corepressor complex can repress LRH-1 activity
[34,35,41,45,49,50] (Figure 2). Importantly, as
described in the previous section, several coregulators
bind to domains whose structure has been changed by
binding of ligands and/or PTMs. Whether the PTMs are
crucial to initiate or maintain or simply facilitate the
interaction has to be studied in more detail for each of
the PTM and the affected coregulators.
SHP & DAX1
SHP (NR0B2) and DAX-1 (NR0B1) are closely related
and atypical NRs that lack a typical DNA binding domain
(DBD) and act as repressors of LRH-1 and SF-1. SHP
binds to the C-terminal activation function (AF-2)
domain of LRH-1 [31,50], reviewed in detail in [2,3].
Importantly, LRH-1 induces the expression of Shp, which
in turn will reduce the transcriptional activity of LRH-1,
thereby inhibiting its own expression in a negative feed-
back loop [34,35]. DAX-1 also represses the activity of
LRH-1 by binding to its LBD [48,51,52]. Importantly,
while Shp is primarily expressed in the liver, pancreas,
stomach and heart, Dax1 expression is mainly limited to
embryonic stem cells, testis and ovary (see bioGPS.org).
Therefore these proteins likely have the same repressive
functions in different tissues.
NCOR1 & NCOR2
As described in detail above, SUMOylation of LRH-1
drives its interaction with a transcriptional corepressor
complex consisting of NCOR1/HDAC3 via association
with GPS2 [41]. One of the consequences of this associ-
ation is the transrepression of acute phase response
proteins [53]. Another study showed that the close hom-
ologue of NCOR1, the silencing mediator for retinoic acid
receptor and thyroid hormone receptor (SMRT, or
NCOR2) also represses the transcriptional activity of
LRH-1 in different cell lines [54]. However, the authors
were not able to detect a direct interaction between
LRH-1 and SMRT. Possibly, as for NCOR1, an associ-
ating protein such as GPS2 is necessary to bring these
proteins into close proximity.
PROX1
The corepressor PROX1 binds to different LRH-1
domains in Drosophila and human cell lines [49,55],
and similar to DAX1 and SHP, its expression is limited
to few organs, such as the liver, heart and hippocampus
(see bioGPS.org). Moreover, PROX1 is essential for lym-
phatic vessel development and maintenance [56,57].
Interaction studies demonstrated that PROX1 interacts
with both the DNA binding domain (DBD) and the LBD
of LRH-1 in different cell lines [49], or requires the entire
LBD in Drosophila [55]. Although PROX1 seems to bind
to different domains, its transrepressive potential affects
similar metabolic pathways in the two organisms. The
LRH-1/PROX1 interaction leads to the transrepression of
different LRH-1 target genes, including Cyp7a1 and Shp,
which play a crucial role in the liver [49,55]. This is
consistent with our own findings, showing that LRH-1/
PROX1 interaction transrepresses the expression of genes
regulating hepatic reverse cholesterol transport in mice
[45]. Importantly, since PROX1 is highly expressed in
the liver, but not in intestinal fractions, only hepatic RCT
regulators are affected by PROX1 transrepression [45].
SRCs
The three homologous members of the steroid receptor
co-activator (SRC) p160 family, SRC-1, SRC-2 and SRC-
3, also act as strong LRH-1 regulators by binding to its
LBD and potentiating its transcriptional activity [50,58].
For example, stimulation of rat primary granulosa cells
with pregnant mare serum gonadotropin (PMSG) leads to
the SRC-1/LRH-1 transactivation of the inhibin alpha-
subunit gene, a gene that inhibits the release of follicle-
stimulating hormone (FSH) [10]. In the transcriptional
regulation of the Cyp11a1 gene, SRC-1 and protein inhibi-
tor of activated STAT (signal transducer and activator of
transcription) y (PIASy) compete to bind LRH-1 [59].
While SRC-1 stimulates, PIASy transrepresses LRH-1-
dependent Cyp11a1 promoter activation. Although
PIASy is an E3 SUMO-ligase, its transrepressive function
does not seem to result from changes in the LRH-1
SUMOylation status [59]. In another study that investi-
gated the transcriptional regulation of the Lrh-1 gene
upon sphingosine-1-phosphate and prostaglandin E2
stimulation, it was shown that CCAAT/enhancer binding
proteins d (C/EBPd) and the coactivators CREB-binding
protein (CBP) and SRC-3 potentiate the interaction of
cAMP response element binding protein (CREB) and
LRH-1 [60].
PGC-1a
Peroxisome proliferator-activated receptor gamma
(PPARg) coactivator 1a (PGC-1a) has been described
as an LRH-1 co-activator [48,61,62]. Binding of PGC-1a
to the AF2 domain of LRH-1 stimulates Cyp7a1 expres-
sion in the liver [61], aromatase (Cyp19a1) expression in
the breast [62], and the expression of steroidogenesis
genes in granulosa cells [48]. The PGC-1a-mediated
transactivation of LRH-1 is blocked by binding of SHP
in the liver or of DAX1 in granulosa cells [48,61].
Beta-catenin
In intestinal crypt cells b-catenin (CTNNB1) works
synergistically with LRH-1 to activate the expression
of cell cycle genes and promote proliferation [18].
LRH-1 drives the expression of cyclin E1 (Ccne1), and
this transcriptional effect is further augmented by b-
catenin. Conversely, LRH-1 acts as a coactivator of b-
catenin in the transcriptional regulation of cyclin D1
(Ccnd1) [18], by direct binding of the b-catenin armadillo
repeat to the LBD of LRH-1 [63].
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MBF-1
Multiprotein bridging factor (MBF-1) is a transcriptional
regulator that interacts with the Drosophila LRH-1 hom-
ologue Ftz-F1 as well as with human LRH-1 in mamma-
lian cells [64,65]. Rather than acting as a direct co-
activator, MBF-1 links LRH-1 to the transcriptional
machinery through its interaction with the transcription
factor IID (TFIID) complex [64].
Combinatorial regulation of NR target genes
Expression of the gene Cyp7a1 encoding the rate-limiting
enzyme of the bile acid biosynthesis pathway, is regulated
by a regulatory cascade of NRs including the farnesoid X
receptor (FXR or NR1H4), LRH-1, hepatic nuclear factor
4a (HNF4a or NR2A1) and SHP [34,35,66]. LRH-1
potentiates the expression of liver X receptors (LXRs)
target genes, including cholesteryl ester transfer protein (Cetp)
[67], fatty acid synthase (Fas) [68], and ATP-binding cassette
sub-family G member 5 and 8 (Abcg5 and Abcg8) [69],
suggesting that LRH-1 acts as a competence factor for
LXR. Whether LRH-1 and FXR act in a similar fashion is
an intriguing question. While one study reported that the
combined activity of FXR and LRH-1 augments the
expression of the FXR target genes Shp, retinol dehydro-
genase 9 (Rdh9), pyruvate carboxylase (Pcx), and phosphati-
dylethanolamine N-methyltransferase (Pemt) [70], another
study showed that FXR mediates Shp expression by
docking to an LRH-1 binding site independent of
LRH-1 [71].
Hepatic functions of LRH-1
The liver plays a crucial role in different metabolic
processes, ranging from glucose processing and pro-
duction to cholesterol and bile acid homeostasis. Hep-
atocytes also exhibit immunoregulatory responses after
various stress stimuli and its high capacity to synthesize
and secrete proteins makes them also susceptible to ER
stress. To illustrate the complexity of the regulatory
circuits controlled by LRH-1, we will here describe
how the above described mechanisms of LRH-1 regula-
tion, including ligand activation, cofactor recruitment or
SUMOylation, can impact on liver homeostasis. For cov-
erage of its role in other tissues, we refer the interested
reader to a series of other recent reviews [3,72].
Bile acid metabolism
The two key genes involved in bile acid synthesis, Cyp7a1
and Cyp8b1, have been amongst the first LRH-1 target
genes identified [73,74]. SHP and PGC-1a compete to
bind to the AF2 domain of LRH-1 in the liver, and thus
modulate the expression of both genes (Figure 2)
[34,35,61]. Interestingly, liver-specific Lrh-1 knockout
mice have an altered composition of bile with basically
no cholic acid and an increased amount of less amphi-
pathic bile acids, such as muricholic acid and ursodeoxy-
cholic acid, which is attributed to the dramatically
reduced expression of Cyp8b1, but not Cyp7a1 [75–77].
Importantly, this altered bile acid composition leads to a
compromised intestinal lipid absorption and enhances the
fecal excretion of lipids [75,77]. Besides regulating sev-
eral enzymes involved in bile acid synthesis, LRH-1 also
activates the transcription of the bile salt export pump
(Bsep) in Huh7 cells, a transporter that drives the cana-
licular secretion of bile acids [78], highlighting its crucial
role in bile acid homeostasis.
Reverse cholesterol transport
Reverse cholesterol transport is an anti-atherogenic pro-
cess in which excessive cholesterol from peripheral tis-
sues is transported to the liver and finally excreted via the
bile. LRH-1 governs the expression of genes involved in
this process [46,79–81]. Of interest, SUMOylation of
LRH-1 promotes its interaction with PROX1 and leads
to the transrepression of hepatic reverse cholesterol trans-
port genes such as Scarb1, Abcg5, and Abcg8 [45]
(Figure 2). The increased biliary sterol excretion and
RCT observed in an atherosclerosis-prone non-SUMOy-
latable LRH-1 K289R mouse model, decreases the de-
velopment of atherosclerosis [45]. Moreover, LRH-1
regulates the expression of Apoa1 and Apom, two proteins
that associate with HDL and facilitate cholesterol clear-
ance (Figure 2) [80,81]. These studies suggest that LRH-
1 could be pharmacologically targeted to prevent athero-
sclerosis development, which is the primary cause of
myocardial infarction and stroke in humans.
Glucose homeostasis
The function of LRH-1 in hepatic glucose sensing and
intermediary metabolism has been studied in liver-
specific Lrh-1 knockout mice under postprandial con-
ditions. These mice display reduced hepatic glucokinase
and glycogen synthase fluxes as a consequence of reduced
expression of glucokinase (GCK), a direct target gene
of LRH-1 (Figure 2). This in turn leads to reduced
availability of glucose-6-phosphate, an intermediate
that acts as a substrate for the pathways that support
glycogen synthesis, glycolysis, and de novo lipogenesis
(DNL) and controls the nuclear translocation and activity
of the glucose-responsive transcription factor ChREBP
(Figure 2) [82].
The role of LRH-1 in glucose management has also been
studied in obese and diabetic mouse models. DLPC, a
phospholipid that binds to and induces LRH-1 activity,
improves glucose tolerance and insulin resistance without
affecting the body weight in diet-induced or genetically
obese and diabetic mice [32]. Another study showed
that the heterozygous Lrh-1+/ mice have a mild but
significant increase in body weight when exposed to a
high-fat diet, but conversely do not exhibit changes in
glucose or insulin tolerance [83]. These studies suggest
that receptor activation has more pronounced metabolic
effects on glucose homeostasis than genetic haploinsuffi-
ciency of Lrh-1.
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Hepatic acute phase response
Upon inflammatory stimuli due to injury, infection or
chronic metabolic stress, immune cells secrete various
cytokines into the bloodstream, which may activate the
acute phase response in the liver. As described above,
SUMOylation of hepatic LRH-1 leads to the recruit-
ment of different co-repressors. Binding of SUMOy-
lated LRH-1 to the NCOR1/HDAC3 complex via
GPS2 mediates the transrepression of acute phase
response genes [41,84], and therefore modulates this
hepatic response. Besides transrepressing APPs, LRH-
1 induces the expression of interleukin-1 receptor
antagonist (IL-1RA), an inhibitor of IL-1 signaling,
thereby exerting additional anti-inflammatory roles in
the liver [85].
ER stress
A recent study suggests that LRH-1 ameliorates hepatic
ER stress resolution independent of the canonical
unfolded protein response (UPR) pathways [86]. The
authors demonstrated that liver-specific Lrh-1 knockout
mice display a defective ER stress resolution due to
reduced expression of polo-like kinase 3 (Plk3), which
phosphorylates activating transcription factor 2 (ATF2)
and thus induces its stress response target genes. Impor-
tantly, ectopic restoration of Plk3 in liver-specific Lrh-1
knockout mice restored phosphorylation of ATF2 and
rescued ER stress resolution [86].
Conclusion and perspective
The identification of small molecule agonists and
antagonists as well as the discovery that specific phos-
pholipid species act as endogenous agonists of LRH-1
[32,87,88,89], suggest that the receptor could be a bona
fide druggable target (Table 1). Given the multiple func-
tions of LRH-1 in different tissues it is not easy to
speculate whether activation or inhibition of this tran-
scription factor could provide therapeutic advantages.
Although increased activation of LRH-1 could be
beneficial to promote RCT and biliary cholesterol
excretion to prevent atherosclerosis development
[45,80,81] or to treat diabetes [32,33], its activation
on the other side could induce the expression of cell-cycle
regulators that could facilitate cell proliferation and
possibly promote cancer development [87,90]. In this
regard, the selective induction of transcriptional programs
by SUMO modification of LRH-1 may offer interesting
therapeutic perspectives that could dissociate these
effects. Further studies however will be required to fully
understand the exact function of LRH-1 and its post-
translational modifications in the different organs to
develop a targeted and safe approach that could be useful
to treat metabolic disorders or cancer.
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Table 1
List of some key studies that show endogenous and synthetic LRH-1 ligands, known posttranslational modifications (PTMs) and their
effects, and binding of other transcription factors or coregulators.
Binding of Specification References
Ligands and drugs
Endogenous ligands Phospholipids and phosphatidyl inositols [28,29]
Dilauroyl phosphatidylcholine (DLPC) [32,33]
Agonists Small molecule agonists [88,89]
Antagonists Small molecule antagonists [87]
PTMs
Phosphorylation Phosphorylation of S238 and S243 of human LRH-1 [36]
Acetylation Acetylation of LRH-1 at basal state [37]
SUMOylation SUMOylation of different lysines residues [39,40,41,42,43]
Regulation of SUMOylation of LRH-1 by adenylate cyclase activators [44]
Recruitment of NCOR1/HDAC3 [41]
Recruitment of PROX1 [45]
Drosophila lipid homeostasis and steroidogenesis [43]
Induction of iPS cells [25]
Coregulators and other NRs
Coactivators PGC-1a [48,61,62]
SRCs [10,50,58–60]
Beta-catenin [18,63]
Corepressors DAX-1 (NR0B1) [48,51,52]
SHP (NR0B2) [31,34,35,50]
PROX1 [41,45,49,55]
NCOR1 & NCOR2 [41,54]
Bridging factor MBF-1 [64,65]
Other NRs FXRs [34,35]
LXRs [67–69]
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LRH-1 mediates anti-inflammatory and antifungal
phenotype of IL-13-activated macrophages through
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Liver receptor homologue-1 (LRH-1) is a nuclear receptor involved in the repression of
inflammatory processes in the hepatointestinal tract. Here we report that LRH-1 is expressed
in macrophages and induced by the Th2 cytokine IL-13 via a mechanism involving STAT6.
We show that loss-of-function of LRH-1 in macrophages impedes IL-13-induced macrophage
polarization due to impaired generation of 15-HETE PPARg ligands. The incapacity to
generate 15-HETE metabolites is at least partially caused by the compromised regulation of
CYP1A1 and CYP1B1. Mice with LRH-1-deficient macrophages are, furthermore, highly
susceptible to gastrointestinal and systemic Candida albicans infection. Altogether, these
results identify LRH-1 as a critical component of the anti-inflammatory and fungicidal
response of alternatively activated macrophages that acts upstream from the IL-13-induced
15-HETE/PPARg axis.
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M
acrophages orchestrate innate immune responses by
initiating and resolving inflammatory signalling pro-
grammes. Emerging evidence indicates that the state of
macrophage polarization plays a critical role in the regulation of
these inflammatory processes. Two different programmes of
macrophage activation, the classical (M1) and the alternative
differentiation, classify polarized macrophages with either
persistence or resolution of inflammation1–3. M1 macrophages
express high levels of opsonic receptors, involved in the
production of pro-inflammatory effector molecules such as
reactive oxygen and nitrogen intermediates and pro-
inflammatory cytokines (interleukin (IL)-1b, tumour-necrosis
factor alpha (TNFa), IL-6 and IL-12). These macrophages
contribute to inflammation, microbial killing, regulation of cell
proliferation and apoptosis. Alternatively activated macrophages
are characterized by abundant levels of the anti-inflammatory
cytokine IL-10 and non-opsonic receptors, such as C-type lectin
receptors and scavenger receptors (CD36), and resolve
inflammation by increasing CD36-mediated efferocytosis and
secretion of tissue remodelling/repair mediators3,4.
The balance of macrophage differentiation in favour of
alternatively activated macrophages can be shifted by the activation
of the nuclear receptor peroxisome proliferator-activated receptor
gamma (PPARg) (refs 5,6). PPARg expression and activity in
macrophages is negatively regulated during inflammatory
processes7,8. In addition, activated PPARg transrepresses many
inflammation-activated transcription factors, including nuclear
factor-kappaB (NF-kB), signal transducers and activators of
transcription (STATs), activator protein 1 (AP1) and nuclear
factor of activated T-cells NFAT), resulting in pro-inflammatory
mediator inhibition9. PPARg is activated by endogenous ligands
derived from the metabolism of arachidonic acid (AA)9. Among
these ligands, 15-deoxy-D12,14PGJ2 (15d-PGJ2), metabolized
through the COX1/COX2 cyclooxygenases, and the 12- and 15-
hydroxyeicosatrienoic acids (HETEs), metabolized through 5 and
12/15 lipoxygenases, are essential for PPARg endogenous
activation5,10,11. In addition to cyclooxygenases and lipoxygenases,
cytochrome P450 (CYP) enzymes are also considered to be critical
for the metabolism of AA in epoxy (EETs) and in hydroxy (HETEs)
derivatives10,11. Within the CYP family, the CYP1 family is mainly
involved in the generation of 12- and 15-HETEs through CYP1A1
and CYP1B1 (refs 12,13).
Liver receptor homologue-1 (LRH-1, NR5A2) is a nuclear
receptor highly expressed in the intestine, liver, pancreas and
ovary14,15. Although LRH-1 has been recognized as an orphan
receptor, phospholipids, including the phosphatidyl inositol second
messengers, and more recently the 12C-fatty acyl-containing
phospholipid, dilauroyl phosphatidylcholine (DLPC), have been
described to bind the ligand-binding pocket and to
act as LRH-1 agonists16–18. LRH-1 plays important roles
in embryonic development, cholesterol and bile acid
homeostasis14,15 and promotes hepatic glucose sensing through
the regulation of the glucokinase enzyme19. Several lines of evidence
also support a role for LRH-1 in the control of the inflammatory
response. While pro-inflammatory factors such as TNFa and
lipopolysaccharide (LPS) decrease LRH-1 expression in murine
models of human colon tumorigenesis, deficiency of LRH-1 in the
intestinal epithelium predisposes mice to intestinal inflammation as
a result of a defect in local glucocorticoid production. In the colon
from patients with inflammatory bowel disease, inflammation is
inversely correlated with the expression of LRH-1 (refs 20,21). In
line with these reports, Venteclef et al.22,23 identified a role for
LRH-1 in the negative modulation of the hepatic acute-phase
response by inhibiting IL-6- and IL-1b-stimulated haptoglobin,
serum amyloid A gene expression in hepatocytes and inducing anti-
inflammatory IL-1ra expression. Despite the numerous studies
documenting the anti-inflammatory properties of LRH-1 in the
liver and gut, no studies so far have focused on the role of LRH-1 in
macrophages.
In the present study, we identify LRH-1 as an important
regulator of the inflammatory response in macrophages. We
demonstrate that LRH-1 is induced by IL-13 via a STAT6-
dependent mechanism, which in turn induces the transcriptional
activation of CYP1A1 and CYP1B1, two enzymes involved in the
generation of 15-HETE PPARg ligand. Finally, we also demonstrate
the importance of intact LRH-1 signalling in the anti-inflammatory
and antifungal functions of alternatively activated macrophages,
indicating that modulators of LRH-1 activity may have therapeutic
potential to restrain infectious and inflammatory diseases.
Results
IL-13-mediated LRH-1 gene expression is dependent on STAT6.
The anti-inflammatory properties of LRH-1 are well established
in the liver and gut24. To elucidate whether LRH-1 also
participates in regulating the inflammatory response in
macrophages, gene expression profiling was performed. In situ
hybridization and reverse transcriptase–quantitative PCR
(RT–qPCR) revealed that LRH-1 (encoded by the Nr5a2 gene),
known to be expressed in the colon and liver, is also expressed in
macrophages but not in B and T immune cells (Fig. 1a).
Consistent with the gene expression data, LRH-1 protein was also
detected in macrophages (Supplementary Fig. 1b). We next
analysed the impact of pro- and anti-inflammatory factors on
Nr5a2 gene expression in primary macrophages. As depicted in
Fig. 1b, pro-inflammatory challenges, such LPS and IFNg
exposure, but not IL-6, significantly reduced or abolished Nr5a2
mRNA expression. Conversely, IL-13, IL-4 and IL-10 cytokines
significantly enhanced Nr5a2 mRNA level in macrophages.
Similar to findings in the murine model, NR5A2 mRNA levels
were significantly increased by IL-13 treatment in human
monocytes (Fig. 1c). These results suggest that LRH-1 could be
part of the transcriptional network mediating alternative
activation of macrophages. To test this hypothesis, we analysed
the downstream signalling components of IL-13 in more detail
(Fig. 1d–i). STAT6, a transcription factor known to be activated
by IL-13 is part of the signalling pathway that governs alternative
activation25. Interestingly, exposure of macrophages with AG490,
a Jak-2/STAT6 inhibitor, prevented the IL-13-mediated induction
of LRH-1 (Fig. 1d). Consistent with these observations, IL-13
failed to increase Nr5a2 mRNA and protein levels in
macrophages deficient for STAT6 (Fig. 1e,f), suggesting that
STAT6 mediates the transcriptional regulation of LRH-1. We
then performed transient transfection assays in primary
macrophages to assess the effect of IL-13 and STAT6 on Nr5a2
promoter activity. While 4 h of IL-13 exposure was already
sufficient to induce Nr5a2 promoter activity in wild-type
macrophages (Fig. 1g,h), chemical inhibition of STAT6 by
AG490 (Fig. 1g) or genetic deletion of STAT6 (Fig. 1h)
attenuated or even abolished this response.
To evaluate whether LRH-1 is subject to direct transcriptional
control by STAT6, we performed an in silico analysis of the Nr5a2
promoter region. Scanning of the Nr5a2 promoter sequence for
the STAT6 response element (STAT6-RE) canonical motif
revealed four putative STAT6-RE (Fig. 1i). Chromatin immuno-
precipitation (ChIP) analysis of macrophage DNA from C57BL/6
mice revealed specific recruitment of STAT6 to site 1 at  541,
which is most proximal to the transcription initiation site of the
gene (Fig. 1i).
To explore the functionality of this site, we next modified by
in vitro mutagenesis its sequence and we evaluated the mutated
Nr5a2 reporter construct activity on IL-13 exposure (Fig. 1j).
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Mutation of the STAT6-RE abolished the activity of the Nr5a2
reporter construct in response to IL-13 in Stat6þ /þ and
Stat6M / macrophages (Fig. 1j). These results demonstrate
that STAT6 directly controls the transcription of LRH-1 in
response to IL-13.
LRH-1 is involved in IL-13-induced macrophage activation. In
order to assess the role of LRH-1 in IL-13-induced alternative
macrophage differentiation, we generated mice in which the
Nr5a2 gene was selectively disrupted in myeloid-derived cells.
To generate these animals, mice carrying floxed Lrh-1 alleles
were crossed with transgenic mice that express the Cre
recombinase under the control of the mouse phagocyte-selective
lysozyme promoter21,26. Compared with control (Lrh-1Mþ /þ )
macrophages, LRH-1 mRNA and protein levels were almost
undetectable in macrophages derived from the myeloid cell-
specific LRH-1-deficient (Lrh-1M / ) mice (Supplementary
Fig. 1a–c). Furthermore, the disruption of LRH-1 could not be
detected in other LRH-1-expressing tissues, such as the liver and
the colon (Supplementary Fig. 1d,e).
We then evaluated the expression of specific markers of
classical and alternative activation in untreated or IL-13-treated
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Figure 1 | IL-13-mediated LRH-1 gene expression is dependent on STAT6. (a) Nr5a2 mRNA expression in the colon, liver, peritoneal macrophages (MF),
B (LB) and T (LT) lymphocytes from C57BL/6 mice determined using RT–PCR. Inset shows in situ hybridization of Nr5a2 mRNA in peritoneal macrophages
from C57BL/6 mice (scale bar, 25mm). (b,c) Nr5a2mRNA expression in macrophages from C57BL/6 mice (b) and in human macrophages (c) treated with
the indicated cytokines for 4 h, determined using RT–PCR. The results were represented in fold induction relative to the untreated control or wild-type
littermate. (d,e) Nr5a2 mRNA expression in macrophages from C57BL/6 mice pretreated with AG490 and stimulated with IL-13 (d) and in macrophages
from Stat6þ /þ and Stat6 / mice stimulated with IL-13 for 4 h (e), determined using RT–PCR. The results were represented in fold induction relative to
the untreated control or wild-type littermate. (f) Immunoblot analysis of the nuclear expression of LRH-1 and TBP (Tata-binding protein) in macrophages
from Stat6þ /þ and Stat6 / mice stimulated with IL-13 for 24 h. (g,h) Luciferase activity in macrophages from C57BL/6 mice transfected with LRH-1
(LRH-1-luc) promoter construct pretreated with AG490 (g) or from Stat6þ /þ and Stat6 / mice (h), and treated with IL-13 for 24 h. The results were
represented in fold induction relative to the untreated control or wild-type littermate. (i) Schematic presentation of the four putative STAT6 response
elements in the mouse Nr5a2 promoter identified by Genomatix algorithm and assessment of STAT6 recruitment to site 1 and to the Arg1 promoter
determined with the ChIP analysis using genomic DNA from C57BL/6 macrophages treated with IL-13 for 4 h. (j) Luciferase activity in macrophages from
Stat6þ /þ and Stat6 / mice transfected with LRH-1 promoter constructs and treated with IL-13 for 18 h. The results were represented in fold induction
relative to the untreated control. Results correspond to mean±s.e.m. of triplicates. Data are representative of three independent experiments. *Po0.05
**Po0.01 compared with the respective untreated control and xPo0.05, xxPo0.01 compared with IL-13-treated wild-type littermate. P values were
determined using Bonferroni–Dunnett method.
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Lrh-1Mþ /þ and Lrh-1M / macrophages during 4 h. Overall,
Lrh-1M / macrophages displayed an upregulation of M1
markers such as Nos2 (encoding the inducible nitric oxide
synthase) and the Fcg-receptors Fcgr3 and Fcgr1 (encoding CD16
and CD64 proteins, respectively), which was mirrored by a
downregulation of Chi3l3 (YM1), Mrc1 (MR), Clec7a (Dectin-1),
Il1rn (IL-1ra) and Tgfb1 (transforming growth factor (TGF)-b1)
alternative activation markers (Fig. 2a,b). This was accompanied
by an increase in the mRNA and protein levels of the
inflammatory cytokines TNFa, IL-1b and IL-6 (encoded by
Tnfa, Il1b and Il-6 genes, respectively; Fig. 2a,c). Il12 pro-
inflammatory and Il10 anti-inflammatory cytokine mRNA levels
remained unchanged in Lrh-1Mþ /þ and Lrh-1M / macro-
phages (Fig. 2a). Furthermore, the induction of MR, Dectin-1,
CD36, Arg1 (encoding the arginase 1), Chi3l3 and Il1rn
expression by IL-13 was strongly diminished in Lrh-1M /
macrophages (Fig. 2a,b). Consistent with reduced alternative
activation markers in Lrh-1M / macrophages, the M1 markers
such as Nos2, Itgam (CD11b), Fcgr3, Fcgr1, Il1b and Il-6 still
remained highly expressed (Fig. 2a–c). Consistent with these
findings, the induction of alternative activation gene markers
observed after 4 h of IL-13 treatment was amplified after 24 h of
IL-13 treatment in Lrh-1Mþ /þ macrophages (Supplementary
Fig. 2a). Moreover, the decrease in alternative activation markers
in Lrh-1M / macrophages after 4 h of IL-13 treatment was
sustained after 24 h of stimulation (Supplementary Fig. 2a).
Altogether, these data indicate that LRH-1 is required for
repression of pro-inflammatory state and for optimal induction
of alternative macrophage activation by IL-13. These findings are
consistent with the robust induction of Il10, Tgfb1, Il1rn, Mrc1,
Clec7a and Cd36 gene expression in Lrh-1Mþ /þ macrophages
treated with the LRH-1 agonist DLPC (Supplementary Fig. 2b).
LRH-1 activates 15-HETE secretion via the control of CYP1s.
The nuclear receptor PPARg is a key component of the signalling
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Figure 2 | LRH-1 is involved in IL-13-induced alternative activation of macrophages. (a) Gene expression analysis of markers of M1 and M2 polarization
in peritoneal macrophages from Lrh-1Mþ /þ and Lrh-1M / mice treated with IL-13 for 4 h, determined using RT–PCR. The results were represented
in fold induction relative to the untreated Lrh-1Mþ /þ littermate. (b) Dot-plot representing Dectin-1, CD36 and MR protein expression in macrophages
from Lrh-1Mþ /þ and Lrh-1M / mice treated with IL-13 for 24 h. Numbers indicate the % of positive cells. Graphs represent geomean fluorescence
quantification for the indicated proteins. (c) Cytokine production of peritoneal macrophages from Lrh-1Mþ /þ and Lrh-1M / mice after IL-13 treatment
and C. albicans challenge for 8 h (ratio: 1 macrophage:3 yeasts), quantified by enzyme-linked immunosorbent assay. Results correspond to mean±s.e.m. of
triplicates. Data are representative of three independent experiments. *Po0.05, **Po0.01 compared to the respective untreated control and xPo0.05,
xxPo0.01 compared with Lrh-1Mþ /þ þ IL-13. P values were determined using the Bonferroni–Dunnett method.
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pathway triggered by IL-13 and directly controls the expression of
markers of alternative activation. To establish whether the
increase in alternative activation markers by IL-13 results from
direct regulation of PPARg transcription by LRH-1, we first
evaluated Pparg mRNA levels in Lrh-1Mþ /þ and
Lrh-1M / macrophages under basal conditions and after
IL-13 exposure. The increased Pparg mRNA level by IL-13 in
Lrh-1Mþ /þ macrophages was not affected in Lrh-1M / mac-
rophages (Fig. 3a). Moreover, in transient transfection studies,
absence of LRH-1 in Lrh-1M / macrophages (Fig. 3b) or
conversely ectopic expression of LRH-1 in wild-type macro-
phages (Fig. 3c) did not significantly affect IL-13-mediated
PPARg promoter induction, further indicating that LRH-1 does
not regulate the transcription rate of PPARg. Next, we examined
whether LRH-1 was required for PPARg activation by assessing
the impact of IL-13 on a heterologous PPARg reporter
transfected in Lrh-1Mþ /þ and Lrh-1M / macrophages.
Remarkably, while in Lrh-1Mþ /þ macrophages IL-13 sig-
nificantly induced the PPRE luciferase reporter, no such response
could be observed in Lrh-1M / macrophages (Fig. 3d).
Conversely, co-transfection of the PPRE luciferase reporter with
an expression vector for LRH-1 robustly increased PPARg acti-
vation (Fig. 3e), suggesting that LRH-1 induces the activity of
PPARg.
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Figure 3 | LRH-1 activates CYP1A1- and CYP1B1-dependent 15-HETE production. (a) Pparg mRNA expression in macrophages from Lrh-1Mþ /þ and
Lrh-1M / mice treated with IL-13 for 4 h, determined using RT–PCR. The results were represented in fold induction relative to the untreated wild-type
littermate. (b) Luciferase activity in macrophages from Lrh-1Mþ /þ and Lrh-1M / mice transfected with PPARg (PPARg-luc) promoter construct and
treated with IL-13 for 4 h. The results were represented in fold induction relative to the respective control. (c) Luciferase activity in macrophages from
C57BL/6 mice co-transfected with PPARg (PPARg-luc) promoter construct in presence (LRH-1) or absence (empty) of LRH-1 (pCMX-LRH-1) and treated
with IL-13 for 4 h. The results were represented in fold induction relative to the untreated control (empty). (d) Luciferase activity in macrophages from
Lrh-1Mþ /þ and Lrh-1M / mice transfected with a PPRE (PPRE-luc) construct treated with IL-13 for 24 h. The results were represented in fold induction
relative to the respective untreated control. (e) Luciferase activity of macrophages from C57BL/6 macrophages co-transfected with PPRE (PPRE-luc)
construct in presence (LRH-1) or absence (empty) of LRH-1 (pCMX-LRH-1), treated with IL-13 for 24 h. The results were represented in fold induction
relative to the respective control. (f) Gene expression analysis of arachidonic acid metabolic enzymes in macrophages from Lrh-1Mþ /þ and Lrh-1M /
mice treated with IL-13 for 4 h, determined using RT–PCR. The results were represented in fold induction relative to untreated Lrh-1Mþ /þ . (g) Immunoblot
analysis of Cyp1b1 and Actin in macrophages from Lrh-1Mþ /þ and Lrh-1M / mice stimulated with IL-13 for 24 h. (h,i) Gene expression analysis of Alox15,
Cyp1a1 and Cyp1b1 in macrophages from Stat6þ /þ and Stat6 / mice treated with IL-13 (h) and in macrophages from Lrh-1M / and Lrh-1Mþ /þ
mice stimulated with DLPC for 4 h (i), determined using RT–PCR. The results were represented in fold induction relative to untreated wild-type littermate.
(j) 15-HETE production by macrophages from Lrh-1M / and Lrh-1Mþ /þ mice stimulated with or without IL-13 quantified by enzyme immunoassay (EIA).
The results were represented in fold induction relative to untreated Lrh-1Mþ /þ . (k) [3H]AA mobilization in membrane phospholipids of macrophages from
Lrh-1M / and Lrh-1Mþ /þ mice stimulated with IL-13 for 2 h. (l) 15-HETE production by macrophages from Alox15 / and Alox15þ /þ mice stimulated
with IL-13 for 24 h and silenced or not for Cyp1a1 and Cyp1b1 (siRNA Cyp) measured by EIA. The results were represented in fold induction relative to
respective untreated control (siRNA C). Results correspond to the mean±s.e.m. of triplicates. Data are representative of three independent experiments.
*Po0.05, **Po0.01 compared with the respective untreated control and xPo0.05, xxPo0.01 compared with the corresponding treated or untreated wild-
type littermate. P values were determined using Bonferroni–Dunnett method.
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PPARg is activated by endogenous ligands derived from the
metabolism of AA. The COX1/COX2 cyclooxygenases, 5 and
12/15 lipoxygenases and CYP enzymes are considered to be
critical for the conversion of AA into endogenous PPARg ligands.
To identify how LRH-1 may have an impact on PPARg
activation, we next explored whether LRH-1 can coordinate
PPARg ligand availability through the control of the expression of
these enzymes. The mRNA levels of Ptgs2 (cyclooxygenase 2),
Alox5 (5 lipoxygenase) and Hpgds (prostaglandin-D synthase)
after IL-13 stimulation were not differentially expressed in
Lrh-1Mþ /þ and Lrh-1M / macrophages (Fig. 3f). However,
IL-13 robustly induced Alox15 (12/15 lipoxygenase), Cyp1a1 and
Cyp1b1 gene expression in Lrh-1Mþ /þ macrophages, while this
induction was blunted in Lrh-1M / macrophages. Moreover,
Cyp1b1 protein levels were only induced in Lrh-1Mþ /þ
macrophages on IL-13 exposure, but not in Lrh-1M /
macrophages (Fig. 3g). Unlike Cyp1a1 and Cyp1b1 mRNA levels,
which were unresponsive to the IL-13 treatment in Lrh-1M /
macrophages, Alox15 expression was still moderately induced
(Fig. 3f), indicating that Alox15 is only partially controlled by
LRH-1.
Consistent with these findings, a strong decrease in Alox15,
Cyp1a1 and Cyp1b1 expression could be observed in both
untreated and IL-13-treated Stat6 / macrophages (Fig. 3h),
further supporting the importance of STAT6 in the regulation of
these genes.
To further explore whether STAT6 controls the expression of
Alox15, Cyp1a1 and Cyp1b1 directly or indirectly through the
induction of LRH-1, we performed an in silico analysis of Alox15,
Cyp1a1 and Cyp1b1 promoters (Supplementary Fig. 3a). This
analysis revealed one putative LRH-1 and two putative STAT6-
RE in the Alox15 promoter, with more than 95% of similarity to
the consensus REs. Scanning of the Cyp1a1 and Cyp1b1 promoter
sequences indicated the presence of conserved LRH-1 REs in both
promoters, while no conserved STAT6 REs (matrix similarity
o0.8) could be identified in these regulatory regions
(Supplementary Fig. 3a). Consistent with these findings, DLPC
treatment increased Alox15, Cyp1a1 and Cyp1b1 gene expression
in Lrh-1Mþ /þ macrophages, but not in Lrh-1M / macro-
phages (Fig. 3i). These data confirm the importance of LRH-1 in
the regulation of Alox15, Cyp1a1 and Cyp1b1.
Finally, to assess whether these effects on gene expression also
translate into changes in endogenous ligand availability, 15-HETE
production was assessed. Interestingly, while IL-13 exposure
robustly enhanced 15-HETE levels in Lrh-1Mþ /þ macrophages,
this effect was completely lost in Lrh-1M / macrophages
(Fig. 3j). These findings indicate that LRH-1 is critically required
for IL-13-induced 15-HETE production in macrophages.
Importantly, IL-13-induced mobilization of AA was similar in
Lrh-1Mþ /þ and Lrh-1M / macrophages (Fig. 3k), indicating
that the generation of 15-HETE metabolites through LRH-1 is
dependent on AA metabolism.
To further dissect how LRH-1 promotes the production of
15-HETEs in response to IL-13, we assessed 15-HETE production
in Alox15-deficient macrophages on Cyp1a1 and Cyp1b1 short
interfering RNA (siRNA)-mediated silencing (Fig. 3l and
Supplementary Fig. 3b). Interestingly, the increased 15-HETE
production by IL-13 was still conserved in Alox15 / macro-
phages. Furthermore, the simultaneous gene silencing for Cyp1a1
and Cyp1b1 in both Alox15 þ /þ and Alox15 / macrophages
abolished this induction (Fig. 3l). Altogether, these data indicate
that LRH-1 drives the generation of 15-HETE metabolites
through its impact on CYP1 gene expression.
To define whether Cyp1a1 and Cyp1b1 are direct transcrip-
tional targets of LRH-1, transfection assays in Lrh-1Mþ /þ and
Lrh-1M / macrophages were performed using a luciferase
reporter containing ±1.2 kb of the promoter of the Cyp1a1 and
Cyp1b1 genes. IL-13 exposure of Lrh-1Mþ /þ macrophages
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resulted in an eightfold increase in reporter activity of both
Cyp1a1 and Cyp1b promoters (Fig. 4a,c). Interestingly, genetic
deletion of LRH-1 abolished this response, demonstrating that
Cyp1a1 and Cyp1b1 promoters are directly activated by LRH-1.
To identify the critical LRH-1 REs in the Cyp1a1 and Cyp1b1
promoters, we mutagenized the putative RE that were found by in
silico analysis (Supplementary Fig. 3a), and their response to
LRH-1 on IL-13 exposure was compared (Fig. 4a–c). For the
Cyp1a1 promoter, mutation of the first LRH-1 RE (site 1)
abolished the activity of the reporter construct in response to
IL-13, whereas mutation of site 2 was still responsive in
Lrh-1Mþ /þ macrophages (Fig. 4a). Furthermore, whole inhibi-
tion of mutated reporter construct activities in Lrh-1M /
macrophages established that site 1 is the principal site
transmitting the effect of LRH-1 on the Cyp1a1 promoter. Thus,
this result identified specific recruitment of LRH-1 to site 1, which
is most distal to the transcription initiation site in the Cyp1a1
promoter.
For the Cyp1b1 promoter, IL-13 treatment failed to increase the
activity of the mutated Cyp1b1 reporter in both Lrh-1Mþ /þ or
Lrh-1M / macrophages (Fig. 4c), indicating that LRH-1 binds
and activates the Cyp1b1 promoter through a unique sequence
between  742 and  728 bp upstream of the transcription
initiation site of the gene. Finally, ChIP assays were performed.
IL-13 enhanced the recruitment of LRH-1 on both Cyp1a1 and
Cyp1b1 sites in Lrh-1Mþ /þ macrophages, but not in Lrh-1M /
macrophages (Fig. 4b–d). Altogether, these results demonstrate
that LRH-1 directly binds Cyp1a1 and Cyp1b1 promoters and
hence controls the transcription of Cyp1a1 and Cyp1b1 genes in
response to IL-13.
LRH-1/CYP1-dependent 15-HETE release induces PPARc
activation. To further determine whether the generation of
15-HETE metabolites through LRH-1 are involved in PPARg
activation, we assessed whether supplementation of 15-HETE can
rescue the loss of PPARg activation in Lrh-1M / macrophages.
In contrast to IL-13, which could not induce PPARg activation
in Lrh-1M / macrophages, addition of exogenous 15-HETE
efficiently restored the induction of both a PPRE luciferase
reporter (Fig. 5a) and of PPARg target genes such asMrc1, Clec7a
and Cd36 (Fig. 5b) in Lrh-1M / macrophages, indicating that
the PPARg activation through LRH-1 is critically dependent on
15-HETE production.
To confirm that 15-HETE production through the LRH-1/
CYP1 axis induces PPARg activation, we evaluated PPARg
activation in macrophages silenced for Cyp1a1 and Cyp1b1.
Interestingly, PPARg activity as determined by the induction of a
PPRE luciferase reporter (Fig. 5c) and the induction of PPARg
target genes (Fig. 5d) by IL-13 were totally inhibited in
macrophages deficient for Cyp1a1 and Cyp1b1. Moreover, the
induction of a PPRE luciferase reporter (Fig. 5c) and of PPARg
target genes (Fig. 5d) was still significantly enhanced by IL-13 in
Alox15 / macrophages, showing that the 12/15 lipoxygenase is
not required for PPARg activation mediated by LRH-1. These
data are in support of a critical role of CYP1A1 and CYP1B1 in
LRH-1-mediated PPARg activation through 15-HETE synthesis.
IL-13 activation of macrophages requires STAT6/LRH-1/PPARc.
To determine whether STAT6 controls both directly the tran-
scription of markers of IL-13-mediated alternative activation and
indirectly through the activation of the LRH-1/PPARg axis, we
studied the mRNA level of alternative activation markers in
STAT6-deficient macrophages. IL-13-augmented induction of
Arg1, Chi3l3 (YM1), Retnla (Fizz1), MR, Clec7a and CD36 was
detected in Stat6þ /þ macrophages but not in Stat6 /
macrophages (Fig. 5e). The lack of IL-13-augmented induction of
alternative markers was associated with a failure of Stat6 /
macrophages to produce 15-HETE in response to IL-13 (Fig. 5f).
Interestingly, the addition of exogenous 15-HETE restored the
induction of alternative polarization markers in Stat6 /
macrophages and not in PpargM / macrophages (Fig. 5e and
Supplementary Fig. 3c). These data suggest that STAT6 is required
for induction of macrophage-alternative activation markers and
further support the existence of a PPARg-dependent mechanism in
the regulation of these genes.
Moreover, induction of Arg1, Retnla (Fizz1) and Chi3l3 (YM1)
in response to IL-13 was slightly decreased in PpargM /
macrophages, whereas the induction of Mrc1 (MR), Clec7a and
CD36 was completely abrogated in PpargM / macrophages
(Fig. 5g). These results indicate the existence of distinct regulatory
mechanisms involving either STAT6 with a modest contribution
of PPARg or predominantly controlled by the LRH-1/PPARg
axis. In line, the overexpression of Mrc1, Clec7a and Cd36 after
treatment with DLPC in PpargMþ /þ macrophages was not
detected in PpargM / macrophages (Fig. 5h), clearly establish-
ing that LRH-1 acts upstream from PPARg in the signalling
cascade leading to the PPARg-dependent gene expression.
IL-13-induced fungicidal properties of macrophages via LRH-1.
Previous work from our laboratory established the importance of
PPARg in the fungicidal functions of alternatively activated
macrophages27. On the basis of the current findings suggesting a
role for LRH-1 in PPARg-mediated alternative polarization
following IL-13 stimulation, we next investigated whether
deletion of LRH-1 in macrophages could have an impact on the
outcome of Candida albicans infection. The severe systemic
infection of mice with C. albicans resulted in a significantly lower
survival rate of Lrh-1M / mice compared with Lrh-1Mþ /þ
mice (Po0.001; Fig. 6a), supporting a role for LRH-1 in
antifungal defence. To further explore the exact function of
LRH-1 in the pathophysiology of fungal infection, we evaluated
the fungal burden in the intestinal tract and the macrophage
microbicidal functions in a murine experimental model of
gastrointestinal candidiasis. Lrh-1M / mice infected with
C. albicans had more severe gastrointestinal infection than their
wild-type littermates and showed worsened fungal burden in
the caecum (Fig. 6b). Remarkably, IL-13, 15-HETE, as well as
DLPC, diminished C. albicans gastrointestinal colonization in
Lrh-1Mþ /þ mice. However, these effects were lost in Lrh-1M /
mice treated with IL-13 or DLPC, but not when the PPARg
ligand, 15-HETE, was administered to the animals (Fig. 6b).
To investigate whether LRH-1 in macrophages has any relevant
microbicidal phenotype, we evaluated the capacity of Lrh-1Mþ /þ
and Lrh-1M / macrophages to kill yeasts in vitro. Compared
with Lrh-1Mþ /þ macrophages, Lrh-1M / macrophages
showed a defect in their ability to kill C. albicans, demonstrating
the contribution of LRH-1 in macrophage-intrinsic antifungal
activity (Fig. 6c). Consistent with our observation, Lrh-1M /
macrophages were less efficient in engulfing C. albicans and
producing reactive oxygen species (ROS) after fungal challenge
(Fig. 6d,e). Moreover, the defect of Lrh-1M / macrophages to
exert their antifungal activity was correlated with lower MR and
Dectin-1 protein levels after C. albicans challenge (Supplementary
Fig. 3d). As expected, treatment with IL-13 of Lrh-1Mþ /þ
macrophages increased the killing and the phagocytosis of
C. albicans and also ROS production in response to C. albicans.
These inductions were abrogated in Lrh-1M / macrophages,
underscoring the importance of LRH-1 in these fungicidal
functions (Fig. 6c–e). Similar effects were obtained when
macrophages were stimulated with DLPC (Fig. 6c–e).
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Interestingly, treatment with 15-HETE increased the fungicidal
functions in both Lrh-1Mþ /þ and Lrh-1M / macrophages
(Fig. 6c–e). Moreover, treatment with IL-13, DLPC and 15-HETE
of PpargM / macrophages did not increase the killing of
C. albicans (Fig. 6f), corroborating our findings that PPARg is
downstream from LRH-1 in the signalling pathway triggered by
IL-13, leading to macrophage fungicidal activities.
To unequivocally establish that the LRH-1/CYP1/HETE axis is
involved in macrophage-intrinsic antifungal activity of IL-13, we
evaluated the ability of macrophages silenced for Cyp1a1 and
Cyp1b1 (Cyp1) to kill C. albicans. Interestingly, the increase in
C. albicans killing by IL-13 and DLPC was inhibited by the
simultaneous gene silencing for Cyp1a1 and Cyp1b1 (Cyp1), but
not after 15-HETE stimulation (Fig. 6g). Taken together, these
data provide in vivo evidence that LRH-1 is involved in the
PPARg-dependent antifungal functions elicited by IL-13 through
CYP1-induced 15-HETE production.
Discussion
The nuclear receptor PPARg is essential for IL-13-induced
alternative differentiation of macrophages6,28,29. We have
previously demonstrated that IL-13, via the cPLA2 signalling
pathway, induced AA mobilization associated with the nuclear
localization of 15d-PGJ2, an endogenous PPARg ligand5. Once
activated, PPARg induces the transcription of Dectin-1, MR
and CD36, three genes characteristic of the alternative
activation5,30,31. Therefore, the processes leading to PPARg
activation, such as AA release and its subsequent metabolic
conversion, could be important aspects of alternative polarization
because they are limiting factors for PPARg ligand synthesis.
AA can be metabolized by the COX1/COX2 cyclooxygenases
to PGH2, which in turn is transformed by the PGD synthase into
15d-PGJ2 (refs 32,33). AA can also be directly metabolized to
12- and HETEs, other endogenous PPARg ligands, through 12/15
lipoxygenases34. A third pathway of AA metabolism leading to
endogenous PPARg ligand production is associated with its
conversion by the enzymes of the CYP family35–37. The CYP
enzymes generate two biological and active classes of eicosanoids,
the epoxy (EETs) and hydroxy (HETEs) derivatives10,11. The
CYP1 family is mainly involved in the formation of mid-chain
HETEs, such as 12- and 15-HETEs, through CYP1A1 and
CYP1B1 (refs 12,13).
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Figure 5 | STAT6/LRH-1/PPARc signaling is required for IL-13-mediated alternative activation of macrophages. (a) Luciferase activity in peritoneal
macrophages from Lrh-1Mþ /þ and Lrh-1M / mice transfected with a PPRE (PPRE-luc) construct and treated with IL-13 or 15-HETE for 24 h.
(b) Gene expression analysis of Mrc1, Clec7a and Cd36 in macrophages from Lrh-1Mþ /þ and Lrh-1M / mice treated with IL-13 or 15-HETE for 4 h,
determined by RT–PCR. (c) Luciferase activity of macrophages from ALox15þ /þ and ALox15 / mice transfected with a PPRE (PPRE-luc) construct and
siRNA targeting Cyp1a1 and Cyp1b1 (siRNA Cyp) and treated with IL-13 for 24 h. (d) Gene expression analysis of Mrc1, Clec7a and Cd36 in macrophages
from ALox15þ /þ and ALox15 / mice transfected with siRNA targeting Cyp1a1 and Cyp1b1 (siRNA Cyp) treated with IL-13 for 4 h and determined by
RT-PCR. (e,g) Gene expression analysis of Arg1 (arginase 1), Retnla (Fizz1), Chi3l3 (YM1), Mrc1, Clec7a and Cd36 in macrophages from Stat6þ /þ and
Stat6 / mice (e) or from PpargMþ /þ and PpargM / mice (g) treated with IL-13 or 15-HETE (e) for 24 h, determined by RT-PCR. (f) 15-HETE
production by macrophages from Stat6 / and Stat6þ /þ mice stimulated with IL-13 for 24 h measured by EIA. (h) Gene expression analysis of Mrc1,
Clec7a and Cd36 in macrophages from PpargMþ /þ and PpargM / treated with DLPC for 4 h, determined by RT-PCR. Results were represented in fold
induction compared to the respective untreated control or wild-type littermate and correspond to mean±s.e.m. of triplicates. Data are representative of
three independent experiments. *Po0.05, **Po0.01 compared to the respective floxed or not untreated control and xPo0.05, xxPo0.01 compared to the
corresponding untreated or treated wild-type littermate or siRNA control. P values were determined using Bonferroni–Dunnett method.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7801
8 NATURE COMMUNICATIONS | 6:6801 | DOI: 10.1038/ncomms7801 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
Here we report that the nuclear receptor LRH-1 is expressed in
macrophages and in response to IL-13 directly binds CYP1A1
and CYP1B1 promoters to positively regulate their transcription.
Moreover, 15-HETE production following IL-13 stimulation is
impaired in macrophages deficient for LRH-1 and not in
macrophages lacking 12/15 lipoxygenase, indicating that LRH-1
drives the generation of 15-HETE metabolites through its impact
on CYP1 gene expression. Consistently, our findings showing that
the concurrent gene silencing of Cyp1a1 and Cyp1b1 in
macrophages abolishes the generation of 15-HETE, provide
evidence that its production through the LRH-1/CYP1s axis is
crucial in PPARg activation. This is corroborated by the findings
that PPARg activation on IL-13 stimulation is lost in macro-
phages silenced simultaneously for CYP1A1/CYP1B1 and
restored by the addition of exogenous 15-HETE in macrophages
lacking LRH-1. Consistent with these observations, treatment of
macrophages with the LRH-1 agonist, DLPC, increased the
expression of CD36, MR and Dectin-1 PPARg target genes in
wild-type macrophages but not in macrophages lacking PPARg.
Altogether, these results establish that PPARg activation by IL-13
is dependent on the LRH-1/CYP1/15-HETE pathway. Another
endogenous activator to consider in PPARg activation is 15d-
PGJ2. Although we have previously shown that IL-13 generates
15d-PGJ2 production and its nuclear localization in macro-
phages5, the results in this study suggest that it is not sufficient to
activate PPARg. This is supported by previous reports showing
that 15d-PGJ2 concentration required to stimulate PPARg is in
the mM range, in contrast to other prostaglandins that are
normally active at low nM concentrations38,39. Thus, the levels
generated in vivo are not sufficient to be compatible with a role
for this metabolite as an endogenous PPARg ligand38,40.
Despite the growing knowledge with regard to the biological
function of LRH-1, little is known about how LRH-1 is controlled
at the transcriptional level. We identified STAT6 as a transcrip-
tional regulator of LRH-1. This was evidenced by the induction of
LRH-1 promoter activity by binding of STAT6 to its RE in the
LRH-1 promoter and by the decrease in LRH-1 mRNA and
protein levels in macrophages lacking STAT6. On the basis of the
established role of STAT6 in PPARg activation and macrophage
polarization41, these findings identify LRH-1 as a critical
component in the signalling cascades that drive PPARg-
mediated alternative macrophage activation. This was further
highlighted by the fact that macrophages lacking LRH-1 present
an increase in pro-inflammatory cytokines and the simultaneous
expression of other M1 markers. The involvement of LRH-1 in
anti-inflammatory responses was supported by the robust
reduction of LRH-1 gene expression in response to Th1
cytokines and conversely by the upregulation by Th2 cytokines.
Interestingly, LRH-1 was also induced in human macrophages in
response to the Th2 cytokine IL-13 via a mechanism that is most
likely also STAT6-dependent, given the presence of several
conserved STAT6 REs in the human LRH-1 promoter
(Supplementary Fig. 3a). Our findings may further explain why
during Crohn’s disease, characterized by a Th1 cytokine profile,
mRNA expression levels of LRH-1 are lower than in ulcerative
colitis, characterized by a Th2 immune response21. Consistent
with the anti-inflammatory role of LRH-1, IL-13-induced
alternative activation was impaired in macrophages lacking
LRH-1. Indeed, on IL-13 treatment, the induction of several
signature genes of alternative activation, including Arginase 1,
YM1, IL-1 receptor antagonist (IL-1ra), MR, Dectin-1 and CD36,
was significantly impaired in macrophages lacking LRH-1. This is
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Figure 6 | IL-13-induced antifungal properties of macrophages require LRH-1. (a) Survival of Lrh-1M / and Lrh-1Mþ /þ mice to an intraperitoneal
injection of C. albicans (1.108 yeasts per mouse, n¼ 32 per group). Survival (%) was assessed twice daily. *Po0.001 compared with Lrh-1Mþ /þ mice using
log-rank test. (b) Lrh-1Mþ /þ and Lrh-1M / mice were infected with C. albicans, and treated i.p. without (C) or with IL-13, DLPC or 15-HETE. C. albicans
gastrointestinal colonization in the caecum was determined on day 7 using RT–PCR. Data are represented as mean±s.e.m. *Po0.05 compared with the
respective untreated control and xPo0.05 compared with the corresponding untreated or treated Lrh-1Mþ /þ . The data are representative of at least two
independent experiments (n¼ 10 per group). (c) Killing assay of Lrh-1Mþ /þ and Lrh-1M / macrophages incubated with C. albicans. (d,e) Phagocytosis
(d) and ROS induction (e) of C. albicans were measured in macrophages from Lrh-1M / and Lrh-1Mþ /þ mice. Data are expressed as fold induction
relative to the fluorescence (c) or chemiluminescence (d) observed for untreated Lrh-1Mþ /þ . (f) Killing assay of PpargMþ /þ and PpargM /
macrophages incubated with C. albicans. (g) Killing assay of macrophages silenced for Cyp1a1 and Cyp1b1 incubated with C. albicans. *Po0.05, **Po0.01
compared with the respective untreated control and xPo0.05 xxPo0.01 compared with the corresponding treated wild-type littermate or siRNA control.
P values were determined using Bonferroni–Dunnett method. Results correspond to mean±s.e.m. of triplicates and are representative of at least three
independent experiments. For indicated measurements, treatments with IL-13, 15-HETE and DLPC were performed 24h before the challenge with
C. albicans.
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in agreement with reports showing that LRH-1 controls the
expression of anti-inflammatory IL-1ra and the scavenger
receptor class B type I, two markers specific of alternatively
activated macrophages22,23,42.
In addition to the key role of LRH-1 in the acquisition of
alternative activation of macrophages, this study also provides
mechanistic insight into the hierarchy between STAT6, LRH-1
and PPARg to achieve this phenotype. Our findings showing that
loss of induction of alternative activation markers in Stat6 /
macrophages can be restored by exogenous 15-HETE support the
notion that STAT6 is required for macrophage-alternative
activation through PPARg-dependent mechanism. Moreover,
the use of PpargM / macrophages provides evidence for the
existence of distinct mechanisms in the transcriptional regulation
of genes characteristics of alternative activation. Our results
demonstrate that the transcriptional regulation of Arginase 1,
Fizz 1 and YM1 involves directly STAT6 with a modest
contribution of PPARg and that Dectin-1, MR and CD36 are
regulated indirectly by STAT6 through the LRH-1/PPARg axis.
These observations are not only consistent with the requirement
of STAT6 to induce the majority of PPARg target genes41 but also
with the identification of PPARg as a positive regulator of
alternative activation6.
Consistent with the involvement of the LRH-1/PPARg path-
way in inducing MR and Dectin-1 expression during IL-13-
mediated alternative activation, loss of LRH-1 and PPARg in
macrophages also severely compromised their capacity to kill, to
engulf C. albicans and to produce ROS. This is in line with the
fact that LRH-1 is upstream from PPARg in the signalling
pathway leading to the induction of MR and Dectin-1, two C-type
lectin receptors strongly involved in the antifungal functions of
macrophages against C. albicans5,27,31. LRH-1 deficiency in
myeloid cells also rendered the mice highly susceptible to
gastrointestinal and systemic C. albicans infection, highlighting
LRH-1 of myeloid lineage as a key effector of host fungicidal
functions. Although we have not characterized the role of
neutrophils in this infectious context, our in vitro and in vivo
results identify LRH-1 as a nuclear receptor indispensable for
alternative activation of macrophages and for its associated
antifungal functions.
In conclusion, we have shown that loss of LRH-1 in
macrophages prevents IL-13-induced alternative activation of
macrophages, demonstrating the pivotal role of LRH-1 in the
differentiation of macrophages towards an anti-inflammatory and
antifungal phenotype. In response to IL-13, LRH-1 expression is
increased in macrophages through STAT6 and controls the
expression of CYP1A1 and CYP1B1 enzymes, which catalyses the
generation of 15-HETE PPARg ligand. Altogether, these results
establish that the alternative polarization of macrophages by
IL-13 is dependent on the STAT6/LRH-1/CYPs/15-HETE/
PPARg axis (Fig. 7). Finally, deletion of LRH-1 in myeloid cells
renders mice susceptible to gastrointestinal and systemic C.
albicans infection, highlighting LRH-1 as a critical factor for
antifungal functions. Synthetic agonists of LRH-1 activity may,
hence, constitute promising compounds for the treatment of
anti-infectious and anti-inflammatory diseases.
Methods
Mice. Male mice aged 10–12 weeks on C57BL/6 background were used for in vitro
and in vivo experiments. Mice were bred and handled by following protocols
approved by the Conseil Scientifique du Centre de Formation et de Recherche
Experimental Médico Chirurgical and the ethics board of the Midi-Pyrénées ethic
committee for animal experimentation (Experimentation permit number 31–067,
approval no. B3155503). All cages were changed twice weekly, and all manipula-
tions of the animals were carried out in a laminal blow hood under aseptic con-
ditions. The photoperiod was adjusted to 12-h light and 12-h dark. C57BL/6 mice
were purchased from Janvier (France) and Stat6 / mice and ALox15 / mice
were purchased from Jackson Laboratories. PpargM / mice deleted for Pparg
specifically in macrophages have been described earlier30,43. Nr5a2 (encoding
LRH-1) macrophage specific knockout mice (referred as Lrh-1M / mice) were
obtained by crossing mice carrying floxed Lrh-1 alleles with transgenic mice
expressing the Cre recombinase under the control of the mouse phagocyte-selective
lysozyme promoter21,26. For Lrh-1M / and PpargM / mice, the
corresponding floxed littermates were used as controls throughout all the
experiments. Corresponding littermates were used as controls for Stat6 /
and ALox15 / mice.
For the in vivo experiments, a gastrointestinal infection with the C. albicans
strain was established by gavage with 50 106 C. albicans per mouse (n¼ 10 per
group). Mice were treated or not intraperitoneally (i.p.) with IL-13 (Clinisciences),
DLPC (Sigma) or 15-HETE (Cayman). For IL-13 treatment, injections of 4 mg per
mouse were performed 1 day before and 3 days after the infection with C. albicans
(two injections). For DLPC (300 mg per 10 g of mouse) and 15-HETE (28 mg per
10 g of mouse), i.p. injections were realized 1 day before the day of the infection
with C. albicans and then every 2 days (five injections). Control groups received
saline solution only with DMSO. After 6 days of infection, the ceca were removed
aseptically for the experiments.
For C. albicans systemic infection, yeasts were administered i.p.
(100 106yeasts per mouse). Survival studies were conducted using 32 mice
per group and were repeated twice.
Human macrophages. Monocytes were obtained from healthy blood donors
(Etablissement Français du Sang, EFS Toulouse). Written informed consents were
obtained from the donors under EFS contract no. 21/PVNT/TOU/UPS04/2010–
0025. Following articles L1243-4 and R1243-61 of the French Public Health Code,
the contract was approved by the French Ministry of Science and Technology
(agreement no. AC 2009-921). Human peripheral blood mononuclear cells were
isolated from the blood of healthy volunteers by a density gradient centrifugation
method on Lymphoprep (Abcys). Monocytes were isolated by adherence to plastic
for 2 h in SFM (Gibco) at 37 C, 5% CO2. The macrophages were obtained after
3 days of culture only in SFM medium.
Preparation of mouse resident peritoneal macrophages. After being killed,
resident peritoneal cells were harvested by washing the peritoneal cavity with 5ml
of sterile NaCl 0.9%. Collected cells were centrifuged at 1,500 r.p.m. for 10min and
the cell pellet was suspended in Dulbecco’s modified Eagle’s medium (Invitrogen)
supplemented with glutamine (Invitrogen), penicillin, streptomycin (Invitrogen)
and 5% heat-inactivated fetal calf serum. Cells were allowed to adhere for 2 h at
37 C and 5% CO2. Nonadherent cells were then removed by washing with PBS.
Reverse transcription and real-time PCR. After washing, adherent macrophages
were immediately stimulated with IFNg (40UIml 1, Clinisciences), IL-6
(50 ngml 1, Clinisciences), LPS (1 ngml 1, Sigma), IL-4 (50 ngml 1, Miltenyi
Biotech), IL-13 (50 ngml 1, Clinisciences), IL-10 (50 ngml 1, Clinisciences),
15-HETE (1 mM, Cayman) or DLPC (50mM, Sigma) for 4 or 24 h. In indicated
experiments, adherent macrophages were pre-incubated or not with a Jak-2/STAT6
inhibitor, AG490 (1 nM, Tebu-Bio).
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Figure 7 | Schematic illustration of the role of LRH-1 in IL-13-alternative
activation program of macrophages and in associated fungicidal
activities. The alternative polarization of macrophages by IL-13 is
dependent on the increase of LRH-1 expression through STAT-6 which
controls the expression of Cyp1a1 and Cyp1b1 enzymes leading to the
generation of 15-HETE PPARg ligand.
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The mRNA preparation was made using the EZ-10 Spin Column Total RNA
Minipreps Super Kit (Bio Basic) using the manufacturer’s protocol. Synthesis of
cDNA was performed according to the manufacturer’s recommendations (Thermo
electron). RT–qPCR was performed on a LightCycler 480 system using LightCycler
SYBR Green I Master (Roche Diagnostics). The primers (Eurogentec) were
designed with the software Primer 3. Actb (Actin) mRNA was used as the invariant
control. Serially diluted samples of pooled cDNA were used as external standards
in each run for the quantification. Primer sequences are listed in Supplementary
Table 1.
In situ hybridization. In situ hybridization was performed with digoxigenin-
labelled RNA probe (Plasmid pBSSK Lrh-1) as previously described44. Briefly,
this manual nonradioactive method allows to detect specific complementary
mRNA sequences at the cellular level using digoxigenin-labelled probes in a
five-step procedure: hybridization of the probe to pretreated tissue at 65 C;
post-hybridization stringent washes; blocking steps to prepare for the
immunodetection; primary antibody anti-DIG-AP incubation; and colorimetric
enzymatic detection. The detection step lasts for 2–3 days.
Western blot analysis. Nuclear protein extracts were prepared, and lysates were
subjected to western blotting as described previously45. Briefly, nuclear protein
lysates were extracted following standard procedures. Protein extracts were
separated using SDS–PAGE. After protein transfer, membranes were incubated
overnight at 4 C with either a rabbit anti-Lrh-1 (ref. 21; 1/1,000), a rabbit
polyclonal anti-Tbp (Abcam, ab63766, ½,000), a rabbit anti-Cyp1b1 (Santa Cruz,
sc-133490, 1/200) or a Actin (Santa Cruz, sc-1615, 1/1,000) and then for 1 h at
room temperature with a peroxidase conjugated secondary antibody. Membranes
were washed, and proteins were visualized with the SuperSignal West Pico
Chemiluminescent Substrate (ThermoScientific). Images have been cropped for
presentation. Full-size images are presented in Supplementary Fig. 4.
Transfection experiments. Macrophages were pre-incubated or not with AG490
(1 nM) and then incubated with 1 mg of DNA per well of the indicated plasmids
(pGL3 promoter LRH-1-luciferase, pCMX-LRH-1, PPRE luciferase, pGL3 pro-
moter PPARg-luciferase, pGL4.12 promoter Cyp1a1-luciferase or pGL4.12 pro-
moter Cyp1b1-luciferase) with JetPei (Polyplus transfection) for 8 h according to
the manufacturer’s instructions. Then, the cells were stimulated or not with IL-13
(50 ngml 1) for 18 h. Supernatant was removed, luciferase substrate was added
and luminescence was measured with the Envision luminometer (Perkin Elmer).
For siRNA experiments, mouse Cyp1a1 and Cyp1b1 and control siRNA were
purchased from Origene. Macrophages were incubated with 20 nM of control
siRNA or Cyp1a1 and Cyp1b1 siRNA and with Lipofectamine 2000 (Invitrogen)
for 18 h according to the manufacturer’s instructions. Cells were then stimulated
with IL-13, DLPC or 15-HETE for 18 h.
ChIP. ChIP analysis was performed as described previously with minor adapta-
tions46. Briefly, the liver and colon from Lrh-1þ /þ and Lrh-1 / mice were
lysed (5mM PIPES pH 8.0, 85mM KCl, 0.5% NP40 with protease inhibitors). The
pellets or adherent macrophages from indicated mice were cross-linked with 1%
formaldehyde for 15min at room temperature. The cells were then lysed in nuclear
lysis buffer (50mM Tris-HCl pH 8.1, 10mM EDTA, 1% SDS with protease
inhibitors) and sonicated at 30% maximum power eight times. The supernatant
was diluted in immunoprecipitation-dilution buffer (0.01% SDS, 1.1% Trition
X-100, 1.2mM EDTA, 16.7mM Tris-Cl pH 8.1 and 167mM NaCl with protease
inhibitor) and precleared with Protein A agarose/salmon sperm DNA beads
(Invitrogen 101141). The samples were immunoprecipitated overnight at 4 C with
a rabbit Lrh-1 antibody21, normal rabbit IgG (Santa Cruz, sc-2027, 7 ml/ml) or with
a rabbit STAT6 antibody (Santa Cruz, sc-981, 7 ml ml 1). The beads were then
washed in low-salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM
Tris-HCl pH 8 and 150mM NaCl), high-salt buffer (0.1% SDS, 1% Triton X-100,
2mM EDTA, 20mM Tris-HCl pH 8 and 500mM NaCl) and LiCl buffer (1%
NP40, 1% deoxycholate, 1mM EDTA, 10mM Tris-HCl pH 8 and 250mM LiCl).
The samples were then boiled in chelex followed by incubation with proteinase K
solution (10 mgml 1 proteinase K; 10mM EDTA; and 37mM Tris-HCl, pH 6.5) at
55 C for 30min. DNA was purified using the EZ-10 Spin Column Total RNA
Minipreps Super Kit (Bio Basic), after which qPCR was performed. Data were
normalized for GAPDH promoter binding and expressed relative to IgG. ChIP
primer sequences are listed in Supplementary Table 2.
Reporter assays and site-directed mutagenesis. Genomic DNA was extracted
from mouse kidneys and the corresponding Cyp1a1 and Cyp1b1 promoter frag-
ments were amplified by PCR with primers containing KpnI and XhoI restriction
sites. The PCR products were then cloned into pENTR-D/TOPO (Invitrogen/
Lifetechnologies) plasmids, which were digested with KpnI and XhoI and then
ligated into pGL4.12 (Promega) reporter plasmids.
Mutagenesis was carried out with the GeneArt mutagenesis kit (Invitrogen/
Lifetechnologies) according to the manufacturer’s instructions. The sequences of
reporter constructs were analysed and confirmed.
Flow cytometry. The analysis was performed on nonadherent macrophages47
harvested by washing the peritoneal cavity with 5ml of sterile NaCl 0.9%. Collected
cells were centrifuged at 1,500 r.p.m. for 10min and the cell pellet was suspended in
PBS medium supplemented with 1% fetal calf serum (FCS). Surface expressed
Dectin-1 or CD36 was detected, respectively, using fluoroscein isothiocyanate
(FITC)-Dectin-1 monoclonal antibody (mAb; Serotec MCA2289F, 1/100) or
PE-CD36 mAb (Santa Cruz, sc-13572, 1/100) and was compared with an irrelevant
appropriate isotype control. To evaluate the mannose receptor (MR) surface
expression, we have used MR-specific ligand conjugated with FITC (Sigma A7790,
1mgml 1). All stainings were performed on PBS—1% FCS medium. A population
of 10,000 cells was analysed for each data point. All analyses were carried out in a
Becton Dickinson FACScalibur using the CellQuestPro software.
B and T lymphocytes were isolated from the mouse spleen with a PE-B220 mAb
(RD System FAB1217P, 1/10) and a PE-CD3 mAb (eBiosciences MCA500, 1/10)
using a Becton Dickinson Influx cell sorter.
ELISA Cytokine titration and EIA quantification of 15-HETE. Peritoneal
macrophages were stimulated with IL-13 for 18 h and challenged with non-
opsonized C. albicans at a yeast-to-macrophage ratio of 3:1 for 8 h. The production
of TNF-a, IL-1b and TGF-b in the cell supernatants was determined with
a commercially available OptiEIA kit (BD Biosciences) according to the
manufacturer’s instructions.
For 15-HETE quantification, the macrophages were stimulated with IL-13 for
18 h and 15-HETE were measured using EIA as recommended by the
manufacturer’s protocol (15(S)-HETE EIA kit, Cayman).
AA mobilization. Peritoneal macrophages were prelabelled with [3H]AA (1mCi
per well, Perkin Elmer) for 18 h. The prelabelled macrophages were then treated
with IL-13 (50 ngml 1) for 1 h. The cellular lipids were extracted twice with
hexane/isopropanol (3:2, v/v) and the [3H]AA content in membrane phospholipids
was quantified by measurement of the radioactivity by beta liquid scintillation
counting, as described with minor adaptations48.
C. albicans strain. The strain of C. albicans used throughout these experiments was
isolated from a blood culture of a Toulouse-Rangueil Hospital patient5. Fluorescent
C. albicans was prepared by adding C. albicans to FITC (Sigma) dissolved in sodium
carbonate buffer (pH 9.5) at room temperature for 3 h and washed by centrifugation
three times in sodium carbonate buffer before storage in aliquots of water at 4 C.
Phagocytosis assay and ROS quantification. For analysis of phagocytosis of
C. albicans, cultured macrophages were pretreated or not with IL-13, 15-HETE or
DLPC for 18 h and then challenged with six FITC-labelled yeasts per macrophage.
Phagocytosis was initiated at 37 C with 5% CO2 and stopped after 1 h by washing
the macrophages with ice-cold PBS. The number of C. albicans engulfed by
macrophages was determined with fluorescence quantification using the Envision
(Perkin Elmer) fluorimetry-based approach.
The oxygen-dependent respiratory burst of macrophages (ROS production) was
measured by chemiluminescence in the presence of 5-amino-2,3-dihydro-1,4-
phthalazinedione (luminol) using a thermostatically (37 C) controlled
luminometer (Wallac 1420 Victor2). The generation of chemoluminescence was
monitored continuously for 1 h after incubation of the cells with luminol (66 mM)
and pretreatment with IL-13, 15-HETE or DLPC for 18 h and challenge with C.
albicans (yeast-to-macrophage ratio: 3:1). Statistical analysis was performed using
the area under the curve expressed in counts  seconds.
Killing assay. The killing assay was performed as previously described49. Cells were
allowed to interact for 30min at 37 C with C. albicans (at a ratio of 0.3 yeast per
macrophage) and unbound yeasts were removed by four washes with medium.
Macrophages were then incubated at 37 C for 4 h. Control plates were kept at 4 C
to provide a measure of live C. albicans in the wells. After incubation, the medium
was removed and cells were lysed by incubation for 5min at 25 C with water at a pH
of 11. An excess of PBS was used to neutralize the lysis buffer, and CFU C. albicans
was determined by plating on Sabouraud plates and incubation overnight at 37 C.
Quantification of C. albicans in the caecum. Cell lysis and DNA extraction. After
mouse infection, ceca were aseptically removed and then crushed using lysing
matrix tubes (MP Biomedicals). Tissue sample homogenate (250 ml) was
resuspended in 200ml of lysis buffer for 2 h at 65 C and DNA was then extracted
with isopropanol and eluted with an elution buffer (High Pure PCR Template
preparation kit, Roche Diagnostics).
Light cycler-based PCR assay. The Light Cycler PCR and detection system
(Roche Diagnostics) was used for amplification and online quantification. PCR
analysis was performed as described previously27. Serially diluted samples of
genomic fungal DNA obtained from C. albicans cultures (40 106 cells) were used
as external standards in each run. Cycle numbers of the logarithmic linear phase
were plotted against the logarithm of the concentration of template DNA to
evaluate the number of yeast cells present in each tissue sample homogenate.
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Statistical analysis. For each experiment, the data were subjected to one-way
analysis of variance followed by the means multiple comparison method of
Bonferroni–Dunnett. For survival study, statistical significance was determined by
a log-rank test. Po0.05 was considered as the level of statistical significance.
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47. Lefèvre, L. et al. PPARg ligands switched high fat diet-induced macrophage
M2b polarization toward M2a thereby improving intestinal Candida
elimination. PLoS ONE 5, e12828 (2010).
48. Del Bufalo, A. et al. Contact sensitizers modulate the arachidonic acid
metabolism of PMA-differentiated U-937 monocytic cells activated by LPS.
Toxicol. Appl. Pharmacol. 256, 35–43 (2011).
49. Taylor, P. R. et al. Dectin-1 is required for beta-glucan recognition and control
of fungal infection. Nat. Immunol. 8, 31–38 (2007).
Acknowledgements
We thank Philippe Batigne and Bénédicte Bertrand from the Université Paul Sabatier
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(TRI imaging platform, IFR150/I2MC) for flow cytometry technical assistance. This
research project has received, through BIOASTER investment, funding from the
French Government through the Investissement d’Avenir programme (grant
nANR-10-AIRT-03). This research was also supported by a grant from l’Association
de la Recherche contre le Cancer (ARC) awarded to L.L. (DOC20120605122) and
Swiss Cancer Ligue (to K.S.).
Author contributions
A.C., K.S., B.P. and L.L. designed the study, analysed the data and wrote the manuscript.
L.L. and A.H. performed and analysed the experiments. S.S., C.M., B.C., C.D., M.A.E.,
E.M., J.B. and A.V. generated tools and/or helped with specific experiments.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing financial interests: The authors declare no competing financial interests.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7801
12 NATURE COMMUNICATIONS | 6:6801 | DOI: 10.1038/ncomms7801 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
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Introduction
Hepatic steatosis is characterized by the excessive accumulation 
of triglycerides as a consequence of an imbalance between the 
acquisition and disposal of fatty acids. Increased hepatic uptake of 
adipose tissue–derived fatty acids, defective breakdown via β-oxi-
dation, reduced VLDL-triglyceride secretion, and induced activity 
of master regulators of de novo lipogenesis, such as sterol element 
binding protein 1 (SREBP-1, encoded by Srebf1), are factors that 
contribute to the development of steatosis (1). Nonalcoholic fatty 
liver disease (NAFLD) comprises a spectrum of disorders, of which 
the earliest stage is characterized by the deposition of lipid drop-
lets within the cytoplasm of the hepatocytes. NAFLD increases the 
susceptibility to hepatocyte damage and inflammation, a condition 
termed nonalcoholic steatohepatitis (NASH), and can ultimately 
progress to cirrhosis and hepatocellular carcinoma (HCC) (1–4).
Liver receptor homolog 1 (LRH-1) is a nuclear receptor with 
diverse biological functions ranging from cell cycle regulation to 
the control of steroid homeostasis. In the liver, LRH-1 is an import-
ant regulator of glucose, cholesterol, and bile acid metabolism (5). 
Liver-specific Lrh-1 knockout mice display reduced glycolytic flux 
and de novo lipogenesis secondary to impaired glucokinase activity 
(6). On the other hand, treatment of mice with the LRH-1 agonist 
1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC) protects ani-
mals from developing NAFLD and insulin resistance in genetic and 
dietary models of diabesity (7, 8). To address this apparent contra-
dictory role of LRH-1 in hepatic triglyceride metabolism, we chose 
to study lipogenesis in our recently described Lrh-1 K289R knockin 
mouse model (LRH-1 K289R mice), which displays selective gain of 
function of LRH-1 as a result of impaired SUMOylation at K289 (9).
In this study, we demonstrate that LRH-1 K289R induces the 
expression of oxysterol binding protein-like 3 (OSBPL3, encoded by 
Osbpl3, also known as Orp3), which in turn promotes the posttrans-
lational activation of SREBP-1. As a consequence, LRH-1 K289R 
mice display increased de novo lipogenesis upon refeeding in com-
parison with WT mice. In fact, compared with what is seen in LRH-1 
WT mice, this chronic lipogenic stress promotes NAFLD in LRH-1 
K289R mice accompanied by early signs of NASH when mice are 
exposed to a lipogenic, high-fat, high-sucrose (HFHS) diet.
Results
Increased hepatic SREBP-1 processing in LRH-1 K289R mice. In order 
to evaluate the role of an LRH-1 SUMO–defective pathway on 
intermediary liver metabolism, we subjected LRH-1 K289R mice, 
which exhibit partial gain of function of LRH-1, and control LRH-1 
WT mice (9) to fasting-refeeding challenges in which mice were 
fasted and then refed for a period of 6 hours. We then evaluated 
the expression of metabolic genes in refed livers of both geno-
types using microarray analysis. Interestingly, the expression of 
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mental Figure 1, A and B; supplemental material available online 
with this article; https://doi.org/10.1172/JCI85499DS1) (10, 11), 
in LRH-1 K289R versus LRH-1 WT livers. Similarly, we did not 
observe differences in Srebf1a and Srebf1c expression in 2-, 6-, or 
12-hour–refed LRH-1 K289R and LRH-1 WT mice (Supplemental 
Figure 1C). Taken together, these data suggest that LRH-1 K289R 
induces SREBP-1 signaling primarily at the posttranscriptional 
level independently of early insulin-AKT signaling.
Enhanced de novo lipogenesis in LRH-1 K289R mice. To verify 
whether the increased expression of lipogenic genes is accompa-
nied by hepatic fat accumulation, we next quantified hepatic tri-
glyceride content in LRH-1 K289R and LRH-1 WT mice. The con-
tent of neutral lipids and triglycerides was significantly increased 
in LRH-1 K289R compared with LRH-1 WT livers upon refeeding 
(Figure 1, D and E). Of note, plasma triglycerides and free fatty 
many SREBP-1 target genes was increased in 6-hour–refed LRH-1 
K289R compared with LRH-1 WT livers, whereas SREBP-2 targets 
were not altered (Figure 1A). Although no changes in Srebf1 mRNA 
(Figure 1B) or uncleaved precursor SREBP-1 (Figure 1C) could 
be observed between both genotypes, refed LRH-1 K289R livers 
displayed significantly more of the cleaved and transcriptionally 
active SREBP-1 protein in comparison with the LRH-1 WT livers 
(Figure 1C), indicating that the posttranslational processing and 
maturation of SREBP-1 is increased in LRH-1 K289R mice. We 
then performed acute insulin challenges as well as shorter 2-hour 
refeeding experiments to analyze whether early signaling events 
could explain the increased SREBP-1 activity. Insulin did not 
induce an additional increase in AKT phosphorylation or a con-
sistent induction of early response genes, such as activating tran-
scription factor 3 (Atf3) or early growth response 1 (Egr1) (Supple-
Figure 1. LRH-1 K289R mice display increased de novo lipogenesis. (A) Heat map showing the expression of genes involved in de novo fatty acid and cho-
lesterol synthesis in refed WT and K289R mice. Normalized expression values are in log
2
 scale. SREBP-1, depicting mainly SREBP-1 target genes; SREBP-2, 
mostly SREBP-2 target genes; NS, transcripts that are not significantly changed between the indicated genotypes. For all other transcripts P < 0.05. (B) 
Hepatic mRNA expression of Srebf1 in K289R and WT mice. n = 10 per genotype. (C) Left, immunoblots of precursor and cleaved (cl) SREBP-1, SCD1, HSP90, 
and P62 in hepatic lysates of WT or K289R livers. Right, graph displaying the ratio of cleaved to precursor SREBP-1. (D) Representative images of liver 
sections of K289R or WT mice stained with oil red O to visualize neutral lipids. Scale bar: 200 μm. (E) Quantification of hepatic triglyceride content in WT 
and K289R mice. n = 10 per group. (F and G) Plasma triglyceride (TG) and free fatty acid (FFA) contents in WT and K289R mice. n = 10 per group. (H–J)  
Fractional de novo synthesis rates of palmitate (H), stearate (I), and oleate (J) in WT and K289R mice. n = 6 per group. Error bars represent mean ± SEM.  
*P < 0.05, **P < 0.01 relative to WT within each nutritional state; §P < 0.001 refed relative to fasted mice, as determined by unpaired Student’s t test (A) 
or 2-way ANOVA with Bonferroni’s post-hoc test (B, C, E–J). WT, LRH-1 WT; K289R, LRH-1 K289R mice.
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recently implicated in the shuttling of lipids between the plasma 
and endoplasmic reticulum membrane (12–14). The expression of 
Osbpl3, and to a lesser extent Osbpl1a, was robustly induced in LRH-1 
K289R livers, while that of most other OSBP family members did 
not differ between the 2 genotypes (Figure 2A). Of interest, overex-
pression of certain oxysterol-binding proteins has been suggested as 
increasing SREBP-1 processing and hepatic lipogenesis (15). Analy-
sis of livers of LRH-1 K289R versus LRH-1 WT mice confirmed the 
enhanced expression of Osbpl3 mRNA during fasting and refeeding 
(Figure 2B), while the expression of other OSBP family members 
did not differ between the 2 genotypes (Supplemental Figure 2A). 
Notably, the expression of Osbpl3 was high during fasting and then 
reduced upon refeeding (Figure 2B). This postprandial suppression 
of Osbpl3 mRNA expression was also observed upon overexpres-
sion of Osbpl3 in mice using an adenovirus (Supplemental Figure 
2B), suggesting that during the refed state, Osbpl3 is regulated by 
posttranscriptional mechanisms occurring independently of LRH-1. 
Despite this feeding-dependent regulation of the mRNA, hepatic 
Osbpl3 mRNA levels were consistently higher in the LRH-1 K289R 
acids did not show significant alterations between LRH-1 K289R 
and LRH-1 WT mice (Figure 1, F and G). To verify whether the 
enhanced expression of lipogenic genes translates into increased 
de novo lipogenesis, animals received 13C-acetate prior to sacri-
fice to quantify de novo lipogenesis (6). In line with the increased 
lipogenic gene expression, de novo synthesis of palmitate (C16:0), 
stearate (C18:0), and oleate (C18:1) was significantly higher in 
LRH-1 K289R compared with LRH-1 WT livers (Figure 1, H–J). Of 
note, chain elongation of preexisting fatty acids was not altered 
between the 2 genotypes (Supplemental Figure 1, D and E). Collec-
tively, these data show that LRH-1 K289R mice display increased 
de novo lipogenesis and that enhanced activation of SREBP-1 like-
ly contributes to this process.
SUMOylation-defective LRH-1 drives the expression of Osbpl3. We 
next analyzed the transcriptome of livers from refed LRH-1 K289R 
and LRH-1 WT mice and searched for transcripts that are linked to 
SREBP-1 processing. One of the top hits on the list of genes that was 
increased in LRH-1 K289R compared with LRH-1 WT livers cor-
responded to Osbpl3, a member of a class of lipid transfer proteins 
Figure 2. Osbpl3 is a direct LRH-1 target gene and overexpressed in LRH-1 K289R mice. (A) Heat map showing the hepatic expression of oxysterol-binding 
protein family members in WT and K289R mice. Normalized expression values are in log
2
 scale. (B and C) Expression of Osbpl3 mRNA in hepatic lysates 
of fasted and refed WT and K289R mice (B) and the fold change between the genotypes (C). n = 4 per fasted, 2-hour–, or 12-hour–refed groups, and n = 5 
per 6-hour–refed groups. (D) Expression levels of OSBPL3 protein in hepatic lysates of fasted and refed WT and K289R mice. (E) Schematic showing the 
genomic area containing the Osbpl3 gene and the sites used for ChIP-qPCR experiments (mouse genome assembly mm10). (F and G) Binding of LRH-1 to 
the different Osbpl3 promoter sites assessed by ChIP analysis using genomic DNA from fasted WT (F) and refed WT livers (G). n = 5 WT fasted, n = 5 WT 
refed. Error bars represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, §P = 2 × 10–7 relative to WT, as determined by unpaired Student’s t test (A), or 
1-way (C) or 2-way (B, F, G) ANOVA with Bonferroni post-hoc test. TSS, transcription start site.
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LRH-1 target genes, including lipogenic genes, are coregulated by 
members of the LXR subfamily (20–22), we assessed the possibil-
ity that the LRH-1 mutant may modulate the recruitment of LXRα 
to its target genes, Abca1, Chrebp, and Srebf1. Although recruit-
ment of LXRα was detected on these promoters in the genom-
ic lysates of LRH-1 K289R and LRH-1 WT livers, no differences 
were observed between both genotypes, suggesting that LXRα 
binding is not altered due to the LRH-1 K289R mutation (Sup-
plemental Figure 3A). Furthermore, Hepa 1.6 and AML-12 cells 
treated with the LXR agonist GW3965 did not alter Osbpl3 expres-
sion (Supplemental Figure 3, B and C), indicating that Osbpl3 
expression is not regulated by LXR.
Osbpl3 silencing rescues the steatotic phenotype of LRH-1 K289R 
mice. To establish whether the increased expression of OSBPL3 in 
LRH-1 K289R livers is causatively linked to exacerbated de novo 
lipogenesis, we performed in vivo overexpression and silencing 
experiments. Adenoviral overexpression of OSBPL3 increased 
mice in all nutritional states, but were particularly high under 
6-hour–refeeding conditions (Figure 2C), and these differences 
were translated into similar changes at the protein level (Figure 2D).
To investigate whether Osbpl3 is directly controlled by LRH-1, 
we first analyzed the Osbpl3 genomic region in available ChIP-Seq 
data for potential LRH-1–binding sites (16, 17). We identified 3 
main sites from the ChIP-Seq data from Holmstrom et al. (sites 1–3; 
ref. 16), and 3 additional sites with an LRH-1 consensus sequence 
close to one of the transcription start sites of the Osbpl3 gene (sites 
4–6) were identified by computational analysis (Figure 2E). We 
then performed site-specific ChIP analysis to evaluate whether 
these sites are bound by LRH-1 in fasted and refed mice. LRH-1 was 
recruited at different sites under both nutritional conditions (Fig-
ure 2, F and G), suggesting that Osbpl3 is a direct LRH-1 target gene.
Based on the fact that LRH-1 and the nuclear receptor liver X 
receptor (LXR) have been shown to crosstalk in the regulation of 
hepatic acute-phase response proteins (18, 19) and that various 
Figure 3. Osbpl3 silencing rescues the lipogenic phenotype of LRH-1 K289R mice. (A) Immunoblots of OSBPL3, HSP90, precursor and cleaved SREBP-1, 
P62, and HDAC3 in hepatic lysates of fasted or refed WT plus Ad-GFP or refed WT plus Ad-OSBPL3 livers. (B–D) Hepatic mRNA expression of Osbpl3 (B), 
Srebf1 (C), and Fasn (D) in refed K289R and WT mice. WT, n = 3; K289R siScr or K289R siOsbpl3, n = 9 per genotype. (E) Immunoblots of OSBPL3, FASN, 
β-actin, precursor and cleaved SREBP-1, and PARP1 in hepatic lysates of refed K289R siScr or K289R siOsbpl3 livers. (F) Hepatic expression of OSBPL3, 
FASN, SCD1, and HSP90 in livers of ad libitum–fed WT, K289R siScr, and K289R siOsbpl3 mice. (G) Hepatic mRNA expression of genes involved in de novo 
lipogenesis in ad libitum–fed WT, K289R siScr, and K289R siOsbpl3 mice. n = 3 per genotype. (H) Quantification of hepatic triglycerides in hepatic lipid 
extracts from ad libitum–fed WT, K289R siScr, and K289R siOsbpl3 mice. n = 3 per genotype. (I and J) Hepatic mRNA expression of Osbpl3 (I) and Fasn 
(J) in 6-hour–refed WT, K289R, or K289R mirOsbpl3 mice. n = 3 per genotype. (K) Representative oil red O staining in liver cryosections from refed K289R 
mirScrambled or K289R mirOsbpl3 mice. Scale bars: 100 μm. Error bars represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 relative to K289R siScr, 
as determined by 1-way ANOVA with Bonferroni’s post-hoc test (B–D, G–J). WT, LRH-1 WT; K289R siOsbpl3, LRH-1 K289R mice injected with Osbpl3- 
siRNA complexes; K289R siScr, LRH-1 K289R mice injected with scrambled-siRNA complexes; K289R mirOsbpl3, LRH-1 K289R mice injected with AAV8 
viral vectors containing an miRNA targeting Osbpl3.
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expression levels of the lipogenic enzymes acetyl–coenzyme A 
carboxylase alpha (Acaca), Fasn, Scd1, and glycerol-3-phosphate 
acyltransferase (Gpam) were often normalized to values observed 
in LRH-1 WT mice (Figure 3G), suggesting that Osbpl3 silencing 
rescues the lipogenic phenotype of LRH-1 K289R mice. In line 
with the reduced expression of lipogenic genes, Osbpl3 silencing 
also decreased hepatic triglyceride and neutral lipid content (Fig-
ure 3H). As an additional approach to silence Osbpl3, we injected 
mice with an AAV8 viral vector containing an miRNA targeting 
Osbpl3 in the liver. Here again, we observed a robust silencing of 
Osbpl3, which was accompanied by the suppression of Fasn and a 
striking reduction of hepatic lipid droplets (Figure 3, I–K).
Finally, we also examined whether other mechanisms, direct-
ly or indirectly regulated by LRH-1, may contribute to the lipo-
genic phenotype. Of interest, both hepatic glucose-6-phosphate 
content (6) and VLDL secretion (23) were unchanged between 
SREBP-1 cleavage in refed LRH-1 WT mice (Figure 3A), suggest-
ing that elevated OSBPL3 levels promote SREBP-1 activation. We 
next silenced Osbpl3 in LRH-1 K289R mice using siRNAs in LRH-1 
K289R mice under fast-refeeding conditions. The hepatic mRNA 
expression of Osbpl3 showed a clear trend of effective silencing 
(Figure 3B), while Srebf1 expression was not altered (Figure 3C). 
Importantly, we observed a robust decrease in OSBPL3 protein 
along with a reduction in the maturation of SREBP-1 and a blunted 
expression of the fatty acid synthase (FASN) transcript and pro-
tein in the livers of refed LRH-1 K289R mice treated with siOsbpl3 
(Figure 3, D and E). We next assessed the effect of Osbpl3 silenc-
ing under normal-fed conditions. Western blot analysis revealed 
reduced OSBPL3 expression (Figure 3F) and a robust decrease in 
the lipogenic proteins FASN and stearoyl–coenzyme A desaturase 1 
(SCD-1) in ad libitum–fed LRH-1 K289R mice treated with siOsbpl3 
compared with control mice (Figure 3F). Of interest, mRNA 
Figure 4. LRH-1 K289R mice develop NAFLD upon HFHS diet feeding. (A) Representative images of liver sections of K289R or WT mice stained with 
H&E or oil red O to visualize the tissue structure and neutral lipids, respectively. Black scale bar: 200 μm; white scale bar: 50 μm. (B and C) Quantification 
of triglyceride content in plasma (B) and in hepatic lipid extracts (C) in WT and K289R mice. WT, n = 7; K289R, n = 10. (D and E) Plasma levels of ALAT (D) 
and ASAT (E) in mice fed a HFHS diet. WT, n = 7; K289R, n = 10. (F and G) Expression of Osbpl3 mRNA (F) and protein (G) levels in livers of WT and K289R 
mice fed chow and HFHS diets. n = 9 per genotype. (H) Heat map displaying the expression of Osbpl3 as well as markers of matrix degradation, fibrosis, 
and inflammation in mice that were classified as LFL responders, LFH responders, HFL responders, and HFH responders according to the development 
of NAFLD/NASH upon chow or high-fat diet feedin g (24). (I) Expression of OSBPL3 and markers of matrix degradation, fibrosis, and inflammation in 
transcriptomic data from human patients that were categorized for mild or advanced NAFLD (25). Normalized expression values are in log
2
 scale. Error bars 
represent mean ± SEM. **P < 0.01, ***P < 0.001 relative to WT; §P < 0.001 refed relative to fasted mice, as determined by unpaired Student’s t test (B, D, 
E) or 2-way ANOVA with Bonferroni’s post-hoc test (C, F).
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LRH-1 K289R and LRH-1 WT mice (Supplemental Figure 4, A–C), 
making it unlikely that these processes account for the exacerbat-
ed lipid accumulation in liver.
Together, these data suggest that the LRH-1-OSBPL3 signal-
ing axis contributes to the increased maturation of SREBP-1, the 
induction of lipogenic enzymes, and the hepatic accumulation of 
triglycerides observed in LRH-1 K289R mice.
LRH-1 K289R mice are prone to developing NAFLD upon lipo-
genic diet feeding. Excessive de novo lipogenesis contributes to the 
development of NAFLD, a condition that can eventually progress 
to NASH (1, 3). In order to investigate whether LRH-1 affects the 
development of NAFLD, LRH-1 K289R and LRH-1 WT mice were 
fed a highly lipogenic HFHS diet or a chow diet for 17 weeks, and 
then sacrificed under normal-fed conditions. Stainings of hepatic 
sections with H&E and oil red O revealed that LRH-1 K289R mice 
developed a stronger steatotic phenotype compared with LRH-1 
WT mice fed a HFHS diet (Figure 4A). While plasma cholester-
ol levels were unchanged (Supplemental Figure 5A), triglyceride 
content in plasma (Figure 4B) or in VLDL fractions (Supplemen-
tal Figure 5B) was reduced in HFHS-fed LRH-1 K289R mice. This 
reduction was accompanied with a robust accumulation of hepatic 
triglycerides (Figure 4C) as well as an induction of plasma levels of 
the enzymes alanine transaminase (ALAT) and aspartate amino-
transferase (ASAT) in the HFHS-challenged LRH-1 K289R mice 
(Figure 4, D and E). Similar to our earlier observations in normal 
chow diet conditions (Figure 2, A–D), Osbpl3 mRNA and OSBPL3 
protein were significantly induced in LRH-1 K289R compared 
with LRH-1 WT mice fed a HFHS diet (Figure 4, F and G), while 
the expression of other Osbp genes did not differ between the gen-
otypes (Supplemental Figure 5C).
The development of hepatic steatosis in mice is known to be 
highly heterogeneous (24). Therefore, we analyzed the data from a 
study in which mice were fed a chow or high-fat diet and then clas-
sified according to the development of NAFLD/NASH into low-
fat low (LFL) responders, low-fat high (LFH) responders, high-fat 
low (HFL) responders, and high-fat high (HFH) responders (24). 
Interestingly, the expression of Osbpl3 was significantly induced 
in the HFH responders along with markers of inflammation and 
Figure 5. LRH-1 K289R mice display increased inflammation and early signs of fibrosis upon HFHS diet feeding. (A) Representative images of liver 
sections of K289R or WT mice stained with sirius red or CD45 to visualize collagen depositions and CD45-positive cells, respectively. Scale bars: 200 μm. CV, 
central vein. (B–E) Hepatic mRNA expression of genes involved in inflammation (B), matrix degradation (C), fibrosis (D), and stellate cells (E) in K289R and 
WT mice. n = 9 per genotype. (F) Graphical presentation showing how the LRH-1/OSBPL3 axis drives the accumulation of hepatic lipids. Error bars represent 
mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 relative to WT within each diet, as determined by 2-way ANOVA with Bonferroni’s post-hoc test (B–E).
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necrosis (Figure 4H) and was by far the most strikingly increased 
Osbp among all family members (Supplemental Figure 5D). We 
also analyzed OSBPL3 expression in 2 cohorts of NAFLD/NASH 
patients. In the first cohort, livers were categorized as showing 
mild or advanced NAFLD (25). In the second study, subjects had 
livers ranging from healthy controls to showing steatosis and fur-
ther to NASH (26). OSBPL3 expression was low in healthy livers, 
but increased in advanced stages of NAFLD/NASH and clustered 
with markers of fibrosis (Figure 4I and Supplemental Figure 6), 
suggesting that OSBPL3 could be a novel biomarker for advanced 
liver diseases, such as NASH. Taken together, these data show that 
Osbpl3 is markedly increased in LRH-1 K289R mice as well as in 
mice and humans with NAFLD/NASH.
LRH-1 K289R mice display increased inflammation and early 
signs of fibrosis in response to lipogenic diet feeding. Given the strong 
steatotic phenotype and the high levels of ALAT and ASAT mark-
ers in LRH-1 K289R mice fed a HFHS diet as well as the cluster-
ing of Osbpl3 with genes involved in inflammation and fibrosis 
in mice and humans with NAFLD, we next analyzed inflamma-
tory and fibrotic markers in LRH-1 K289R and LRH-1 WT mice. 
Stainings of hepatic sections with sirius red and CD45 revealed 
that, in contrast with LRH-1 WT mice, LRH-1 K289R mice devel-
oped small fibrotic lesions and accumulated CD45-positive 
immune cells upon HFHS feeding (Figure 5A). Moreover, LRH-1 
K289R livers displayed higher levels of the inflammatory genes 
Tnfα, monocyte chemoattractant protein-1 (Mcp1 or Ccl2), and 
macrophage inflammatory protein-1 α (Mip1α or Ccl3) (Figure 
5B), indicating increased inflammation in livers of HFHS-fed 
LRH-1 K289R mice. The expression of MMPs, such as Mmp2 
and Mmp13, as well as early markers of fibrosis, such as α-1 type I 
collagen (Col1a1) and Tgfb1, was also elevated in LRH-1 K289R 
in comparison with LRH-1 WT mice fed a HFHS diet (Figure 5, 
C and D). Hepatic stellate cells are the primary hepatic cell type 
promoting fibrogenesis (27). The expression of different hepatic 
stellate cell markers, such as desmin (Des), glial fibrillary acidic 
protein (Gfap), and reelin (Reln), was also increased in HFHS-
fed LRH-1 K289R compared with LRH-1 WT mice (Figure 5E), 
suggesting that HFHS-treated LRH-1 K289R mice exhibit early 
signs of NASH.
Previous studies showed that LRH-1 and the SUMOylation 
machinery might affect the hepatic acute phase response (APR) 
(18, 19, 28). While induction of the APR by short exposure of LPS 
led to reduced hepatic expression of Crp and Tnf in LRH-1 K289R 
compared with LRH-1 WT mice, it did not alter the hepatic expres-
sion of other APR and inflammatory genes (Supplemental Figure 
7A). Moreover, no difference in plasma IL-6, MCP-1 (also known 
as CCL-2), or TNF-α could be observed in LPS-challenged LRH-1 
K289R and LRH-1 WT mice (Supplemental Figure 7B), suggesting 
that the APR is likely not driving the observed inflammatory phe-
notype in our NAFLD-model.
Taken together, these data show that SUMOylation-defective 
LRH-1 promotes the development of NAFLD and displays early 
signs of NASH in mice fed a HFHS diet. This process is at least 
partially driven by the LRH-1-OSBPL3 signaling axis, which con-
tributes to increased maturation of SREBP-1, the induction of lipo-
genic enzyme expression, and hepatic triglyceride accumulation 
in LRH-1 K289R mice (Figure 5F).
Discussion
In this study, we analyzed the contribution of a selective LRH-1 
gain of function on hepatic de novo lipogenesis and fatty liver 
development and identified Osbpl3 as a critical component in the 
regulation of this process. While the hepatic expression of Osbpl3 is 
normally low in mice under basal conditions, LRH-1 K289R mice 
express high levels of this specific OSBP family member. Consis-
tent with our observations, the analyses of independent mouse 
and human transcriptomic data sets revealed that Osbpl3 expres-
sion is often induced in NAFLD/NASH. Our work furthermore 
strengthens the putative role of OSBPL3 in SREBP-1 maturation. 
As a consequence, LRH-1 K289R mice display increased de novo 
lipogenesis and accumulation of triglycerides upon refeeding 
in a manner that is independent of enhanced LXRα recruitment 
or activity. Importantly, silencing of OSBPL3 in vivo reverts the 
increased lipogenesis observed in these animals. Moreover, when 
exposed to a lipogenic HFHS diet, LRH-1 K289R mice develop 
NAFLD accompanied by early signs of NASH, most likely as a con-
sequence of chronic fat accumulation (1, 3).
The excessive accumulation of hepatic lipids and increased de 
novo lipogenesis could also have other causes. A previous study 
using liver-specific Lrh-1 knockout mice showed that LRH-1 pro-
motes glucokinase expression, hence regulating glycolysis and de 
novo lipogenesis (6). However, we did not observe a difference 
in hepatic glucose-6-phosphate content between LRH-1 WT and 
LRH-1 K289R mice, suggesting that the selective gain of function 
of LRH-1 driven by the K289R mutation does not increase substrate 
availability for the glycolytic pathway. Based on the finding that 
the primary corepressor of LRH-1 affects microsomal triglyceride 
transfer protein levels and consequently hepatic VLDL-triglyceride 
secretion (23), we also performed in vivo VLDL-secretion assays, 
but could not detect any difference between refed LRH-1 K289R 
and LRH-1 WT mice. Finally, LRH-1 SUMOylation has been linked 
to the induction of the hepatic APR (18, 19, 28), which could explain 
the excessive inflammation observed in the livers of mice receiv-
ing a chronic HFHS diet. To study the APR in vivo, we challenged 
LRH-1 WT and LRH-1 K289R mice with lipopolysaccharide for 2.5 
hours. Besides the reduction in Crp and Tnf, the inflammatory sig-
nature was comparable between the genotypes, suggesting that the 
exacerbated inflammatory phenotype of the LRH-1 K289R mice is 
most likely not driven by changes in the APR.
While the induction of SREBP-2 processing has been well 
described, the mechanisms that trigger SREBP-1 processing are 
less well understood (29). Insulin receptor/AKT/mTOR signaling 
is considered one of the main pathways triggering SREBP-1 sig-
naling (30). A recent study showed that insulin promotes SREBP-1 
activation and de novo lipogenesis via mTORC1-dependent 
and -independent mechanisms (31). Others proposed that while 
insulin signaling is required for SREBP-1 activation in insulin- 
resistant conditions, it is not critical for inducing the feeding- 
dependent induction of SREBP-1 under physiological conditions 
(32, 33). In breast epithelial cells, the expression of oncogenic 
forms of the PI3K or K-Ras are sufficient to induce SREBP-1 matu-
ration and de novo lipogenesis through induction of mTOR signal-
ing (34). Whereas these and many other studies demonstrate that 
the expression of Srebf1 and the posttranslational maturation of 
SREBP-1 can be triggered by insulin signaling, other downstream 
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old male mice were initially fasted for 24 hours, followed by refeeding 
for 12 hours (8 pm to 8 am), 6 hours (2 am to 8 am), or 2 hours (6 am 
to 8 am), and finally sacrificed together at 8 am to avoid confounding 
effects of the circadian rhythm. To induce a chronic hepatic steatosis, 
male mice were fed ad libitum with a HFHS diet (TD.08811, Harlan 
Laboratories) for 17 weeks and sacrificed at 9 am. To study the APR, 
male mice fed a chow diet received an intraperitoneal injection of 
either 500 μl PBS or 40 μg LPS dissolved in 500 μl PBS. Mice were 
sacrificed 2.5 hours after injection and tissues collected.
Subcellular fractionation of liver tissues and Western blotting. From 
50 to 100 mg of liver pieces were incubated in 400 μl of hypotonic buf-
fer (10 mM HEPES-KOH, pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM 
DTT, protease and phosphatase inhibitor cocktails; Roche) and lysed 
with 10 strokes in a Dounce homogenizer. The supernatant fraction 
containing mainly cytoplasmic proteins was collected after centrifuga-
tion (14,000 g for 5 minutes, 4°C), and the pellets were washed twice 
with hypotonic buffer. The pellets were resuspended in 100 to 200 μl 
of hypertonic buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1 % 
NP-40, protease and phosphatase inhibitor cocktails) for 30 minutes 
on ice. The supernatant containing mainly nucleoplasm and mem-
brane fractions was collected by centrifugation (2,000 g for 5 minutes, 
4°C), and the remaining insoluble pellet containing mainly chromatin 
was resuspended in 100 μl of hypertonic buffer and sonicated. Before 
running SDS-PAGE, protein lysates were boiled for 5 minutes at 95°C. 
The following proteins were used for Western blotting: anti-Hsp90, 
anti–SREBP-1, and anti-P62 (BD Biosciences catalog 610418, 557036, 
and 610497); anti-OSBPL3 (Novus Biologicals, catalog NBP-155151), 
anti-FASN (Abcam, catalog ab22759), anti-SCD1 (Thermo Fisher, 
catalog A13996), anti–α-tubulin, anti-PARP1, and anti–β-actin (San-
ta Cruz Biotechnology Inc., catalog sc-5286, sc-7150, and sc-47778). 
Anti–SREBP-1, anti-P62, and anti-PARP1 were blotted on nuclear/
membrane fractions and all other antibodies on cytoplasmic fractions.
Gene expression and analysis. RNA was extracted from the livers of 
mice that were fasted for 24 hours followed by 6 hours of refeeding, 
LRH-1 WT (n = 6) and LRH-1 K289R (n = 6). Extraction was performed 
using TRIZOL (Invitrogen) and purified with the RNeasy Cleanup Kit 
for Microarray Analysis (QIAGEN). For quantitative reverse-tran-
scription PCR (RT-qPCR), cDNA was generated using the QuantiTect 
Reverse Transcription Kit (QIAGEN) and analyzed by qPCR using a 
LightCycler 480 Real-Time PCR System (Roche) and the primers list-
ed in Supplemental Table 1. Expression data were normalized to 36b4 
or B2m mRNA levels. Microarray analysis was performed using the 
Affymetrix MouseGene 1.0 ST array and normalized using the robust 
multi-array average (RMA) method. All original microarray data were 
deposited in the NCBI’s Gene Expression Omnibus (GEO GSE89877). 
Heat maps were generated using GENE-E (http://www.broadinstitute. 
org/cancer/software/GENE-E/index.html), and rows were clustered 
using the one minus Pearson correlation metric.
ChIP-PCR. ChIP analysis was performed as described previous-
ly, with minor modifications (9). ChIPed DNA was purified using the 
PCR Clean-up Extraction Kit (Macherey-Nagel), after which qPCR 
was performed as described previously (47). Data were normalized to 
the input (fold differences = 2– (Ct-sample – Ct-input)). ChIP primer sequences 
are listed in Supplemental Table 2. For LXR ChIP assays, an anti-LXRα 
antibody (Abcam, catalog ab41902) was used. For LRH-1 ChIP exper-
iments, a custom LRH-1 antibody was generated. A synthetic peptide 
([H]-QEQSNRNRQEKLSAFG-[NH2]) was used to immunize 2 rab-
or parallel pathways exist. One recent example is the induction of 
SREBP-1 processing upon depletion of phosphatidylcholine, whose 
synthesis is dependent on S-adenosylmethionine, a methionine 
derivative that is generated in the one-carbon cycle (35). We did 
not observe a difference in AKT phosphorylation between LRH-1 
WT and LRH-1 K289R mice, suggesting other signaling pathways 
to induce the processing of SREBP-1. Indeed, our current study 
highlights the existence of an alternative mechanism of SREBP-1 
activation involving a SUMO-dependent LRH-1/OSBPL3 pathway.
The first oxysterol-binding proteins were identified, puri-
fied, and cloned in the 1980s (36–38). Recent studies suggest that 
OSBPs act as sterol transfer and/or sensor proteins that may also 
play important roles in cell signaling (39, 40). OSBPL3, a mem-
ber of subfamily III, contains a conserved sterol-binding OSBP 
homology domain (OHD) as well as a phosphatidylinositol lipid 
species–binding pleckstrin homology (PH) domain and two 2-phe-
nylalanines in an acidic tract (FFAT) domains that bind to the ves-
icle-associated membrane protein–associated (VAMP-associated) 
protein (VAP) (39, 41, 42). Recently, it has been shown that this 
last interaction can activate R-RAS, thus reorganizing the actin 
cytoskeleton and affecting cell polarity and cell-cell adhesion (43). 
Future studies will be necessary to dissect the exact mechanisms 
by which OSBPL3 modulates SREBP-1 processing, but its associa-
tion with the ER could indicate a possible site of regulation.
In addition to the identification of OSBPL3 as a target of LRH-1, 
our study also highlights the existence of complex regulatory 
mechanisms to which OSBPL3 is subjected. We observed a discrep-
ancy between mRNA and protein levels of OSBPL3 between fast-
ing and refed conditions despite its persistent increase in LRH-1 
K289R mice. The marked reduction in mRNA levels upon refeed-
ing was also noticed when OSBPL3 was overexpressed using an 
adenovirus, indicating that additional posttranscriptional mecha-
nisms independent of LRH-1 regulate the expression of OSBPL3. 
Moreover, while the expression of OSBPL3 is low in healthy livers, 
it is increased in NAFLD, suggesting that this protein could be a 
novel biomarker for NAFLD.
In this study, we described a function of LRH-1 in the devel-
opment of fatty liver disease. It is noteworthy that other nuclear 
receptors also contribute to the development of NAFLD by affect-
ing steatosis, glucose homeostasis, inflammation, and/or fibrosis 
in the liver. For instance, while activation of LXRs or pregnane 
x receptor (PXR) promotes lipogenesis and the development of 
NAFLD, activation of other nuclear receptors such as PPARs 
or farnesoid X-activated receptor (FXR) has opposite effects 
(reviewed in ref. 44). Clinical trials performed in NASH patients 
using PPARγ or FXR agonists showed that the beneficial effects 
observed on hepatic steatosis and inflammation were accom-
panied by adverse effects on obesity and hypercholesterolemia, 
respectively (45, 46), highlighting the functional complexity of 
nuclear receptors (44). Therefore, the development of drugs tar-
geting specific nuclear receptor targets, such as OSBPL3, might 
provide alternative therapeutic options for treating NAFLD.
Methods
Animal studies. Congenic C57BL/6J LRH-1 WT or LRH-1 K289R (9) as 
well as C57BL/6J Lrh-1hep–/– and Lrh-1hep+/+ mice (6) were kept under nor-
mal housing conditions. For fast-refeeding protocols, 12- to 16-week-
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Immunohistochemistry. Liver sections were cut into 5-μm–thick seri-
al cryosections for oil red O staining to visualize neutral lipids or paraffin 
cryosections to stain collagen with sirius red, CD45-positive cells using 
rat anti-CD45 antibody (eBioscience, catalog 30-F11), or H&E.
Statistics. Data are expressed as mean ± SEM. Comparison of differ-
ences between 2 groups was assessed using unpaired 2-tailed Student’s 
t tests. Multiple group comparisons were assessed by ANOVA and Bon-
ferroni’s post-hoc t tests. P < 0.05 was considered statistically significant.
Study approval. All animal procedures were approved by the 
Swiss authorities (Canton of Vaud, animal protocols ID 2380, 2561, 
and 2768) and performed in accordance with École Polytechnique 
Fédérale de Lausanne institutional guidelines.
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bits (AbFRONTIER). The antiserum with the highest ELISA titer was 
selected and used in ChIP experiments. The preimmunization serum 
from the same rabbit was used as a negative control.
LXR agonist treatment. Hepa 1.6 (ATCC, catalog CRL1830) or 
AML-12 (ATCC, catalog CRL2254) cells were treated with 1 μM of 
GW3965 (Selleckchem), a dual LXRα and LXRβ agonist, for 6 hours 
in full medium.
In vivo siRNA transfection. siRNA sequences are listed in Supple-
mental Table 4. HPLC-purified siRNAs (3 nmol, Microsynth) were tail-
vein injected into each recipient mouse using in vivo-JetPEI (Polyplus) 
according to the manufacturer’s instructions. Mice were fast-refed as 
described above and sacrificed 2 days after injection.
Adenoviral infection. Osbpl3 cDNA was cloned into a pENTR/ 
D-TOPO plasmid (Invitrogen; the Topo primer is listed in Supple-
mental Table 3) and then subcloned in the pAd/CMV-DEST plasmid 
(Invitrogen). After linearization with PacI, the construct was trans-
fected into HEK 293A cells to produce the adenoviruses. Mice were 
tail-vein injected with Ad-gfp or Ad-Osbpl3, 2.5 × 109 PFU, fast-refed as 
described above, and sacrificed 3 days after injection.
AAV8 miRNA injection. The Osbpl3-siRNA sequence (Supplemen-
tal Table 4) was engineered to create a pre-miRNA sequence target-
ing Osbpl3, which was cloned into an AAV vector construct driven by 
the liver-specific hAAT promoter. AAV8 mirOsbpl3 viral vectors were 
generated and titrated as described previously (48, 49) and injected 
into jugular vein under isoflurane anesthesia (5 × 1011 vg). Two weeks 
after the injection, mice were fasted for 24 hours followed by 6 hours 
refeeding, then sacrificed, and tissues were snap-frozen.
Lipid analyses and plasma parameters. Hepatic lipids were extract-
ed according to the Bligh and Dyer protocol (50). Triglycerides, free 
fatty acids, and cholesterol contents in plasma and/or hepatic lipid 
fractions were quantified using enzymatic assays (Roche). To asses 
fatty acid synthesis rates in vivo, mice received sodium [1-13C] ace-
tate via their drinking water (2%) 24 hours prior to sacrifice. Fatty 
acids derived from hepatic lipid extracts were liberated, derivatized, 
and subjected to gas chromatography–mass spectrometry (GC-MS) 
analysis in order to calculate the fractional synthesis rates from the 
incorporation of 13C-acetate as described previously (51). ASAT and 
ALAT concentrations in blood were determined using standard clin-
ical chemistry methods.
VLDL secretion assay and glucose-6-phosphate quantification. The 
VLDL secretion assay was performed as described previously (51). 
Thirteen-week-old male LRH-1 K289R or LRH-1 WT mice were sub-
jected to the fasting-refeeding protocol and treated with 50 mg/ml 
poloxamer 407 (Sigma-Aldrich, catalog 16758) 8 hours after refeed-
ing was initiated. Blood samples were collected once before and every 
hour after poloxamer treatment to determine the triglyceride content. 
Glucose-6-phosphate content was determined using enzymatic assays 
as described previously (6).
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Various tumors develop addiction to glutamine to support
uncontrolled cell proliferation. Here we identify the
nuclear receptor liver receptor homolog 1 (LRH-1) as a
key regulator in the process of hepatic tumorigenesis
through the coordination of a noncanonical glutamine
pathway that is reliant on themitochondrial and cytosolic
transaminases glutamate pyruvate transaminase 2 (GPT2)
and glutamate oxaloacetate transaminase 1 (GOT1),
which fuel anabolic metabolism. In particular, we show
that gain and loss of function of hepatic LRH-1 modulate
the expression and activity of mitochondrial glutaminase
2 (GLS2), the first and rate-limiting step of this pathway.
Acute and chronic deletion of hepatic LRH-1 blunts the
deamination of glutamine and reduces glutamine-depen-
dent anaplerosis. The robust reduction in glutaminolysis
and the limiting availability of α-ketoglutarate in turn in-
hibit mTORC1 signaling to eventually block cell growth
and proliferation. Collectively, these studies highlight
the importance of LRH-1 in coordinating glutamine-
induced metabolism and signaling to promote hepatocel-
lular carcinogenesis.
Supplemental material is available for this article.
Received January 7, 2016; revised version acceptedMay 12, 2016.
During tumorigenesis, cancer cells usually switch from
oxidativemetabolism to a highly glycolyticmetabolic sta-
tus (Vander Heiden et al. 2009). While glucose is predom-
inantly metabolized into lactate rather than entering the
tricarboxylic acid (TCA) cycle, cancer cells particularly
rely on glutamine to replenish TCA cycle intermediates.
This process, termed anaplerosis, is accomplished
through the conversion of glutamine to α-ketoglutarate
(α-KG) via a two-step deamination reaction catalyzed by
glutaminases and then by glutamate dehydrogenase 1
(GLUD1) or transaminases (DeBerardinis et al. 2008;
Wise et al. 2008; Csibi et al. 2013; Son et al. 2013). Cancer
cells therefore critically depend on glutamine as a fuel for
proliferation, and abrogation of glutamine metabolism
blocks tumorigenesis, indicating an accessible therapeu-
tic window for cancer treatment (Hensley et al. 2013).
Liver receptor homolog 1 (LRH-1; also called NR5A2) is
a nuclear receptor that is enriched in enterohepatic tis-
sues, where it has diverse molecular and physiological
functions (Stein and Schoonjans 2015). LRH-1 has been
linked to cell proliferation and cancer development in
the intestine (Botrugno et al. 2004; Schoonjans et al.
2005) and pancreas (Petersen et al. 2010; Benod et al.
2011). In the liver, LRH-1 regulates variousmetabolic pro-
cesses, including bile acid synthesis (Mataki et al. 2007;
Lee et al. 2008; Out et al. 2011), glucose sensing and pro-
cessing (Oosterveer et al. 2012), and reverse cholesterol
transport (Stein et al. 2014). Although the function of
LRH-1 in the liver has been extensively studied, its com-
manding role in intermediary metabolism has never
been connected to tumorigenesis.
In this study, we report that LRH-1 promotes diethylni-
trosamine (DEN)-induced hepatocellular carcinoma
(HCC) by coordinating glutamine-induced anabolic me-
tabolism. We demonstrate that LRH-1 facilitates the
production of NADPH from glutamine by favoring a non-
canonical glutamine pathway that optimizes reductive
biosynthesis. Importantly, chronic and acute disruption
of LRH-1 also impairs glutamine-induced anaplerosis
and α-KG availability, ultimately leading to reduced
mTORC1 signaling. These results unveil an unexpected
role of LRH-1 in cancer intermediary metabolism with
broad-ranging implications on mTORC1 signaling.
Results and Discussion
Hepatic loss of LRH-1 prevents DEN-induced liver
carcinogenesis
To investigate the specific contribution of hepatic LRH-1
on HCC formation, we used the well-established DEN
method to induce liver cancer (Bakiri and Wagner 2013).
Liver-specific Lrh-1-deficient (Lrh-1hep−/−) and wild-type
control (Lrh-1hep+/+) mice were injected with DEN on
postnatal day 14. Tumor burden was assessed 6 mo
(mid-term) or 10 mo (long-term) after injection (Fig. 1A).
While long-term DEN-challenged Lrh-1hep+/+ littermates
developed multiple hepatic tumors, Lrh-1hep−/− mice
were strikingly protected (Fig. 1B,C). The robust reduction
of total tumor number and size was not caused by differ-
ences in DEN carcinogenicity as evidenced by the equal
accumulation of DNA adducts induced by DEN[Keywords: Hepatocellular carcinoma; cancer metabolism; nuclear
receptor NR5A2; mitochondria; anaplerosis; mTOR; NADPH]
6These authors contributed equally to this work.
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exposure in 14-d-oldLrh-1hep+/+ andLrh-1hep−/− livers (Fig.
1D; see the Supplemental Material for more details). Fur-
thermore, DEN moderately increased LRH-1 protein
abundance but did not affect its nuclear compartmentali-
zation (Fig. 1E). We then performed histological and
immunohistochemical analysis on the long-term DEN-
treated liver sections. H&E staining of Lrh-1hep−/− liver
sections demonstrated fewer microscopic tumor foci,
while BrdU and Ki67 staining confirmed reduced cell pro-
liferation in Lrh-1-deficient livers (Supplemental Fig.
S1A). Moreover, long-termDEN-treated Lrh-1hep−/− livers
were significantly lighter compared with Lrh-1hep+/+ liv-
ers, while the body weight did not differ between the
two genotypes (Supplemental Fig. S1B–D). Together,
these results indicate that LRH-1 is required for efficient
HCC induction and progression in response to DEN
treatment.
Hepatic loss of LRH-1 inhibits noncanonical glutamine
processing
LRH-1 coordinates intestinal cell renewal and tumor for-
mation through cross-talk with the β-catenin pathway
(Botrugno et al. 2004; Schoonjans et al. 2005). It is also re-
quired for hepatic endoplasmic reticu-
lum (ER) stress resolution through
transcriptional control of polo-like
kinase 3 (Plk3) and subsequent phos-
phorylation of activating transcription
factor 2 (ATF2) (Mamrosh et al. 2014).
To understand the robust tumor-sup-
pressive phenotype, we first assessed
the β-catenin pathway in mid-term
DEN-treated livers in which tumors
were not yet developed (Supplemental
Fig. S1E). In contrast to the findings in
intestinal crypts of germline Lrh-1+/−
mice (Botrugno et al. 2004), β-catenin
targets c-Myc, Ccnd1, and Ccne1
were not reduced in the unchallenged
(Supplemental Fig. S1F) or DEN-chal-
lenged (Supplemental Fig. S1G) Lrh-
1hep−/− livers. We also evaluated the
Plk3–ATF2 cascade in response to
acuteDEN exposure. Plk3mRNA lev-
els and ATF2 phosphorylation were
not induced by DEN (Supplemental
Fig. S1H; data not shown), indicat-
ing that, in our model, LRH-1 im-
pacts hepatocarcinogenesis via other
mechanisms. We then performed
microarray analysis to compare the
transcriptomes of mid-term DEN-
exposed Lrh-1hep+/+ and Lrh-1hep−/−
livers. As expected, gene set enrich-
ment analysis (GSEA) confirmed pre-
viously established functions and
target pathways of LRH-1, such as syn-
thesis of bile acids (Fig. 1F; Sup-
plemental Fig. S1I,J). Of interest,
metabolism of amino acid and deriva-
tives scored among the most signifi-
cantly enriched pathways (Fig. 1F;
Supplemental Fig. S1K). We next ana-
lyzed this gene set in more detail.
While transcripts of several proteasomal subunits were
down-regulated in Lrh-1hep−/− livers, a more striking re-
duction of several enzymes involved in glutamine catabo-
lism was observed (Fig. 1G). Glutamine plays an essential
role in tumor growth to support anaplerosis and reductive
biosynthesis (DeBerardinis et al. 2008). Several genes in-
volved in the processing of glutamine were reduced in
mid-term DEN-exposed Lrh-1hep−/− livers, including mi-
tochondrial glutaminase 2 (Gls2), cytosolic glutamate
oxaloacetate transaminase 1 (Got1), and mitochondrial
glutamate pyruvate transaminase 2 (Gpt2) (Fig. 1G,H).
This pathway is reminiscent of a noncanonical pathway
of glutamine breakdown that was earlier reported in hu-
man glioma (Wise et al. 2008) and pancreatic ductal ade-
nocarcinoma (PDAC) cells as an alternative mechanism
to support NADPH production via malic enzyme (Son
et al. 2013). Not only these genes but also malic enzyme
1 (Me1) were significantly blunted, as confirmed by quan-
titative RT–PCR (qRT–PCR) (Fig. 1I). Many cancer cells
typically rely on GLUD1 to fuel the TCA cycle through
repleting α-KG (DeBerardinis et al. 2008). Transcript lev-
els ofGlud1, however, remained unchanged upon hepatic
loss of function (LOF) of LRH-1 (Supplemental Fig. S1L).
Moreover, mRNA expression of Gls1, Got2, and TCA cy-
cle-related genes was not altered between the two
Figure 1. Hepatic Lrh-1-deficient mice are protected against DEN-induced HCC formation
and display reduced glutamine-dependent anaplerosis. (A) Experimental strategies of DEN ad-
ministration. (DOB) Date of birth. (B) Representative livers of 10-mo DEN-treated Lrh-1hep+/+
and Lrh-1hep−/− mice. (C ) Hepatic tumor number (left) and tumor size (right) in the correspond-
ing genotypes. (D) Hepatic O6-ethylguanine DNA adducts 6, 24, and 48 h after DEN injection
to 14-d-old Lrh-1hep+/+ and Lrh-1hep−/− mice. n = 5–6 per genotype and time point. (E) LRH-1
protein levels in cytosol and nucleus fractions of livers from untreated control (Ctrl), 6-mo
DEN-treated (MT), and 10-mo DEN-treated (LT) Lrh-1hep+/+ and Lrh-1hep−/− mice. (F ) Gene
set enrichment analysis (GSEA) demonstrates down-regulated pathways that were ranked by
normalized enrichment scores (NES) in livers of 6-mo DEN-treated Lrh-1hep−/− (n = 6) mice
compared with Lrh-1hep+/+ (n = 7) mice. Specific pathways are indicated. (G) Heat map display-
ing the core-enriched gene set “metabolism of amino acids and derivatives,” expressed in the
livers of the mice described in F. (H) Graphical representation of enzymes involved in gluta-
mine breakdown and metabolism. Enzymes highlighted in red are reduced in Lrh-1hep−/− livers,
as shown in I. (I ) Hepatic mRNA levels of glutaminase 2 (Gls2), glutamate oxaloacetate trans-
aminase 1 (Got1), glutamate pyruvate transaminase 2 (Gpt2), andmalic enzyme 1 (Me1) in liv-
ers of mice described in F. Data represent mean ± SEM. (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P < 0.001 by
two-tailed Student’s t-test.
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genotypes (Supplemental Fig. S1L,M). Col-
lectively, these data indicate that an alterna-
tive pathway involved in hepatic glutamine
processing is most likely compromised in
Lrh-1hep−/− mice.
LRH-1 regulates reductive biosynthesis
fueled by glutamine processing
We previously showed that LRH-1
coordinates glucose intermediary metabo-
lism via glucokinase (GCK) activation and
subsequent carbohydrate response ele-
ment-binding protein (ChREBP) nuclear
translocation (Oosterveer et al. 2012). Con-
sistent with this study, the ChREBP path-
way was significantly enriched between
both genotypes (Supplemental Fig. S2A,B).
Because Me1 is a known ChREBP target
gene (Iizuka et al. 2004; Chambers et al.
2013), we first analyzed whether the reduc-
tion of our candidate genes (Fig. 1I) results
from impaired GCK–ChREBP signaling.
GCK reconstitution in Lrh-1hep−/− livers re-
stored Chrebpβ and Me1 (Fig. 2A), but not
Gls2,Got1, orGpt2 expression (Supplemen-
tal Fig. S2C), indicating that LRH-1 regu-
lates only Me1 via the GCK–ChREBP axis.
In parallel to the reduced Me1 expression,
NADPH/NADP+ levels were significantly
reduced in unchallenged (Fig. 2B) or DEN-
challenged (Fig. 2C) Lrh-1hep−/− livers and
was accompanied by a corresponding reduc-
tion of the GSH/GSSG ratio in DEN-treated
livers (Fig. 2D). Although Me1 was readily
rescued upon GCK reconstitution (Fig. 2A),
normalization of NADPH/NADP+ levels
was still incomplete (Fig. 2B), supporting
the notion that the generation of NADPH
from glutamine is also attenuated in Lrh-
1hep−/− livers.
We next investigated the molecular mechanism
through which LRH-1 regulates glutamine metabolism.
Overexpression of LRH-1 in mouse hepatoma Hepa 1.6
cells resulted in an increase of GLS2 transcripts and pro-
tein, while Got1 and Gpt2 transcripts were unchanged
(Fig. 2E,F). Conversely, siRNA-mediated silencing of
LRH-1 exclusively reduced the expression of GLS2
mRNA and protein (Fig. 2G,H). In Lrh-1hep−/− mice, re-
duced hepaticGls2mRNA expression (Fig. 1H) translated
into lower GLS2 protein levels (Fig. 2I). Of interest, Gls2
is highly expressed in the liver compared with Gls1 (Sup-
plemental Fig. S2D). GLS2 deaminatesmitochondrial glu-
tamine, thus controlling a major anaplerotic step for
hepatic glutamine utilization (Hensley et al. 2013). We
then asked whether Gls2 is subjected to direct transcrip-
tional regulation by LRH-1. Analysis of a genome-wide he-
patic LRH-1 ChIP-seq (chromatin immunoprecipitation
[ChIP] combined with high-throughput sequencing) data
set (Chong et al. 2012) revealed LRH-1 recruitment at
the Gls2 promoter (Fig. 2J), and computational analysis
identified five putative LRH-1 response elements within
the Gls2 promoter under the LRH-1 ChIP-seq peak (Fig.
2K). Site-specific ChIP assays using DNA from mid-term
DEN-treated Lrh-1hep+/+ and Lrh-1hep−/− livers revealed
LRH-1 recruitment to putative binding sites 1, 2, and 3
(Fig. 2L). Mutation of these binding sites in mouse Gls2-
luciferase reporter constructs furthermapped site 3,which
is conserved in the human Gls2 promoter (Supplemental
Fig. S2E), as the major site that confers LRH-1 responsive-
ness (Fig. 2M). Accordingly, silencing of LRH-1 in human
hepatoma HepG2 cells also led to a significant reduction
of Gls2 transcripts (Supplemental Fig. S2F).
LRH-1 regulates GLS2 to promote glutamine-induced
anaplerosis
Given the marked reduction of GLS2 in Lrh-1hep−/−mice,
we hypothesized that hepatic loss of LRH-1 blunts
the conversion of glutamine to glutamate. To test the
flux throughGLS2 in vivo, we performed 13Cnuclearmag-
netic resonance (13CMR) spectroscopymeasurements fol-
lowinghyperpolarized [5-13C]glutamine injection (Cabella
et al. 2013;Cheng et al. 2013). [5-13C]glutaminewashyper-
polarized using dissolution dynamic nuclear polarization
(DNP) and rapidly injected into DEN-treated Lrh-1hep−/−
and Lrh-1hep+/+ mice followed by real-time recording
of its conversion to [5-13C]glutamate (Fig. 3A,B). As ex-
pected, Lrh-1hep−/− showed a strong decrease in hepatic
Figure 2. Gls2 is a direct transcriptional target of LRH-1. (A,B) Hepatic mRNA levels of
Gck, Chrebpβ, andMe1 (A) and NADPH/NADP+ levels (B) in control virus-infected Lrh-
1hep+/+ and Lrh-1hep−/−mice and AAV8-GCK virus-infected Lrh-1hep−/−mice. n = 4–5 per
group. Data represent mean ± SEM. (∗) P < 0.05 versus Lrh-1hep+/+; (#) P < 0.05 versus Lrh-
1hep−/− by one-way ANOVA and Tukey’s post-hoc test. (C,D) Relative NADPH/NADP+
(C ) and GSH/GSSG (D) levels in livers of 6-mo DEN-treated Lrh-1hep+/+ (n = 7) and Lrh-
1hep−/− (n = 6) mice. (E,F ) mRNA levels of Gls2, Got1, and Gpt2 (E) and protein levels of
GLS2 (F ) in Hepa 1.6 cells transfected with control or Lrh-1 expression plasmids. n = 3
per group. (G,H) mRNA levels of Gls2, Got1, and Gpt2 (G) and protein levels of GLS2
(H) inHepa 1.6 cells transfectedwith scrambled or Lrh-1 targeted siRNAs. n = 3 per group.
Data represent mean ± SEM. (∗∗) P < 0.01; (∗∗∗) P < 0.001 by two-tailed Student’s t-test. (I )
Hepatic protein levels of GLS2 inmice described inC. (J) University of California at Santa
Cruz (UCSC) genomebrowser (mm9) viewdisplaying the occupancyofmouseGls2by IgG
and LRH-1 (Chong et al. 2012). (K ) Schematic representation of the five putative LRH-1
response elements in the proximal mouseGls2 promoter. (L) ChIP-qPCR (chromatin im-
munoprecipitation [ChIP] combined with qPCR) assay to evaluate the relative LRH-1
binding to the mouseGls2 promoter. Amplified regions (a, b and c) are depicted in Figure
1K. (M ) Luciferase activities in HEK293A cells after cotransfection of a Lrh-1 expression
vector and with empty luciferase reporter (pGL4) and long or short Gls2 promoter con-
structs with or without the indicated mutations. Data represent mean ± SEM. (∗∗∗) P <
0.001 versus empty reporter (pGL4); (#) P < 0.05 versus long Gls2 promoter construct by
one-way ANOVA and Tukey’s post-hoc test.
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[5-13C]glutamate content compared with
Lrh-1hep+/+mice (Fig. 3C). Unlike the expres-
sion levels of glutamine transporters Slc1a5
and Slc7a5, which were unchanged (Supple-
mental Fig. S3A), hepatic α-KG levels were
diminished in Lrh-1hep−/−mice (Fig. 3D), in-
dicating that LRH-1 LOF may attenuate
glutamine-fueled anaplerosis. To further ex-
plore the direct roles of LRH-1 and GLS2 in
maintaining glutaminolysis and intracellu-
larα-KGpools,weexamined the effect of glu-
taminemetabolismon α-KG levels.Hepa 1.6
cells were starved of glutamine for 6 h, and
removal of glutamine significantly reduced
the intracellular levels of α-KG (Supplemen-
tal Fig. S3B), demonstrating that glutamine
sustains glutaminolysis. We then acutely
modulated LRH-1 or GLS2 expression in
Hepa 1.6 cells. In line with the reduced
α-KG abundance in Lrh-1hep−/− livers, over-
expression of LRH-1 or GLS2 increased,
while siRNA-mediated silencing of LRH-1
or GLS2 decreased, α-KG levels in Hepa 1.6
cells (Fig. 3E–H). Together, these results
demonstrate that LRH-1 promotes gluta-
mine-induced anaplerosis via the induction
of GLS2.
LRH-1 modulates the mTORC1 pathway
in an α-KG-dependent manner
Glutamine is metabolized through glutami-
nolysis to produce α-KG. Previous studies showed that in-
creased glutamine (Duran et al. 2012; Bar-Peled and
Sabatini 2014) or α-KG (Duran et al. 2012) availability
stimulates the mTORC1 signaling pathway. Of note, a ro-
bust reduction of mTORC1 activation was observed in
Lrh-1hep−/− livers, as evidencedby thedecreasedphosphor-
ylationof 4EBP1andS6K (Fig. 3I).We then investigated the
importance of glutamine in the activation of mTORC1 in
Hepa 1.6 cells. Depletion of glutamine for 6 h reduced α-
KG levels (Supplemental Fig. S3B) and inhibitedmTORC1
activity (Supplemental Fig. S3C).Moreover, supplementa-
tion of a cell-permeable α-KG analog, dimethyl-KG (DM-
KG), restored the activation of mTORC1 signaling upon
glutaminedeprivation (Supplemental Fig. S3D), indicating
that intracellular glutamine and its derived α-KG are es-
sential to stimulate mTORC1. Based on these results, we
overexpressed LRH-1 or GLS2 in Hepa 1.6 cells. In both
settings, mTORC1 activity was induced in the presence
of glutamine (Fig. 3J,K). These effects were reversed upon
glutamine starvation (Supplemental Fig. S3E,F). Further-
more, RNAi-mediated suppression of LRH-1 or GLS2 in-
terfered with phosphorylation of 4EBP1 and S6K in the
presence of glutamine, while addition of DM-KG or over-
expression of GLS2 or LRH-1, respectively, rescued
mTORC1 activities (Fig. 3L,M; Supplemental Fig. S3G,
H). These datahence suggest that theLRH-1–GLS2axis in-
creases α-KG levels and consequently activatesmTORC1.
The LRH-1–GLS2 axis promotes cell proliferation
Activation of mTORC1 inhibits autophagy (Kim et al.
2011), activates protein translation (Ma and Blenis 2009),
and promotes cell growth (Schmelzle and Hall 2000). To
investigate the importance of the LRH-1–GLS2–mTORC1
pathway, we first assessed autophagy in mid-term DEN-
treated livers. As expected, disruption of LRH-1 induced
autophagy, as evidenced by reduced phosphorylation of
ULK-1 at Ser757, blunted P62, and increased LC3-II levels
(Supplemental Fig. S4A). Silencing of LRH-1 or GLS2 de-
creased global protein translation asmeasured by incorpo-
ration of 35S-labelledmethionine inHepa 1.6 cells (Fig. 4A,
B), while their overexpression enhanced translation (Sup-
plemental Fig. S4B,C).We thenevaluated the linkbetween
LRH-1, α-KG, and cell proliferation.As expected, LRH-1 or
GLS2 overexpression promoted cell proliferation, while
additional glutamine deprivation prevented the increase
in cell proliferation (Fig. 4C,D). Conversely, inhibition
of glutaminolysis by LRH-1 or GLS2 silencing inhibited
cell proliferation, while overexpression of LRH-1 or
GLS2 rescued this effect (Supplemental Fig. S4D,E).More-
over, diminished cell proliferation upon LRH-1 or GLS2
suppression could also be rescued by addition of DM-KG
(Fig. 4E,F), indicating that the LRH-1–GLS2 axis activates
cell proliferation in an α-KG-dependent manner. It has
been shown that GLS2-catalyzed deamination of glu-
tamine is also essential for the control of intracellular
reactive oxygen species (ROS) levels (Hu et al. 2010). Sup-
plementation with the antioxidant N-acetyl-cysteine
(NAC), however, could not rescue the inhibited cell pro-
liferation upon LRH-1 or GLS2 silencing in Hepa 1.6
cells (Supplemental Fig. S4F,G), suggesting that reduced
mTORC1 signaling rather than induced oxidative stress
accounts for the reduction in cell proliferation. Further-
more, Hepa 1.6 cells silenced for LRH-1 or GLS2 induced
significantly less tumor growth after propagation in athy-
mic nude mice (Fig. 4G). Taken together, these findings
Figure 3. LRH-1 controls glutamine-induced anaplerosis and regulates mTORC1 activ-
ity. (A) GLS2-mediated biochemical reaction with hyperpolarized [5-13C]glutamine. Red
dots indicate the labelling of C5. (B–D) Representative in vivo 13C MR spectra showing
hyperpolarized [5-13C]glutamate productionwith the by-product signal of hyperpolarized
[5-13C]pyroglutamate (B), the mean signal intensity of the hyperpolarized [5-13C]gluta-
mate formed via glutaminase (C ), and intracellular α-KG levels (D) in the livers of
DEN-treated Lrh-1hep+/+ and Lrh-1hep−/− mice. (E–H) Intracellular α-KG levels in Hepa
1.6 cells transfected with either control or Lrh-1 expression plasmids (n = 3 per group
(E) or scrambled or Lrh-1 targeted siRNAs (n = 3 per group) (F ), transduced with either
AdGFP or AdGLS2 viruses (n = 3 per group) (G), or transfectedwith scrambled orGls2 tar-
geted siRNAs (n = 3 per group) (H). (I ) Phosphorylation states of S6K and 4EBP1 in the liv-
ers of mice described in B. (J–M ) Phosphorylation states of S6K and 4EBP1 in Hepa 1.6
cells transfected as in E (J), transduced as in G (K ), transfected as in F (L), or transfected
as in H (M ) with or without dimethyl-KG (DM-KG) supplementation (L,M ). Data repre-
sent mean ± SEM. (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P < 0.001 by two-tailed Student’s t-test.
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highlight that LRH-1 promotes cell proliferation through
glutaminolysis and mTORC1 signaling.
In conclusion, our study assigns a critical role to LRH-1
in hepatic fuel metabolism with a striking impact on he-
patic tumorigenesis. Unlike the role of LRH-1 in the intes-
tine and pancreas, the oncogenic potential of hepatic
LRH-1 is independent from the β-catenin/Wnt signaling
pathway and is instead driven by the regulation of specific
gene programs involved in mitochondrial glutamine ca-
tabolism (Fig. 4H). The enhanced mTORC1 signaling
upon LRH-1-induced glutaminolysis indicates that the ef-
fect of LRH-1 on glutamine processing also impinges on
established kinases in cell growth and cancer, thereby fur-
ther amplifying the overall growth-stimulating effect.
These observations, together with our previous findings
linking LRH-1 to glucose-dependent fatty acid biosynthe-
sis via ChREBP activation (Oosterveer et al. 2012), support
the notion that LRH-1 confers a protumorigenic status to
hepatocytes by promoting themetabolism of the principal
fuel substrates of cancer cells. Further studies arewarrant-
ed to fully understand its role in human HCC and explore
its potential as a drug target.
Materials and methods
Animal studies
Hepatocyte-specific LRH-1 knockout (Lrh-1hep−/−) and wild-type
(Lrh-1hep+/+) mice were previously reported (Oosterveer et al. 2012). Con-
genic neonatal mice at 14 d old were intraperitoneally injected with
DEN at a dose of 25 mg per kilogram of body weight to initiate tumor for-
mation. Six months (mid-term DEN) or 10 mo (long-term DEN) after in-
jection, mice were sacrificed, and liver tissue was collected. The
experiments with the AAV8 viruses have been described previously (Oos-
terveer et al. 2012). Five-week-old male BALB/c nu/nu mice were pur-
chased from Charles River and maintained in the animal facilities. All
animal procedures were approved by the Swiss authorities (Canton of
Vaud, animal protocol IDs 2375 and 2768) and performed in accordance
with our institutional guidelines.
ChIP
ChIP analysiswas performed as described previouslywithminormodifica-
tions (Stein et al. 2014). DNAwas purified using the PCR clean-up extrac-
tion kit (Macherey-Nagel), after which qRT-PCR was performed as
described previously (Mataki et al. 2007). Data were normalized to the in-
put [fold differences = 2−(Ct sample−Ct input)]. ChIP primer sequences are list-
ed in Supplemental Table 1.
Measurements of metabolites
For NADPH/NADP+ and GSH/GSSG ratios, liver biopsies were extracted
with 70% ethanol, and biomass was separated by centrifugation at 4000
rpm for 10min. Liquid extracts were then dried by vacuum centrifugation,
resuspended in 10 µL of water per milligram of wet weight, and analyzed
by targeted liquid chromatography-tandem mass spectrometry on a
ThermoQuantumUltra instrument equipped with aWaters Acquity ultra
high performance liquid chromatographer (UPLC). Intracellular α-KG lev-
els were determined using commercial kits (Abcam, ab83431) according to
the manufacturer’s instructions.
In vivo hyperpolarized 13C MR measurements
DEN-treated Lrh-1hep+/+ and Lrh-1hep−/− mice were anesthetized with
∼1.8% isoflurane, 0.5% O2, and 0.5% air. A 750-µL bolus containing a
dose of 0.57 mmol/kg ± 0.02 mmol/kg hyperpolarized [5-13C]glutamine
was administered in 9 sec. A series of 30°C BIR4 adiabatic RF excitation
pulses were applied using a custom-built dual 1H/13C probe (two 1H sur-
face coils placed in quadrature on top of a 13C single-loop surface coil)
placed under the animal on the shaved skin located above the mouse’s
liver. In vivo 13C MR measurements were respiratory-gated and triggered
with simulated cardiac signal with a repetition time of 1 sec. Acquisi-
tions were performed with an INOVA spectrometer (Varian/Magnex).
The peak integrals were obtained from summed spectra analyzed using
VNMRJ.
Allograft tumor study
Hepa 1.6 cells suspended in phosphate-buffered salinewere injected subcu-
taneously into the left flanks of nude mice (4 × 106 cells per flank). The di-
ameters of the tumors were measured every 3 d, and tumor volumes (V)
were calculated using the formula V = L×W2/2, where L is length, and W
is width.
Statistical analysis
Data represent mean ± SEM. Comparison of differences between two
groups was assessed using two-tailed Student’s t-tests. Multiple group
comparisons were assessed by one-way ANOVA and Tukey’s post-hoc
test. Differences under P < 0.05 were considered statistically significant
(P < 0.05 [∗], P < 0.01 [∗∗], and P < 0.001 [∗∗∗]).
More experimental Materials and Methods are included in the Supple-
mental Material.
Figure 4. The LRH-1–GLS2 axis promotes protein translation and
cell proliferation. (A,B) Global protein synthesis measured by 35S-la-
belledmethionine incorporation inHepa 1.6 cells transfectedwith ei-
ther scrambled or Lrh-1 targeted siRNAs (n = 3 per group) (A) or
scrambled or Gls2 targeted siRNAs (n = 3 per group) (B). Relative 35S
methionine signals were normalized to Tubulin. Data represent
mean ± SEM. (∗) P < 0.05; (∗∗) P < 0.01 by two-tailed Student’s t-test.
(C–F ) Relative viable cells and representative Crystal Violet staining
images of Hepa 1.6 cells transfected with either control or Lrh-1 ex-
pression plasmids (n = 3 per group) (C ) or transduced with either
AdGFP or AdGLS2 viruses (n = 3 per group) (D) with or without gluta-
mine deprivation or scrambled or Lrh-1 targeted siRNAs (n = 3 per
group) (E) or scrambled or Gls2 targeted siRNAs (n = 3 per group) (F )
with or without DM-KG supplementation. Data represent mean ±
SEM. (∗) P < 0.05; (∗∗∗) P < 0.001 by one-way ANOVA and Tukey’s
post-hoc test. (G) Comparison of tumor growth and volume of mice
subcutaneously injected with Hepa 1.6 cells that were transduced
with scrambled, LRH-1 targeted, or GLS2 targeted shRNA. n = 6 per
group. (H) Graphical summary illustrating how LRH-1 promotes glu-
tamine-induced anaplerosis and reductive biosynthesis in hepatic
cancer cells. Enzymes highlighted in red are reduced in Lrh-1hep−/−
livers, and an asterisk indicates indirect regulation by LRH-1.
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SUMMARY
Mitochondrial activity is controlled by proteins en-
coded by both nuclear and mitochondrial DNA.
Here, we identify Sirt7 as a crucial regulator of mito-
chondrial homeostasis. Sirt7 deficiency in mice
induces multisystemic mitochondrial dysfunction,
which is reflected by increased blood lactate levels,
reduced exercise performance, cardiac dysfunction,
hepatic microvesicular steatosis, and age-related
hearing loss. This link between SIRT7 and mitochon-
drial function is translatable in humans, where SIRT7
overexpression rescues the mitochondrial functional
defect in fibroblasts with a mutation in NDUFSI.
These wide-ranging effects of SIRT7 on mitochon-
drial homeostasis are the consequence of the deace-
tylation of distinct lysine residues located in the
hetero- and homodimerization domains of GABPb1,
a master regulator of nuclear-encodedmitochondrial
genes. SIRT7-mediated deacetylation of GABPb1
facilitates complex formation with GABPa and the
transcriptional activation of the GABPa/GABPb het-
erotetramer. Altogether, these data suggest that
SIRT7 is a dynamic nuclear regulator ofmitochondrial
function through its impact on GABPb1 function.
INTRODUCTION
Mitochondria are unique cellular organelles derived from endo-
symbiotic a-proteobacteria that evolved within our cells (Gray
et al., 1999). Mitochondria contain multiple copies of their own
circular DNA (mtDNA), which encodes for only 13 proteins.
Hence, the bulk of the mitochondrial proteins are encoded by
nuclear DNA (nDNA) and subsequently imported, folded, and
assembled within the mitochondria, exposing them to proteo-
toxic stress (Schmidt et al., 2010; Wallace, 1999). Mitochondria
harvest energy from nutrients and convert it via oxidative phos-
phorylation (OXPHOS) into ATP, the cellular energy source, mak-
ing them also vulnerable to metabolic stress. This exposure to
distinct stressors explains the existence of multiple quality con-
trol mechanisms and adaptive pathways, including mitochon-
drial biogenesis, mitophagy, and the mitochondrial unfolded
protein response, which all act to maintain proper mitochondrial
function (Andreux et al., 2014; Poyton and McEwen, 1996).
Chronic overload of these quality control pathways is a major
cause for mitochondrial dysfunction and contributes to the path-
ogenesis of mitochondrial diseases, ranging from rare inherited
mitochondrial diseases to a palette of common age-related dis-
orders that include metabolic diseases, neurodegeneration, and
cancer (Larsson, 2010; Nunnari and Suomalainen, 2012; Wal-
lace, 1999). Many of the adaptive processes in the mitochondria
are governed by a small set of nuclear transcription factors,
including nuclear respiratory factor 1 (NRF1), GA binding protein
(GABP, also known as nuclear respiratory factor or NRF2 [NCBI
Gene Expression Omnibus (GEO) IDs 14390 for GABPa and
14391 for GABPb1] but not to be confused with Nrf2/Nfe2l2
[NCBI GEO ID 18024]) and nuclear receptors, such as the perox-
isome proliferator-activated receptors (PPARs) and estrogen-
related receptors (ERRs) as well as transcriptional coregulators,
such as PPARg coactivator 1a, nuclear receptor corepressor 1,
and the sirtuins (Andreux et al., 2013; Houtkooper et al., 2012;
Scarpulla, 2008).
The sirtuins, an evolutionarily conserved protein family
named after the prototypical yeast sirtuin enzyme Sir2p (Ivy
et al., 1985; Shore et al., 1984), are central regulators of mito-
chondrial homeostasis (Guarente, 2008; Haigis and Sinclair,
2010; Houtkooper et al., 2012). Mammals have seven sirtuins
(SIRT1–SIRT7) with distinct subcellular localization and biolog-
ical actions (Houtkooper et al., 2012). The enzymatic activity
of sirtuins is critically dependent on the obligatory cosubstrate
NAD+, making them intracellular sensors of the metabolic envi-
ronment (Houtkooper et al., 2010; Imai and Guarente, 2010).
The function of SIRT7, which, along with SIRT1 and SIRT6, is
present in the nucleus, is only partially understood. SIRT7 is
enriched in the nucleoli, where it facilitates the activation of
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the DNA-dependent RNA polymerase I holoenzyme by inter-
acting with one of its subunits (Ford et al., 2006) and the up-
stream binding transcription factor (UBTF) (Grob et al., 2009)
and by the deacetylation of PAF53 (Chen et al., 2013). SIRT7
also deacetylates lysine 18 of histone H3, which is involved in
the stabilization of transformed cancer cells (Barber et al.,
2012), and Sirt7/ mice display cardiac hypertrophy, which
has been linked to p53 hyperacetylation (Vakhrusheva et al.,
2008). Interestingly, two very recent studies linked SIRT7 to
the control of liver function using independently generated
mouse models, though diametrically opposed effects on liver
lipid accumulation were observed (Shin et al., 2013; Yoshizawa
et al., 2014).
By the combination of bioinformatic, molecular, and in vivo
studies using independently generated germline- and liver-
specific Sirt7/ mouse models, we show that SIRT7 deacety-
lates GABPb1, thereby enabling it to form the transcriptionally
active GABPa/GABPb heterotetramer. Through this effect on
GABPb1 acetylation, SIRT7 is crucial for promoting proper
mitochondrial function and preventing mitochondrial-related
diseases.
RESULTS
Sirt7 Expression Positively Correlates with
nDNA-Encoded Mitochondrial Genes
As a first step for identifying functions of SIRT7, we applied a
reverse genetic approach with the GeneNetwork database
(www.genenetwork.org) (Andreux et al., 2012). The Sirt7 expres-
sion pattern in livers or hematopoietic cells varied across the
different BXD (Singer et al., 2004) or B6XBTBR-F2-ob/ob (F2)
(Keller et al., 2008) mouse strains (Figures S1A–S1C available
online). To identify putative targets of SIRT7, we selected those
strains showing the highest or lowest Sirt7 expression levels in
each data set (indicated in red or blue, respectively; Figures
S1A–S1C) and performed gene set enrichment analysis (GSEA;
www.broadinstitute.org/gsea). Interestingly, GSEA showed a
significant positive correlation between Sirt7 and the gene set
encompassing mitochondrial ribosomal proteins (MRPs; Fig-
ure 1A), whereas no correlation was observed with cytosolic
ribosomal proteins (CRPs; Figures 1B–1C and Table S1). Next,
to avoid possible inbreeding-related confounding factors poten-
tially present in the recombinant inbred BXD strains, we analyzed
the correlation of Sirt7 tomitochondrial genes in lungs of outbred
heterogeneous mice stocks (Valdar et al., 2006) and 457 human
liver biopsies (Schadt et al., 2008). Again, a highly significant
positive correlation between Sirt7 andMRP geneswas observed
in both the lungs of heterogeneous outbred mice strains (Figures
1D–1E and S1D and Table S2) and human liver biopsies (Figures
1F and S1E and Table S3). In addition, the expression of several
other nDNA-encodedmitochondrial genes such asClpp, Polrmt,
Mfn1, Fars2, Elac2, andNt5m also correlated positively withSirt7
(Figures 1D–1F and Tables S2 and S3).
Multisystemic Mitochondrial Dysfunction in
Sirt7–/– Mice
These results encouraged us to explore the role of SIRT7 in mito-
chondrial homeostasis with the use of a different Sirt7-deficient
mouse line (Sirt7/), which was generated by the targeted dele-
tion of exons 6–9 of the Sirt7 gene (see the Supplemental Infor-
mation). Exons 6–9 encode the sirtuin deacetylase domain; in
particular, exon 6 includes the putative proton acceptor histidine
188, the critical residue for the enzymatic activity of sirtuins
(Figure S2A). The offspring of heterozygous Sirt7 breeders
(Sirt7+/) were born under normal Mendelian (+/+:+/:/ =
22.8%:52.4%:24.9%) and sex ratio (male:female = 48%:52%;
Figure S2B).
A frequent feature of mitochondrial disease is the accumula-
tion of lactate in the blood (Chi et al., 1992). Therefore, we moni-
tored lactate and glucose levels in the basal state, during an
oral glucose tolerance test (OGTT), and after exercise. Although
basal lactate and glucose levels were not different between
genotypes, lactate, but not glucose, was higher in Sirt7/
mice after a glucose challenge (Figure 2A) and a 30 min tread-
mill run (Figure 2B). Consistent with increased lactate levels,
endurance performance was reduced in Sirt7/ mice (Fig-
ure 2C). Given that SIRT7 was undetectable in skeletal muscle
(Figure S2C), this phenotype likely originates from cardiac
dysfunction in our Sirt7/ mice, which was ascertained by a
comprehensive set of functional, molecular, and morphological
analyses (Figures S2D–S2M) and was consistent with a previ-
ous report in an independently generated SIRT7 knockout
mouse line (Vakhrusheva et al., 2008). The liver, the main tissue
for metabolic transformation, is also sensitive to mitochondrial
dysfunction. Although body weight and composition were indis-
tinguishable between both genotypes (Figures S2N and S2O),
livers of Sirt7/ mice were heavier because of microvesicular
hepatosteatosis, a hallmark of hepatic mitochondrial dysfunc-
tion (Figures 2D–2F) (Fromenty et al., 1997). In addition to
the microvesicular hepatosteatosis, plasma triglycerides and
free fatty acids were also elevated in Sirt7/ mice (Figures
2G and 2H).
Inherited forms of deafness as well as age-related hearing loss
are linked with mitochondrial dysfunction (Yamasoba et al.,
2007). Among all nuclear sirtuins, Sirt7 is highest expressed in
the inner ear (Ct values: Sirt1 = 29.18 ± 0.479, Sirt6 = 38.29 ±
1.162, and Sirt7 = 25.60 ± 0.343; Figure S2P). On the basis of
this finding, we analyzed the auditory brainstem response
(ABR), a standard electrophysiological test for auditory function.
Hearing loss usually initiates from the high-frequency region and
then extends to the low-frequency region (Hunter and Willott,
1987). ABR was not different in young Sirt7+/+ and Sirt7/
mice (Figure 2I, left and right). However, in older mice, Sirt7/
deficiency increased the ABR threshold at all the frequencies
(Figure 2I, right) although this was only evident for the highest fre-
quency (30 kHz) in wild-type (WT) littermates (Figure 2I, left).
Collectively, these phenotypic changes suggest that Sirt7/
mice suffer from a multisystemic mitochondrial dysfunction.
Perturbed OXPHOS Function in Sirt7–/– Mice
As a next step, we analyzed gene and protein expression in
different tissues. Although expression of several nDNA-encoded
mitochondrial transcripts was reduced in the heart, liver, inner
ear, bone-marrow-derived cells, and lung of Sirt7/ mice, the
expression of the CRP genes, such as Rpl32, Rpl24, and
Rps12, was not altered (Figures 3A and S3A–S3C). Expression
of the nDNA-encoded MRPL49, a component of the mitochon-
drial large ribosomal subunit, and ClpP, an ATP-dependent Clp
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protease, as well as the mtDNA-encoded MT-CO1 protein was
reduced in the heart and liver of Sirt7/ mice (Figures 3B and
3C). Other OXPHOS subunits, such as ATP5A and UQCRC2,
were only reduced in the heart and not in the liver (Figures 3B
and 3C). To verify whether the changes in individual OXPHOS
proteins impacted on the OXPHOS complexes, we performed
blue native PAGE (BN-PAGE). SIRT7 deficiency differently
affected OXPHOS composition in heart and liver. Complex IV
was decreased in both tissues, whereas complex III was stable.
Complexes I and II were slightly reduced in heart, whereas com-
plexes II and V were slightly reduced in liver (Figures 3D and 3E).
Moreover, complex I activity was clearly reduced during in-gel
activity assays in both heart and liver (Figures 3D–3E, bottom).
In line with the BN-PAGE results, respiration through complexes
I, II, and IV was reduced in heart, liver, inner ear, and lung tissues,
as determined by high-resolution respirometry (Figures 3F–3H
and S3D).
Mitochondrial Dysfunction Is Induced in a Cell-
Autonomous Fashion
Then, we tested whether the effect of SIRT7 on mitochondrial
function was cell autonomous. After infection of Sirt7-floxed
mouse embryonic fibroblasts (Sirt7L2/L2 MEFs) with a Cre-
recombinase (Ad-Cre), but not the control GFP-expressing
(Ad-GFP) adenovirus, mRNA levels of various mitochondrial
genes were reduced (Figure S4A). Moreover, nDNA-encoded
MRPL49 as well as mtDNA-encoded MT-CO1 and MT-ND1 pro-
teins were robustly reduced upon induction of Sirt7 deficiency in
primary mouse hepatocytes (Figure S4B). Although a recent
report suggested that SIRT7 suppresses ER stress in the liver
(Shin et al., 2013), the expression of the ER stress marker
GRP78/BiP was not altered in Sirt7-deficient primary hepato-
cytes (Figure S4B), suggesting that a different mechanism
underlies our phenotype. In addition, Sirt7-deficient hepato-
cytes also had a reduced oxygen consumption rate (OCR) in
Figure 1. Sirt7 Correlates with Nuclear-Encoded Mitochondrial Genes
(A) GSEA of the gene expression profiles in livers of B6xBTBR-F2-ob/ob (F2) mice. The gene set encompassing mitochondrial ribosomal proteins has an
enrichment score = 0.55, nominal p = 0.02, false discovery rate (FDR) q = 0.05, and family-wise error rate p = 0.01.
(B) Corresponding heat maps displaying the expression values forSirt7 (S7) and theMRP andCRPgenes in livers of BXD and F2 strains and in hematopoietic cells
(Hem) of the BXD strains.
(C) Volcano plots of the p values (Student’s t test) versus fold change in BXD and F2 livers and hematopoietic cells of the BXDs. MRP genes showing positive
correlations with statistically significant p values are represented in red. See Table S1.
(D) Covariation between mRNA expression of Sirt7 (x axis) and indicated mitochondrial genes (y axis) in lungs of heterogeneous mice stocks (n = 279). PCA
combined all positively correlated mitochondrial genes. See Table S2.
(E) Interaction network between Sirt7, MRPs, CRPs, and genes involved in mitochondrial function from the lung mRNA data set in heterogeneous mice stocks.
Positive (r > 0.5) and negative correlations (r <0.5, Pearson’s correlation coefficient) between the nodes are represented by red and green edges, respectively.
(F) Covariation between mRNA expression of Sirt7 (x axis) and each indicated gene (y axis) in the human livers (n = 427). See also Table S3, including Pearson’s r
correlation coefficient with corresponding p values.
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low-glucose medium, whereas the glycolytic activity was un-
changed as measured through the extracellular acidification
rate (ECAR) (Figure S4C, left). In high glucose, ECAR was
increased, whereas OCR was unaltered (Figure S4C, right).
Cellular fatty acid uptake and ATP levels were reduced, whereas
more superoxide was produced, in Sirt7-deficient primary hepa-
tocytes (Figures S4D–S4F). Interestingly, no major alterations in
the levels of key enzymes involved in lipogenesis and fatty acid
oxidation (i.e., medium-chain acyl-CoA dehydrogenase and
acetyl-CoA carboxylase; Figure S4G) and of transcripts of lipo-
genesis, fatty acid oxidation, lipid uptake, lipid storage, and tri-
glyceride (TG) secretion genes were observed (Figure S4H).
In addition to primary hepatocytes, we also evaluated the cell-
autonomous effect of SIRT7 onmitochondrial function in primary
cardiomyocytes that were isolated from 1- to 2-day-old C57BL/
6J WT pups and infected with either shCtrl- or shSirt7-RNA-ex-
pressing adenoviruses. As in Sirt7-deficient primary hepato-
cytes, the expression level of nDNA-encoded mitochondrial
genes was clearly attenuated in Sirt7-deficient primary cardio-
myocytes (Figure S4I). Furthermore, levels of both nDNA-
(ClpP, UBQCR3, and SDHB) and mtDNA-encoded (MT-CO1)
mitochondrial proteins were reduced (Figure S4J), which trans-
lated into reduced complexes II and IV activity upon respirometry
performedwith homogenized lysates of primary cardiomyocytes
(Figure S4K).
A recent study used adeno-associated virus 8 (AAV8)-medi-
ated silencing of SIRT7 to support the cell-autonomous nature
of its effects in vivo (Shin et al., 2013). Given that tail vein-injec-
tion of AAV8 infects various tissues besides the liver, including
heart, skeletal muscle, lung, and brain (Zincarelli et al., 2008),
we have chosen to generate liver-specific Sirt7 KO (Sirt7hep/)
mice in order to analyze its cell-autonomous effects. In full sup-
port of a cell-autonomous effect of SIRT7 onmitochondrial func-
tion, Sirt7hep/mice displayed similar clinical (e.g., normal body
weight with microvesicular steatosis; Figures 4A–4E), molecular
(e.g., reduction inMrpl49mRNA and MRPL49 and MT-CO1 pro-
tein expression; Figures 4F and 4G), and mitochondrial (reduc-
tion in mitochondrial complexes on BN-PAGE and in OXPHOS
complexes I, II, and IV activity; Figures 4H and 4I) phenotypic
alterations. However, we did not detect alterations in the expres-
sion of a comprehensive gene set involved in hepatic lipid meta-
bolism (Figure 4J).
SIRT7 Is a Dynamic Nuclear Protein
Although SIRT7 was initially identified as a nucleolar protein
(Ford et al., 2006), recent data have also attributed a role for
SIRT7 outside the nucleolus (Barber et al., 2012; Chen et al.,
2013; Pfister et al., 2008). We detected SIRT7 in both nucleoli
and extranucleoli fractions upon subnuclear fractionation (Fig-
ure 5A). Immunocytochemistry assays further supported the ex-
tranucleolar localization of SIRT7 (Figure 5B). To unequivocally
establish whether SIRT7 is a dynamic factor, we performed
fluorescence recovery after photobleaching (FRAP) assays.
SIRT7 showed a very high ‘‘diffusional mobility,’’ given that
Figure 2. Sirt7 KO Mice Show the Hallmarks of Mitochondrial Disease
(A) Blood lactate (left) and glucose (right) levels before and during OGTT in 30-week-old male Sirt7+/+ (n = 11) and Sirt7/ (n = 12) mice.
(B) Exercise-induced blood lactate levels after a 30 min treadmill run in 34-week-old male Sirt7+/+ (n = 11) and Sirt7/ (n = 12) mice.
(C) Maximum endurancewas determined, and the running distance achieved by eachmouse is represented (Sirt7+/+, n = 10;Sirt7/, n = 10, 34-week-oldmales).
(D) Liver weights of Sirt7+/+ (n = 10) and Sirt7/ (n = 10) mice of 42 weeks of age normalized to body weight.
(E) Triglyceride (TG) content in Sirt7+/+ and Sirt7/ livers (n = 8 per group, 42-week-old males).
(F) Hematoxylin and eosin staining of representative 42-week-old male livers of the indicated genotype.
(G and H) Plasma TG (G) and free fatty acid levels (H) in Sirt7+/+ and Sirt7/ mice (n = 8 per group, 42-week-old males).
(I) ABR auditory thresholds were monitored at 5, 8, 10, 15, and 30 kHz (Sirt7+/+, n = 8; Sirt7/, n = 10).
Graphs in (B–E) and (G and H) are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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approximately 50% of the initial fluorescence intensity was
recovered in 2 s after photobleaching SIRT7-GFP in both nucle-
oplasm and nucleoli (Figures 5C and S5A). These cellular studies
demonstrate that SIRT7 is a dynamic nuclear protein that is not
restricted to nucleoli.
Bioinformatic Analysis Links SIRT7 Tightly to GABPb1
On the basis of the striking correlations between the expression
of Sirt7 and mitochondrial genes, the mitochondrial dysfunction
inSirt7/mice, and the fact that SIRT7 is a dynamic nuclear fac-
tor, we hypothesized that SIRT7 might affect the expression of
nDNA-encoded mitochondrial genes by impacting on transcrip-
tion factors such as NRF1, GABPa, GABPb1, GABPb2, ERRa,
and ERRg (Scarpulla, 2008). Interestingly, the expression of
Sirt7 positively correlated with that of Gabpa, Gabpb1, Gabpb2,
and Esrrg, but not Nrf1 and Esrra (Figures 5D and S5B and Table
S4). Pearson’s and Spearman’s correlation coefficients indi-
cated that Sirt7, Gabpa, Gabpb1, Gabpb2, and Esrrg belong to
the same gene cluster (Figure 5E and Table S4), and principal
component analysis (PCA) confirmed the strong positive correla-
tion between Sirt7 and the components of the GABP complex
(GABPa, GABPb1, and GABPb2; Figure 5F). Finally, in a factor-
loading plot based on Pearson’s correlation coefficients,
Gabpb1was the strongest Sirt7 correlate (Figure 5G). In addition
to our bioinformatics analysis, we also reanalyzed data from
three independent studies (Barber et al., 2012; Hollenhorst
et al., 2009; Mercer et al., 2011). A recent genome-wide
chromatin immunoprecipitation sequencing (ChIP-seq) study
Figure 3. Lack of SIRT7 Triggers Mitochondrial Dysfunction
(A) mRNA levels of Sirt7,Mrpl49,Mrps5,Mrps9,Mrps12,Clpp,Polrmt,Mfn1, andRpl32 in heart, liver, and inner ear of 42-week-oldSirt7+/+ (n = 4) andSirt7/ (n =
5) male mice.
(B and C) Western blot analysis showing SIRT7, MRPL49, ATP5A, UQCRC2, MT-CO1, TOM40, and ClpP levels in heart (B) and liver (C) of 42-week-old male
Sirt7+/+ and Sirt7/ mice. HSP90 was used as a loading control.
(D and E) BN-PAGE of OXPHOS complexes (top) and complex I in-gel activity (bottom) in mitochondria isolated from heart (D) and liver (E) of 42-week-old male
Sirt7+/+ and Sirt7/ mice.
(F–H) Oxygen consumption rates (OCR) of heart (F; n = 5), liver (G; n = 5), and inner ear (H; n = 4 per genotype) tissues of 42-week-old Sirt7+/+ and Sirt7/ male
mice were monitored with specific substrates for each OXPHOS complex.
Data in (A) and (F–H) are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 4. Sirt7hep–/– Mice Have Hepatic Mitochondrial Dysfunction
(A–C) Body weight (A), normalized liver weights (B), and hepatic TG content (C) of 55-week-old chow-fed male Sirt7hep+/+ (n = 5) and Sirt7hep/ (n = 7) mice.
(D and E) Hematoxylin and eosin (D) and Oil Red O staining (E) of representative 55-week-old male livers of the indicated genotype.
(F) Hepatic mRNA levels ofMRP, Polrmt, Tfam,Mfn1,Clpp,Hspe1,Hspc5,CRP, and Sirtuin genes were evaluated by quantitative RT-PCR (qRT-PCR; Sirt7hep+/+
n = 4 andSirt7hep/; n = 8, 55-week-oldmalemice;MRP,mitochondrial ribosomal proteins; Mt Txn,mitochondrial transcription related; Mt Quality, mitochondria
quality control related; and CRP, cytosolic ribosomal proteins). Abbreviations are the same as in Figures 3A and S3A.
(G) Western blot analysis showing SIRT7, MRPL49, various OXPHOS subunits, and TOM40 in liver of Sirt7hep+/+ and Sirt7hep/. HSP90 was used as a loading
control.
(H) BN-PAGE of hepatic OXPHOS complexes of the mice in (G).
(I) OCR of liver lysates from 42-week-old male Sirt7hep+/+ and Sirt7hep/ mice (n = 5 per group).
(J) Expression levels of hepatic genes involved in fatty acid and TG synthesis, fatty acid uptake, fatty acid oxidation, and TG secretion as evaluated by qRT-PCR
(Sirt7hep+/+ n = 4 and Sirt7hep/ n = 8, 55-week-old male mice).
Graphs in (A–C), (F), and (I–J) are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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demonstrated that SIRT7 occupies the promoters of 232 mito-
chondrial genes (Figure 5H and Table S5), including the MRP
promoters (Barber et al., 2012). Another study demonstrated
that GABPa occupies the promoters of 389 mitochondrial genes
(Hollenhorst et al., 2009). Interestingly, 75% of SIRT7-occupied
genes were also identified in the GABPa-ChIP-seq. Moreover,
56% of the genes that are part of the human mitochondrial tran-
scriptome (Mercer et al., 2011) are covered in these independent
studies (Figure 5H and Table S5). In combination, these data
suggest the existence of a link between SIRT7-GABP and the
control of mitochondrial gene expression.
SIRT7 Impacts on Mitochondrial Function via the
Deacetylation of GABPb1
To analyze whether there is a functional link between SIRT7 and
GABPb1, we compared the acetylation of immunoprecipitated
GABPb1-Myc protein in human embryonic kidney 293T
(HEK293T) cells overexpressing the nuclear sirtuins. Notably,
Figure 5. SIRT7 Is a Dynamic Nuclear Protein Regulating Mitochondrial Target Genes
(A) Western blot assays demonstrating the subnuclear localization of SIRT7. Whole-cell lysate (WCL), nucleoli (N), and extranucleoli (Ex-N) fractions were pre-
pared from primary hepatocytes isolated from WT C57Bl/6J mice. B23 (also known as nucleophosmin) was used as a control for nucleoli, and histone H3 was
used as a loading control (NS; a nonspecific band).
(B) Confocal microscopy of HeLa cells showing endogenous SIRT7 in the nucleus. UBTF was used as a positive control of nucleoli, and the nucleus was stained
with DAPI.
(C) FRAP assay of SIRT7-GFP demonstrates the highly dynamic nature of SIRT7 in HEK293T cells. Time-series confocal images of SIRT7-GFP (left) and the
fluorescence quantification of bleached areas (nucleolus, n = 9, and nucleoplasm, n = 6). Unbleached control areas were used for normalization of fluorescence
intensity (right). Data shown as mean ± SEM.
(D and E) In order to evaluate a possible link between Sirt7 expression and key transcription factors that control mitochondrial activity, a correlation analysis with
gene expression data from the hippocampus, which contains all these nuclear factors (Figure S5B and Table S4) was performed. Correlation matrix (D) and
interaction network (E) showing correlations between Sirt7 and transcription factors involved in the expression of mitochondrial gene expression. Positive and
statistically significant Pearson’s correlation coefficients are represented by red edges (r = 0.5–1.0).
(F) PCA showing a significant positive correlation between the expression of Sirt7 and all three genes in the GABP complex.
(G) Factor-loading plot based on Pearson’s correlation coefficients highlighting that Gabpb1 is most related to Sirt7.
(H) Area-proportional Venn diagram representing common genes between SIRT7-ChIP-seq (Barber et al., 2012), GABPa-ChIP-seq (Hollenhorst et al., 2009), and
the human mitochondrial transcriptome data (Mercer et al., 2011).
See Table S5.
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the level of acetylated GABPb1 was specifically reduced upon
overexpression of SIRT7 but not SIRT1 or SIRT6 (Figure 6A). In
addition, we observed a clear interaction between ectopically
expressed SIRT7-GFP andGABPb1-Myc in HEK293T cells, sug-
gesting that SIRT7 could act as a GABPb1 deacetylase (Fig-
ure S6A). To validate whether SIRT7 directly deacetylates
GABPb1, we performed an in vitro acetylation and deacetylation
assay. Although p300 robustly acetylated GABPb1, GCN5 and
P/CAF displayed moderate or undetectable acetylation activity
(data not shown). Notably, the strong p300-induced acetylation
of GABPb1 was reverted by SIRT7 (Figure 6B). Mass spectro-
metric analysis identified three acetylated lysines (K69, K340,
and K369) in GABPb1 displaying SIRT7-dependent deacetyla-
tion (Figures 6C and S6B–S6C). We generated a nonacetylatable
GABPb1 mutant in which these three lysine residues were
replaced by arginines (GABPb1-3KR). Upon transfection of
HEK293T cells, the mutant GABPb1-Myc-3KR displayed low
acetylation levels in comparison to the GABPb1-Myc-WT pro-
tein, and SIRT7 was unable to further reduce acetylation
(Figure 6D). The same effect was observed in vitro, where
GST-GABPb1-3KR was poorly acetylated by p300, and SIRT7
had no deacetylase activity (Figure 6E). In addition, acetylated
Figure 6. SIRT7 Is a Deacetylase of GABPb1
(A) Western blot assay displaying reduced GABPb1 acetylation in SIRT7-, but not SIRT1- or SIRT6-, overexpressing HEK293T cells.
(B) In vitro deacetylation assay demonstrating that p300 acetylates and SIRT7 deacetylates GABPb1.
(C) Nano-LC-MS/MS analysis showing SIRT7-dependent in vitro deacetylation of AcK69, AcK340, and AcK396 of GABPb1.
(D) Western blot assay demonstrating that, in contrast to theWTGABPb1 protein, the GABPb1-3KRmutant is not deacetylated in HEK293T cells overexpressing
SIRT7.
(E) Reduced p300-mediated acetylation and abolished SIRT7-dependent deacetylation of the GABPb1 3KR mutant relative to the WT GABPb1 protein during
in vitro acetylation/deacetylation studies.
(F–I) Western blot showing acetylated GABPb1, total GABPb1, SIRT7, and HSP90 (or GAPDH) expression in Sirt7 L2/L2 (F), Sirt1L2/L2 (G), and Sirt6L2/L2 (H) primary
hepatocytes infected with either an Ad-GFP or Ad-Cre adenovirus. Bar graphs (I) show the quantification of the relative acetylation level of GABPb1 in these Sirt1,
Sirt6, and Sirt7L2/L2 primary hepatocytes. Data are shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 7. Deacetylation of GABPb1 Promotes GABP Complex Formation and Governs Mitochondrial Activity In Vivo
(A) Sequence alignment showing three conserved lysine residues (K69, K340, and K369) in GABPb1 of Homo sapiens, Pan troglodytes, Macaca mulatta, Canis
lupus,Bos taurus,Musmusculus,Rattus norvegicus,Gallus gallus, andDanio rerio (top). Sequence alignment of the homodimerization domain of mouseGABPb1
and GABPb2. The residues K340 and K369 are unique to GABPb1 (bottom).
(B and C) GST pulldown assays for comparing the heterodimerization between GABPa-FLAG with GST-GABPb1 or acetylated GST-GABPb1 (B) and the
homodimerization between GABPb1-FLAG with GST-GABPb1 or acetylated GST-GABPb1 (C). Acetylation of GABPb1 reduces the hetero- as well as homo-
dimerization in vitro. (Non; nonacetylated GABPb1; Ac, acetylated GABPb1).
(D) mRNA levels of Sirt7, Mrpl49, Mrps5, Mrps9, Polrmt, and Rps12 in transiently transfected AML12 mouse hepatocytes expressing either a control shRNA
(shCtrl), an shRNA targeting SIRT7 (shSirt7), or the shSirt7 in combination with a GABPb1 3KR (3KR) expression vector.
(E) Western blot assay showing SIRT7, HSP90, ATP5A UQCRC2, MT-CO1, TOM40, and GABPb1 proteins in AML12 cells in identical conditions as mentioned
in (D).
(F) Western blot showing endogenous acetylated GABPb1 levels in liver and heart of 42-week-old male Sirt7+/+ and Sirt7/ mice.
(G) Western blot assay showing reduced levels of SIRT7, ATP5A, and MT-CO1 proteins and increased acetylation levels of GABPb1 in livers of 6 hr refed (Refed)
versus 24 hr fasted (fast) 17-week-old male C57BL6/J mice.
(H) Western blot assay demonstrating reduced levels of SIRT7 and selected OXPHOS proteins and increased levels of GABPb1 acetylation in livers of 2-year-old
compared to 0.5-year-old male C57BL6/J mice.
(legend continued on next page)
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GABPb1 levels were specifically increased in Sirt7-, but not
Sirt1- or Sirt6-, deficient primary hepatocytes (Figures 6F–6I).
These studies indicate that SIRT7 deacetylates GABPb1 on
three specific lysine residues.
Deacetylation of GABPb1 Promotes GABP Complex
Formation and Activation
Previous reports showed that K69 of GABPb1 is a critical residue
facilitating the heterodimerization with GABPa and docking on
DNA (Thompson et al., 1991), whereas the lysines K340 and
K369 in the C-terminal domain (CTD) mediate GABPb1 homodi-
merization (de la Brousse et al., 1994; Gugneja et al., 1995).
These lysines are conserved in all vertebrate orthologs of
GABPb1 (Figure 7A, top), whereas the two lysines in the CTD
are not conserved in GABPb2, which also interacts with GABPa
(Figure 7A, bottom). Notably, we found that heterodimerization
between GABPa and b1 (Figure 7B) and homodimerization of
GABPb1 (Figure 7C) were reduced upon acetylation of these ly-
sines. Then, we used a GABP-responsive luciferase reporter to
test the effect of SIRT7-dependent deacetylation of GABPb1
on its transcriptional activity. Therefore, murine AML12 hepato-
cyte cells were cotransfected with this GABP reporter and rele-
vant combinations of SIRT7, WT GABPb1, the nonacetylatable
GABPb1-3KR, or the acetylation-mimicking GABPb1-3KQ.
Notably, the nonacetylatable GABPb1-3KR mutant induced
GABP reporter activity to an equal extent as the coexpression
of SIRT7 and GABPb1, whereas the acetylation-mimicking
GABPb1-3KQ mutant failed to activate the reporter even in the
presence of SIRT7 (Figure S7A). In addition, the effect of overex-
pressing the GABPb1-3KRmutant was evaluated in AML12 cells
in which SIRT7 was silenced (Figures 7D and 7E). Consistent
with the results obtained in SIRT7-deficient tissues and cells,
transcripts and protein levels of key mitochondrial genes, were
reduced by the SIRT7 knockdown. The ectopic expression of
GABPb1-3KR in these SIRT7 silenced AML12 cells partially
rescued the expression of several mitochondrial transcripts,
including those encoding for MRP, Polrmt (Figure 7D), and the
MT-CO1 protein (Figure 7E). These findings underscore the
functional importance of the SIRT7-dependent GABPb1
deacetylation.
Complementary to these in vitro interaction and cell-based
studies, we next tested whether the acetylation levels of
GABPb1 also differ in vivo. As expected, endogenous acetyla-
tion levels of GABPb1 (Ac-GABPb1) were increased in hearts
and livers of germline Sirt7/ mice (Figure 7F) as well as those
of Sirt7hep/ mice in vivo (Figure S7B).
SIRT7/GABPb1 Signaling and the Control of
Mitochondrial Activity
Finally, we analyzed whether the SIRT7/GABPb1 axis could con-
trol mitochondrial activity under physiological challenges. Food
restriction is known to induce the expression of OXPHOS genes
in the liver (Báez-Ruiz et al., 2005). Interestingly, SIRT7 expres-
sion was increased, whereas GABPb1 acetylation was reduced
in livers of fasted mice (Figure 7G). This was accompanied with
induced MT-CO1 and ATPA5A levels. Reduced OXPHOS is
associated with age-related decline in organ function (Yen
et al., 1989). Previously, we also reported that OXPHOS is
reduced in livers of old mice (Houtkooper et al., 2011). Expres-
sion of SIRT7 and some OXPHOS subunits, including MT-CO1,
was robustly reduced, whereas Ac-GABPb1 levels were induced
in livers of 2-year- versus 6-month-old mice (Figure 7H). More-
over, adenoviral-mediated SIRT7 overexpression improved
OCR and expression of mitochondrial proteins in human fibro-
blasts harboring amutated NDUFSI (Figures 7I and 7J), testifying
that SIRT7 can also improve humanmitochondrial function. Alto-
gether, our data suggest that the SIRT7/GABPb1 signaling is
linked to mitochondrial function in different genetic and physio-
logical contexts.
DISCUSSION
Our work proposes that SIRT7 is a dynamic nuclear regulator of
mitochondrial homeostasis acting on GABPb1, a master re-
gulator of mitochondrial biogenesis and function. A series of
experimental observations led us to this conclusion. First, the
expression of Sirt7 is tightly correlated with the expression of
many genes involved in the control of mitochondrial homeosta-
sis. Second, from all the transcription factors known to regulate
mitochondrial biogenesis and function, including PPARs, ERRs,
NRF-1, and GABPs, SIRT7 expression tightly correlates only
with that of GABPs. Third, two independent genome-wide
ChIP-seq analyses suggest that SIRT7 and the GABP complex
co-occupy multiple promoters of nDNA-encoded mitochondrial
genes. Fourth, SIRT7 deacetylates GABPb1 in critical residues
including K69, which induces dimerization with GABPa (Batche-
lor et al., 1998), and K340 and K369, which stabilize GABPb ho-
modimerization (de la Brousse et al., 1994; Thompson et al.,
1991). Fifth, deletion of Sirt7 in the mouse induces multiple de-
fects in a wide range of tissues as a consequence of generalized
mitochondrial dysfunction. Finally, SIRT7/GABPb1 signaling is
involved inmitochondrial adaptation to physiological challenges,
such as fasting, feeding, and aging. In combination, these inde-
pendent lines of evidence indicate a major role of SIRT7 in the
nuclear control of mitochondrial homeostasis.
As stated above, the phenotype of Sirt7/ mice, character-
ized by lactate accumulation, reduced exercise performance,
cardiac dysfunction and hypertrophy, hepatic microvesicular
steatosis, and hearing defects, resembles the clinical abnormal-
ities observed in patients with mitochondrial disorders (Chinnery
et al., 1999; Fosslien, 2003; Leone and Kelly, 2011; Nunnari and
Suomalainen, 2012; Wallace, 1999; Yamasoba et al., 2007). The
(I) Oxygen consumption rates (OCR) were measured in human fibroblasts harboring a mutant NDUFS1 (BB2693: BoAI cells) infected with either a control Ad-GFP
or Ad-SIRT7 adenovirus and grown in high glucose medium.
(J) Western blot assay showing increased OXPHOS in human fibroblasts harboring mutant NDUFS1, transduced with either Ad-SIRT7 adenovirus. Ad-GFP was
used as a control.
(K) A schematic model summarizing how SIRT7 controls mitochondrial homeostasis via the deacetylation of GABPb1 and the regulation of GABP complex
formation (based on a model shown in Thompson et al., 1991).
Graphs in (D) and (F–I) show mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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cardiac dysfunction phenotype was already reported in another
study using an independently generated Sirt7/ mouse line
showing an increased rate of apoptosis in the myocardium
(Vakhrusheva et al., 2008). However, our data indicate that, aside
from regulating apoptosis, a pathway intimately linked to the
mitochondria, SIRT7 has a broader role in mitochondrial homeo-
stasis in the heart, through its impact on GABP activity. Hence, it
is plausible that altered cardiac mitochondrial homeostasis con-
tributes to the development of cardiac hypertrophy and dysfunc-
tion in the Sirt7/ mice (Fosslien, 2003; Leone and Kelly, 2011;
Wallace, 1999). The exercise intolerance in Sirt7/ mice was
most likely a consequence of cardiac problems, given that
Sirt7 is not or only marginally expressed in skeletal muscle.
Liver steatosis subsequent to reduced fatty acid oxidation
and, in particular, microvesicular steatosis, as observed in our
Sirt7/ mice, is likewise a known feature of mitochondrial
dysfunction (Fromenty et al., 1997). Two very recent studies
(Shin et al., 2013; Yoshizawa et al., 2014) reported opposite he-
patic phenotypes in Sirt7-deficient mice. Shin et al. (2013)
observed a fatty liver, whereas Yoshizawa et al. (2014) report
protection of their Sirt7-deficient mice against high-fat diet
(HFD)-induced hepatic lipid accumulation. Although the Sirt7-
deficient mouse lines and the proposed mechanisms in all three
studies are different, our results showing that aged Sirt7-defi-
cient mice fed a normal chow (NC) accumulate hepatic triglycer-
ides (Figures 2E and 2F) aremore consistent with the data of Shin
et al. (2013). The fact that Yoshizawa et al. (2014) measured far
fewer lipids in the livers of Sirt7-deficient mice under an HFD in
comparison to WT or Sirt7-deficient mice under NC as well as
the absence of acetylation changes in the proposed SIRT7
effector molecules makes their observations puzzling and
devoid of conclusive mechanistic support. Altogether, all these
phenotypic abnormalities in the Sirt7/ mouse line reflect a se-
vere multisystem mitochondrial dysfunction, supporting our
hypothesis that SIRT7 is intimately linked to mitochondrial
homeostasis.
From a more mechanistic point of view, the aforementioned
correlation between SIRT7 and nDNA-encoded mitochondrial
transcripts implies a more dynamic behavior of nuclear SIRT7,
which seems not to be restricted to the nucleoli as previously re-
ported (Ford et al., 2006; Grob et al., 2009). A purely nucleolar
localization would dismiss a possible involvement of SIRT7 in
the control of mRNA transcription and limit its function to the
control of nucleoli-derived transcripts such as noncoding rRNAs
and tRNAs. Using subnuclear fractionation, immunocytochem-
istry, and FRAP assays (Figures 5A–5C and S5), we confirmed
that SIRT7 can shuttle between different nuclear compartments
(Chen et al., 2013; Pfister et al., 2008). This dynamic nature of
SIRT7 in the nucleus mechanistically underpins also how
SIRT7 impacts on transcription factors involved in the control
of nDNA-encoded mitochondrial genes. Nevertheless, future
studies will be necessary to define whether the subnuclear local-
ization of SIRT7 is a regulated process.
Although the transcription of nDNA-encoded mitochondrial
genes involves several transcription factors, we established a
specific link between SIRT7 and the activity of GABPa/GABPb
heterotetramer. GABPa continuously occupies its response ele-
ments on nuclear-encoded mitochondrial target genes but only
induces their transcription when it forms the GABPa/GABPb het-
erotetramer (de la Brousse et al., 1994; Scarpulla, 2008; Thomp-
son et al., 1991; Virbasius et al., 1993). We demonstrated that
SIRT7 deacetylates three critical residues of GABPb1, K69,
K340, and K369, which are involved in the stabilization of the
GABPa/GABPb complex (de la Brousse et al., 1994; Gugneja
et al., 1995; Thompson et al., 1991). In particular, the hydrogen
bond between Q321 of GABPa and K69 of GABPb1 is vital for
the stabilization of the GABPa-DNA complex (Batchelor et al.,
1998), whereas K340 and K369, located in CTD of GABPb1, sta-
bilize GABPb1 homodimerization (de la Brousse et al., 1994;
Thompson et al., 1991). Interestingly, these two lysine residues
(K340 and K369) are conserved in GABPb1 but not GABPb2 (Fig-
ure 7A). The acetylation of these two lysine residues could hence
indicate a distinct role of GABPb1 from GABPb2. To our knowl-
edge, this is the first study to unequivocally demonstrate the
importance of acetylation on these lysine residues, which re-
duces GABPb1 homodimerization. Furthermore, our work
suggests a unique role of SIRT7 in the dynamic control of this
acetylation switch, which stabilizes DNA binding and activation
of the GABPa/GABPb heterotetramer. This switch also allows
the fine-tuning and synchronization of GABP activity with cellular
energy levels, given that the activity of SIRT7, like that of all sir-
tuins, is strictly NAD+-dependent (Haigis and Sinclair, 2010;
Houtkooper et al., 2010; Imai et al., 2000). Through the control
of the activity of the GABPa/GABPb heterotetramer, which is vi-
tal for the expression of many mitochondrial gene sets, SIRT7
acquires a dominant position in the hierarchy of mitochondrial
homeostasis.
This premise is not only corroborated by the phenotypic ab-
normalities seen in the Sirt7/ mouse (see above) but also by
a number of bioinformatic and physiological studies. The very
tight correlation between the expression of Sirt7 and that of
many mitochondrial genes in several human and mouse tissues
suggested a strong link between SIRT7 and mitochondrial activ-
ity (Figure 1). Many of the promoters of these mitochondrial pro-
teins, including the MRP gene set, Polrmt, Tfam, andMfn1, were
further occupied by SIRT7 in an independent genome-wide
ChIP-seq analysis in a human cell line (Barber et al., 2012).
Notably, GABPa was shown to be permanently located on the
promoter of many of the same genes that were occupied by
SIRT7 (Hollenhorst et al., 2009). These two independent ChIP-
seq analyses hence show that 75% of SIRT7-occupied genes
are also bound by GABPa. In addition, more than half of the
genes reported as being part of the mitochondrial transcriptome
(Mercer et al., 2011) are covered in these two independent ana-
lyses (Figure 5H and Table S5), illustrating the wide ranging
impact of the SIRT7/GABP tandem on the transcription of
nDNA-encoded mitochondrial proteins. Finally, the reactivity of
the SIRT7/GABP axis to physiological changes, such as fast-
ing/feeding and aging, provides yet another compelling argu-
ment for their connectivity to mitochondrial function. It is also
of note that the effect of the SIRT7/GABP signaling axis on mito-
chondrial function is amplified by their impact on the transcrip-
tion of mitochondrial ribosomal proteins.
In summary, our work identifies a critical role for SIRT7/
GABPb1 signaling in the control of mitochondrial function. Mech-
anistically, SIRT7 controls mitochondrial homeostasis by the de-
acetylation of GABPb1, which in turn triggers the formation of the
active GABPa/GABPb complex and enhance the expression of
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mitochondrial genes (Figure 7K). Consequently, Sirt7 deficiency
in mice leads to multisystemic mitochondrial dysfunction.
Furthermore, dynamic changes in SIRT7/GABPb1 signaling
might contribute to mitochondrial adaptation to physiological
challenges, such as fasting recovery and aging. In combination,
these genetic and physiological data underscore the importance
of SIRT7/GABPb1 signaling in mitochondrial homeostasis. A
notable example was provided by the recovery of respiration
rates and mitochondrial protein expression in fibroblasts of a
patient with a mutation in NDUFSI. Activation of the SIRT7/
GABPb1 regulatory axis may offer an interesting approach for
preventing and/or treating mitochondrial dysfunction in patients
with inherited or acquired mitochondrial diseases.
EXPERIMENTAL PROCEDURES
All procedures are described in detail in the Supplemental Information.
Bioinformatic Analyses
Bioinformatic analyses with GSEA (http://www.broadinstitute.org/gsea) and
GeneNetwork (http://www.genenetwork.org/) were performed as described
in previous studies (Andreux et al., 2012; Lagouge et al., 2006). All transcrip-
tome data sets were downloaded from GeneNetwork. Hepatic transcriptome
data came from B6xBTBR-F2-ob/ob (B6XBTBR-F2 liver mRNA M430 RMA),
BXD inbred mice (BXD GN373 GSE16780 UCLA Hybrid MDP-liver-Sep11
RMA), and a human population (the Human Liver Cohort). Hematopoietic
cell transcriptome data came from BXD inbred mice (UMCG Stem Cells
ILM6v1.1 original database). Lung transcriptome data came from heteroge-
neous stock mice (OX UK HS ILM6v1.1 lung RankInv). Hippocampus tran-
scriptome data came from the BXD inbred mice (Hippocampus Consortium
M430v2 PDNN).
In brief, GSEA was applied in these data sets as an unbiased bioinformatic
analysis in order to define gene sets showing statistical correlation with Sirt7
expression in both human and murine transcriptome data sets (Figures 1A–
1C). Volcano plots were prepared on the basis of fold change and Student’s
t test. Correlation analyses were based on both Pearson product-moment
correlation coefficient and Spearman’s rank correlation coefficient with the
GeneNetwork website (Figures 1D–1F and 5D–5H). The correlation analysis
between Sirt7 and specific transcription factors (NRF1, GABP complex,
ERRa, and ERRg) was performed only in the hippocampus, given that all tran-
scription factors are simultaneously expressed there, unlike in other tissues.
Animal Studies
Sirt7/ mice were generated by a classical gene targeting strategy in 129Sv
embryonic stem cells. Detailed information on gene targeting an be found in
the Supplemental Experimental Procedures. The Sirt7/ and Sirt7L2/L2 mice
were backcrossed for ten generations onto theC57BL/6J background. Pheno-
typing experiments were performed with validated Eumorphia /EMPReSS
standard operating protocols (www.eumorphia.org). Animal experiments
were approved by the ethics committee of the Canton of Vaud with permit
ID #2444.
In Vitro Acetylation and Deacetylation Assays
In vitro acetylation and deacetylation assays were performed as originally
described (Rothgiesser et al., 2010). In brief, 1 mg of recombinant GABPb1 pro-
tein obtained fromBL21 strain was incubated with 500 ng of recombinant p300
in acetylation buffer (50mMTris-HCl [pH 8], 100mMNaCl, 10%glycerol, 1mM
phenylmethylsulfonyl fluoride [PMSF], 1 mM dithiothreitol [DTT], 1 mg/ml bep-
statin, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mM sodium butyrate, and
150 mM acetyl-CoA) for 1 hr at 30C. After incubation, samples were resolved
on SDS-PAGE and analyzed by western blot or used for in vitro deacetylation
assays. For deacetylation assays, 1 mg of acetylated GABPb1 was incubated
with 500 ng recombinant of SIRT7 protein in the deacetylation buffer (50 mM
Tris-HCl [pH 9], 4 mMMgCl2, 0.2 mM DTT, 1 mg/ml bepstatin, 1 mg/ml leupep-
tin, 1 mg/ml pepstatin, and 1 mMNAD+) for 30 min with constant agitation. The
incubated samples were resolved on SDS-PAGE and analyzed bywestern blot
or used tomap an acetylated residuewith nano liquid chromatography tandem
mass spectrometry (LC-MS/MS). Recombinant proteins p300 and SIRT7 were
kindly supplied by Michael O. Hottiger (University of Zurich).
Mass Spectrometry
Gel lanes were cut into pieces and subjected to in-gel digestion with endopro-
teinase Glu-C or trypsin. Peptide digests were resuspended and analyzed by
nano LC-MS/MS with an Orbitrap Elite Mass Spectrometer (Thermo Fischer
Scientific) coupled to an ultraperformance LC system (Thermo Fischer Scien-
tific Ultimate 3000 RSLC). Data analysis was performed with Proteome
Discoverer (v. 1.3), and searches were performed with Mascot and Sequest
against a mouse database (UniProt release 2013_01). Data were further pro-
cessed, inspected, and visualized with Scaffold 3.
Statistical Analyses
The comparison of different groups was carried out with Student’s t test and
two-way ANOVA, and differences under p < 0.05 were considered statistically
significant (*p < 0.05, **p < 0.01, ***p < 0.001).
SUPPLEMENTAL INFORMATION
Supplemental Information contains Supplemental Experimental Procedures,
seven figures, and six tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cmet.2014.08.001.
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is the Nestlé Chair in Energy Metabolism. The research in his laboratory is sup-
ported by the EPFL, the EU Ideas program (AdG-231138), the NIH
(R01AG043930), the Velux Stiftung, and the SNSF (31003A-140780 and
CSRII3-136201 awarded to J.A. and 310030-143748 awarded to K.S.). We
thank S.B. Lee, K. Kim, K.H. Kim (Sungkyunkwan University School of Medi-
cine), and S.H. Koo (Korea University) and the members of the J.A. lab for
discussion.
Received: April 14, 2014
Revised: June 30, 2014
Accepted: July 29, 2014
Published: September 4, 2014
REFERENCES
Andreux, P.A., Williams, E.G., Koutnikova, H., Houtkooper, R.H., Champy,
M.F., Henry, H., Schoonjans, K., Williams, R.W., and Auwerx, J. (2012).
Systems genetics of metabolism: the use of the BXD murine reference panel
for multiscalar integration of traits. Cell 150, 1287–1299.
Andreux, P.A., Houtkooper, R.H., and Auwerx, J. (2013). Pharmacological ap-
proaches to restore mitochondrial function. Nat. Rev. Drug Discov. 12,
465–483.
Cell Metabolism
SIRT7 Is a Deacetylase of GABPb1
Cell Metabolism 20, 856–869, November 4, 2014 ª2014 Elsevier Inc. 867
Andreux, P.A., Mouchiroud, L., Wang, X., Jovaisaite, V., Mottis, A., Bichet, S.,
Moullan, N., Houtkooper, R.H., and Auwerx, J. (2014). Amethod to identify and
validate mitochondrial modulators using mammalian cells and the worm C. el-
egans. Sci Rep 4, 5285.
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